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Summary 
To date, there are no encouraging treatment options for patients with malignant melanoma 
available. In search of therapeutic opportunities for these patients, the MAPK pathway called 
attention due to the discovery that components of this pathway are frequently mutated in 
cutaneous melanoma cells. 44% of melanoma patients have activating mutations in BRaf, and a 
single mutation, V600EBRaf, accounts for 90% of these BRaf mutations. Upstream, NRas is 
mutated in 22% of patients. The two mutations are mutually exclusive, indicating that one “driver” 
mutation is sufficient to constitutively activate the pathway. Several small molecule inhibitors have 
been developed to inhibit MAPK signaling by targeting BRaf or MEK. In a system comprising a 
V600EBRaf mutated melanoma cell line and three primary melanoma lines from one patient which 
carry a G469RBRaf mutation, I have comprehensively analyzed the effects of MAPK inhibition 
through U0126 and AZD6244 (specific MEK inhibitors) and Sorafenib (multi-kinase BRaf inhibitor) 
on recognition by NK cells, modulation of other cell signaling pathways in melanoma cells and 
their fate between apoptosis and autophagy. 
Surface expression of NK cell ligands on melanoma cells was strongly modulated by MAPK 
inhibition. Expression of CD155, a ligand for the activating NK cell receptor DNAM-1 was 
decreased following MEK inhibition with U0126 and AZD6244 but increased by Sorafenib-
mediated BRaf inhibition. This regulation of CD155 in melanoma cells had functional 
consequences for activation of NK cells because reduced CD155 expression following MEK 
inhibition correlated with reduced levels of NK cell cytotoxicity.  
Besides the analysis of NK cell activation against treated melanoma cells, the tumor cell fate was 
also investigated in detail. The core of my comprehensive analysis was based on the 
simultaneous inspection of multiple cell signaling pathways in tight kinetics up to 96 hours. I was 
able to unravel differences in the mechanisms of action between the two MEK inhibitors and the 
BRaf inhibitor with respect to phosphorylation of MEK and kinase stability in general. In addition, I 
could identify consequences of MAPK inhibition on Akt, JNK, and p53 signaling pathways, which 
are all involved in the regulation of apoptosis and autophagy. En route to the evaluation of 
autophagy regulation in response to MAPK treatment, I have established a new ImageStream-
based method for the quantification of autophagy, combining flow cytometry and single cell 
imaging. JNK was identified as a critical negative, and NFκB as a positive regulator of autophagy. 
The combination of this quantification of autophagy with an approach to measure apoptotic cells 
allowed the simultaneous detection of autophagy and apoptosis in the same cell under conditions 
of MAPK inhibition. These results indicate that Sorafenib, but not U0126 or AZD6244, effectively 
inhibits autophagy and promotes apoptosis. 
Taken together, my studies clearly demonstrate that interference of the oncogenic MAPK 
pathway has consequences for immune recognition of tumor cells, the tumor microenvironment 
and the balance between autophagy and apoptosis. 
Zusammenfassung 
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Zusammenfassung 
Derzeit existieren leider keine ermutigenden Therapiemöglichkeiten für Patienten mit 
metastasiertem Melanom. Auf der Suche nach gezielten Interventionen hat der MAPK Signalweg 
besonderes Aufsehen erregt, weil einige der Komponenten in Melanomen häufig mutiert sind. 
44% der kutanen Melanome weisen aktivierende BRaf-Mutationen auf, wobei die V600EBRaf-
Mutation mit 90% am häufigsten zu finden ist. NRas ist dagegen in 22% der Melanome mutiert. 
BRaf und NRas Mutationen schließen sich gegenseitig aus, was darauf hindeutet, dass eine 
Hauptmutation für eine konstitutive Aktivierung des Signalweges ausreicht. Seitdem wurden 
mehrere Inhibitoren für eine Blockade verschiedenen Stellen entwickelt. Ich habe die Effekte der 
MAPK Blockierung durch U0126 und AZD6244 (spezifische MEK Inhibitoren), sowie durch 
Sorafenib (multi-Kinase BRaf Inhibitor) auf die NK-Zell-Erkennung, die Modulation weiterer 
Zellsignalwege und das Zellschicksal im Hinblick auf Apoptose und Autophagie umfassend 
untersucht. Das von mir verwendete Zellsystem beinhaltet eine V600EBRaf mutierte Melanomlinie, 
sowie drei primäre Melanomlinien aus einem Patienten mit identischer G469RBRaf Mutation.  
Die Inhibition des MAPK Weges führte zu einer deutlichen Modulation der Expression von NK 
Zell Liganden. Die CD155-Expression, ein Ligand des aktivierenden NK Zell Rezeptors DNAM-1, 
wurde nach MEK-Inhibition durch U0126 und AZD6244 verringert, durch die BRaf-Inhibition mit 
Sorafenib jedoch erhöht. Die funktionelle Relevanz dieser CD155-Regulation wurde in 
Degranulationsexperimenten gezeigt, wobei die verringerte CD155-Expression zu einer 
verringerten NK-Zellaktivierung führte. Neben der Untersuchung der NK-Zellaktivierung habe ich 
mich ausführlich mit dem Schicksal der Tumorzellen beschäftigt. Im Zentrum meiner 
Untersuchung stand die Analyse mehrerer Signalwege nach Behandlung mit MAPK Inhibitoren in 
96-Stunden-Kinetiken. Dabei ließen sich unterschiedliche Wirkmechanismen zwischen MEK- und 
BRaf-Inhibitoren im Hinblick auf die MEK-Phosphorylierung und die generelle Stabilität der 
Kinasen feststellen. Die Blockierung des MAPK Wegs bewirkte weitreichende Effekte auf die Akt, 
JNK und p53 Signalwege, die an der Regulation von Apoptose und Autophagie beteiligt sind. Um 
die Auswirkungen der MAPK Blockierung auf diese Regulation zu untersuchen, habe ich eine 
neue ImageStream-basierte Methode für die Quantifizierung von Autophagie etabliert, die 
Durchflusszytometrie mit Mikroskopie kombiniert. JNK wurde als kritischer negativer Regulator, 
und NFκB als positiver Regulator von Autophagie identifiziert. Die parallele Quantifizierung von 
Autophagie und Apoptose in einem Ansatz habe ich angewandt, um die Auswirkungen der 
MAPK-Inhibition auf beide Wege definieren zu können. Meine Ergebnisse zeigen, dass 
Sorafenib, aber nicht U0126 und AZD6244, die Induktion von Autophagie deutlich verringert, und 
gleichzeitig die Apoptose begünstigt. 
Meine Untersuchungen zeigen deutlich, dass die Störung des onkogenen MAPK-Signalweges 
Konsequenzen für die Immunerkennung der Tumorzellen, das Tumor-Milieu und die Balance 
zwischen Apoptose und Autophagie hat. 
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I. Introduction 
Cancer is a leading cause of death worldwide. According to WHO (World Health Organization) 
statistics, cancer accounted for 7.9 million deaths in 2007, around 13% of all deaths. Deaths from 
cancer worldwide are projected to continuously rise, with an estimated 12 million deaths in 2030. 
By the broadest definition, cancer is a term used for diseases in which abnormal cells divide 
without control and, as malignant cells, are able to invade other tissues. Cancer cells can spread 
to other parts of the body through the blood and lymphatic systems. To date, there are more than 
300 different defined types of cancer, depending on their type of origin. Research over the past 
decades has shown that cancer development and progression involves dynamic changes in the 
genome of cells and their microenvironment. Discovery of tumorspecific mutations which produce 
oncogenes with dominant gain of function mutations on the one hand, and tumor suppressor 
genes with recessive loss of function on the other hand, has opened an entire research field in 
the context of oncogenic signaling events. While cancer research has become a very complex 
field, and research is continuously adding to this with additional layers of complexity, it has 
become clear that the origin of cancer and its development follows logical rules, and thus the 
complexity is understandable in terms of underlying principles and driving forces: 
Cancer progresses through aquisition of functional capabilities, leading to defects in regulatory 
pathways that govern cell proliferation and homeostasis. Hanahan and Weinberg suggested that 
the vast catalog of cancer cell genotypes is a manifestation of essential principles, referred to as 
the hallmarks of cancer [1], and proposed six essential alterations in cell physiology, that 
collectively dictate malignant growth: Self-sufficiency in growth signals, insensitivity to growth 
inhibitory signals, evasion of programmed cell death (apoptosis), limitless replicative potential, 
sustained angiogenesis, and tissue invasion and metastasis. 
 
 
Figure I-1 - Hanahan and Weinberg suggested the “hallmarks of cancer”, which include six essential alterations in cell 
physiology. They postulated the hypothesis, that cancer cell genotypes are a manifestation of essential principles, which 
collectively dictate malignant growth. 
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Cancer self-sufficiency in growth signals liberates cancer from the dependence on exogeneously 
derived signals from the normal tissue micronenvironment. This disrupts a critically important 
homeostatic mechanism, which normally functions to ensure proper behavior of various cell types 
within a tissue. Autonomy from growth signals can be achieved over three common molecular 
strategies, involving the alteration of (i) extracellular growth signals, of (ii) transcellular 
transducers of those signals, or of (iii) intracellular circuits that translate those signals into a 
cascade that leads to alterations in gene expression. 
One of the driving forces for a variety of malignancies is the mitogen-activated protein kinase 
(MAPK) pathway, which plays a central role in the latter translational step: It integrates and 
processes signals from ligand activated growth factor receptors and integrins, resulting in 
increased gene expression and proliferation.  
I.1 Melanoma 
Skin cancer is the third most common human malignancy and its global incidence is rising at an 
alarming rate, with basal cell carcinoma, squamous cell carcinoma and malignant melanoma 
being the most common forms. There are an estimated 2–3 million new cases of skin cancer 
across the world each year, and although melanoma only accounts for about 132,000 of these 
(WHO), it is the most dangerous form, accounting for most skin cancer deaths due to its high 
prevalence and early metastasizing capacitiy. If melanoma is diagnosed before metastasis (Stage 
I and II), it can be cured by surgical resection, to about 80% of cases. However, metastatic 
malignant melanoma (Stage III and IV) is largely refractory to existing therapies and has a very 
poor prognosis, with a median survival rate of 6 months and a 5-year survival rate of less than 5% 
[2]. Therefore, new treatment strategies are urgently needed and under constant development. 
 
I.1.1 Oncogenic MAPK signaling 
The transmission of extracellular signals into their intracellular targets has been an intense field of 
research for more than three decades. It is generally accepted now, that this process is mediated 
by a network of interacting proteins (Serine/Threonine kinases in particular), and that this network 
regulates a large number of cellular processes. In 1995, Seger et al reviewed the pathway that 
has been newly elucidated by that time: The mitogen-activated protein kinase (MAPK) signaling 
cascade [3]. They described it as a cellular highway, which takes an extracellular stimulus, e.g. 
from growth factors, all the way from the plasma membrane to the cell nucleus: Extracellular 
growth factors bind to their cell-surface receptor tyrosine kinases (RTKs). There is a broad and 
diverse spectrum of RTKs in different tissues, including epidermal growth factor receptor (EGFR), 
c-KIT, platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor 
receptor (VEGFR), fibroblast growth factor receptor (FGFR) and fms-related tyrosine kinase-3 
(FLT-3). The incoming signal is transduced via adaptor molecules such as growth factor receptor 
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bound 2 (GRB2) and exchange factors such as Son-of-sevenless (SOS) which lead to the 
activation of the Ras small guanine-nucleotide binding protein. Ras is attached to the inner face 
of the plasma membrane, and occurs in two activity states: It is inactive in its GDP-bound form, 
and becomes activated when GTP-bound [4-6]. The binding of GTP leads to a conformational 
change of Ras, and allows binding and activation of different effector molecules, two of the best-
described are phosphatidylinositol-3-kinase (PI3K) and Raf.  
 
 
Figure I-2 - Basic schematic of Ras-ERK MAPK signaling. Extracellular growth factors bind to receptor tyrosine kinases 
(RTKs). This results in activation of Ras, which can activate Raf and PI3K. PI3K activation ultimately leads to Akt activation. The 
Akt pathway controls induction of apoptosis, as well as cell metabolism. Raf phosphorylates and activates MEK, MEK 
phosphorylates and activates ERK. Downstream effects of ERK include survival and control of proliferation.  
 
Activation of PI3K leads to phosphorylation of phosphatidylinositol-4,5-biphosphate (PIP2) to 
phosphatidylinositol-3,4,5-triphosphate (PIP3) and ultimately results in activation of Akt. The Akt 
pathway controls cellular survival, apoptosis, cytoskeletal rearrangement and tumor cell chemo-
resistance [7, 8]. Activation of Akt through PI3K can be inhibited by the tumor suppressor PTEN 
(phosphatase and tensin homologue), which is reportedly mutated in up to 25% of melanomas 
[9], leading to loss of its regulating function. 
 
The Raf/MEK/ERK pathway represents the major signaling cascade initiated through Ras 
activation. Active Ras recruits Raf to the membrane for activation through a complex process 
involving changes in phosphorylation and binding to other enzymes and scaffold proteins, which 
stabilize and coordinate the assembly of the signaling complex [10]. Activated Raf in turn leads to 
the activation of the dualspecificity mitogen-activated protein kinase (MAPK) and extracellular 
signal-regulated kinase (ERK) kinases (MEK) and subsequently ERK. ERK phosphorylates many 
substrates and the duration and intensity of its activity affects how cells respond to extracellular 
signals [11]. The complexity of the pathway is further increased by the multiplicity of its 
components. The Ras family comprises HRas, NRas and KRas, the Raf family comprises ARaf, 
Introduction 
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BRaf and CRaf. In addition, there are two MEK isoforms (MEK1 and MEK2) and two ERK 
isoforms (ERK1 and ERK2) and the composition of these isoforms may vary between cells. 
These genes encode proteins with nonredundant functions.  
Obviously, this pathway has to be carefully controlled to ensure appropriate responses to 
environmental stimuli. In normal cells, signaling results in survival and proliferation, but can also 
lead to senescence and differentiation. In cancer cells, the constitutive activation of the 
Ras/Raf/MEK/ERK pathway shifts the outcome towards proliferation and survival only. The MAPK 
pathway has been associated with several human tumor entities, because oncogenic mutations in 
Ras occur in ~15% of cancers [12] and ERK is hyperactivated in ~30% of cancers on average. 
Ras has been a main focus of cancer research for a long time, because it is mutated in around 
50% of colon cancer, one of the most common-cancer forms. Raf recently took center stage 
when it was discovered that B-Raf is also very frequently mutated in human cancers particularly 
melanoma (44%), thyroid cancer (30–50%), colorectal cancer (5–20%) and ovarian cancer 
(~30%), but also at a low frequency (1–3%) in a number of other cancers. Therefore Ras-ERK 
signaling is particularly important in melanoma, because somatic mutations occur in BRaf, NRas, 
and KRas in 43%, 20% and 2% of melanomas respectively 
(www.sanger.ac.uk/genetics/CGP/cosmic/), which implies that Ras-ERK signaling represents one 
of the driving forces in melanoma. 
I.1.2 MAPK mutations in melanoma 
Ras mutations that have been observed in melanoma usually trap Ras in its GTP-bound active 
conformation and mostly involve glycine 12 (G12), glycine 13 (G13), and glutamine 61 (Q61). 
Even more important in melanoma is the mutational status of BRaf, mutated in 44% of 
melanomas. A glutamic acid substitution for the valine at position 600 (V600EBRaf) accounts for 
over 90% of mutations in BRaf. V600EBRaf is a gain of function mutation, and has been shown to 
be constitutively 500-fold activated. It can stimulate constitutive MEK-ERK signaling in cells [13] 
and induce melanoma in mice [14, 15], showing that it can be quoted as a founder mutation in 
melanoma. However, more than 100 other rare mutations have been described for BRaf in 
melanoma, most of which cluster to the glycine-rich loop resulting in gate-keeper mutations, and 
to the activation segment in the kinase domain, resulting in “Kinase dead” variants. Normally, 
these regions trap BRaf in an inactive conformation, because they form an atypical intramolecular 
interaction. It is postulated, that mutations in the glycine-rich loop and in the activation segment 
disrupt this inhibiting interaction, thereby allowing the active conformation to prevail [16]. 
Functional studies have shown that most of the mutations in BRaf are activating and enhance its 
ability to directly phosphorylate MEK [16]. But ongoing research has shown, that the position of 
BRaf mutation matters, activating mutations are not all alike, and even inhibitory mutations can 
have activating effects [17, 18]:  
Of 22 tested BRaf mutants, 18 proved to activate BRaf in vitro and stimulated ERK signaling in 
vivo, confirming the phenotype of an activated oncogene. Activity increases varied between the 
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different mutations. A high activity group showed 130-700 fold increases in kinase activity 
compared to wild-type. An intermediate activity group showed increases ranging from 1.3 to 64 
fold which placed them above wild-type BRaf levels, but below mutationally activated Ras. The 
study also identified 4 mutants with only 30% to 80% of wtBRaf kinase activity in vitro, described 
as the impaired activity group. In vivo however, three of the four mutants still showed elevated 
levels of MEK signaling, through the transactivation of CRas in a Ras dependent manner, which 
then signals to activate MEK [17].  
In BRaf, so-called “kinase dead” mutations occur at aspartic acid 594 (D594V). The carboxy 
oxygen of this highly conserved residue plays a critical role in chelating Mg2+ and stabilizing ATP 
binding in the catalytic site. As in other “kinase dead” mutations, D594V mutants appear 
catalytically and biologically inactive, so D594VBRaf for example cannot phosphorylate MEK, 
activate CRaf, or stimulate cell signaling. While V600EBRaf and NRas mutations occur in a 
mutually exclusive manner, in four of 34 BRaf kinase-dead mutants a second Ras mutations was 
found (p<0,0001). Elegant studies have shown, that kinase-dead BRaf in combination with 
mutant NRas cooperates to drive tumor progression through CRaf [17].  
 
In conclusion, constitutively active Ras-ERK signaling plays a key role in melanoma development 
and progression. The downstream effects of this oncogenic pathway in human cancer include 
increased proliferation due to tumor suppressor inactivation and downregulation of cyclin-
dependent kinases [19]. In addition, increased survival through modulation of MITF, a central 
regulator of melanocyte development [13, 20], and protection against FAS-induced apoptosis [21] 
are consequences of constitutively active MAPK signaling. Finally, invasion and metastasis are 
promoted through extracellular matrix remodeling [22] and angiogenesis [23]. These events are 
resulting from altered gene expression of direct downstream targets of Ras-dependent 
transcription factors. Furthermore, epigenetic changes in promoter DNA-methylation and histone-
modification can be linked to this pathway. [24]. In addition, protein modifications like 
phosphorylation or acetylation modify signaling cascades as a consequence of this constitutively 
active pathway. Thus, the complexity of MAPK signaling allows the analysis of its relevance at 
different levels, and I have focused on immunological consequences of interference with this 
pathway. 
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I.1.3 Therapeutic strategies in melanoma treatment 
As one of the central players in melanoma initiation, the oncogenic MAPK pathway represents 
one of the main targets for new therapeutic strategies. Various agents aim to inhibit either NRas, 
BRaf or MEK signaling in order to inhibit melanoma growth and to provide a therapeutic 
opportunity for patients with metastatic melanoma, alongside with chemotherapy and IFN-α 
treatment [25]. Many of them are small-molecule kinase inhibitors, which have been used to 
inhibit Raf or MEK in melanoma and other cancer types. During the last decade, a variety of small 
molecule inhibitors has been developed for experimental as well as clinical applications. The 
specificity ranges from multi-kinase inhibitors to the most recent drugs, i.e. mutation-specific 
inhibitors of BRaf. 
Sorafenib (Nexavar®) is an example of a multikinase tyrosine kinase inhibitor whose spectrum of 
targets includes BRaf, in addition to CRaf, VEGFR-2, VEGFR-3, PDGFR, c-KIT and others. It has 
been shown to inhibit MAPK phosphorylation in vitro in most human tumor cell lines, but the 
inhibiting effect varies in vivo depending on the murine tumor model. Besides inhibition of MAPK 
phosphorylation it provides antiangiogenic activites [26]. 
Importantly, a phase II randomized trial showed that Sorafenib as a single agent did not provide 
any benefit in advanced stage melanoma [27]. Sorafenib has also been under evaluation in 
combination with chemotherapy and was well tolerated in Phase II trials [28, 29], but in 
conclusion, Sorafenib treatment disappointingly failed to produce objective responses in 
melanoma patients. All studies showed that BRaf mutational status did not prove to be associated 
with response rates [30], which is not surprising considering that Sorafenib inhibits independently 
from BRaf mutations. Therefore, it also showed effectiveness in renal cell carcinoma and 
hepatocellular carcinoma treatment, two tumors that do not possess BRaf mutations [31, 32]. 
Among the different MEK inhibitors, AZD6244 (Selumetinib®) has been described as a highly 
selective MEK1/2 inhibitor with good efficacy in in vitro and in vivo models [33]. Phase I studies 
showed inhibition of phosphorylated ERK in PBMC of the patients, as well as in paired tumor 
biopsies. Phase II studies are currently ongoing [34]. U0126 is another MEK specific inhibitor, 
which has been used to inhibit MEK phosphorylation in vitro and is only utilized experimentally.  
  Introduction 
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Figure I-3 - Small molecule inhibitors of MAPK signaling. Sorafenib is a multi-kinase inhibitor with anti BRaf activity. 
AZD6244 and U0126 are MEK-specific inhibitors. AZD6244 and Sorafenib are currently undergoing phase II trials for the 
treatment of melanoma patients.  
 
Even though no clear clinical benefit in metastatic melanoma could be achieved so far, the search 
for new MAPK inhibitors to treat melanoma is ongoing. PLX4720 is a new selective BRaf inhibitor, 
due to its inhibition of mutated V600EBRaf [35]. It showed high selectivity for BRaf in vitro and 
preferentially inhibited BRaf signaling. PLX4720 has entered the clinic quite fast, and is now 
under evaluation in clinical trials. Despite some early success in phase I clinical trials, it remains 
to be seen if this new drug can achieve sustained benefit for metastatic melanoma patients. 
There is an increasing amount of adverse effects reported following treatment with PLX4720, and 
possible mechanisms are currently intensively investigated [17, 18, 36].  
 
Sensitivity of tumor cell lines to different MAPK inhibitors varies to a great extent, independently 
of their mutational status. Just recently it was demonstrated that V600EBRaf melanoma lines 
showed large variations in susceptibility to PLX4720 [37], and other studies also suggested novel 
mechanisms of resistance to MEK or BRaf inhibitors [38]. The evaluation of new drugs usually 
focuses on the direct impact on MAPK signaling, measured as inhibited phosphorylation of MEK 
and ERK respectively. Yet, MAPK signaling plays a central role in tumor and normal cell 
signaling, and is connected to various other pathways. While most studies focus on intracellular 
consequences of MAPK inhibition such as phophorylation of kinases or induction of apoptosis, it 
is also relevant to address further downstream events like influence on chemokine and growth 
factor secretion, or modulated surface expression of immunological relevant molecules like HLA 
class I or NK receptor ligands. Thus, the effects of MAPK signaling perturbation should be 
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evaluated in kinetics over different time periods, taking into account immediate signaling events, 
as well as long-term effects of treatment. 
With respect to the immune system, it has been reported that Sorafenib inhibits cytotoxicity and 
cytokine production of IL-2 treated and resting PBMC [39]. This is due to impaired NK cell 
reactivity, regulated directly through ERK and PI3K phosphorylation, which was inhibited with 
Sorafenib at pharmacological concentrations [40]. These studies implicate a connection between 
MAPK inhibition and immune recognition of tumor cells, an aspect which is investigated in detail 
in my thesis. 
I.1.4 Natural Killer cells and recognition of melanoma cells 
NK cells are a central component of the innate immune system, which acts as a first line of 
defense against pathogens or transformed cells. They are large granular lymphocytes, regulated 
by a big spectrum of activating and inhibitory receptors expressed on their surface. The existence 
of activating and inhibitory receptors implies that a delicate balance between these contradictory 
signals regulates NK cell effector function, i.e. cytotoxicity and cytokine/chemokine production. If 
a given target cell activates NK cell activity, they can induce apoptosis of target cells through 
release of cytotoxic molecules, perforin and granzyme a/b, or through triggering receptor 
mediated cell death pathways via Fas-ligand or tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL). Besides this natural cytotoxicity, NK cells can be activated by antibody-loaded 
target cells because CD16, the low affinity Fcγ receptor III, binds the Fc part of IgG-antibody 
complexes. Antibody-loaded target cells can then be eliminated through antibody-dependent 
cellular cytotoxicity (ADCC), which shows the tight connection between the innate (NK cells) and 
adaptive (IgG) immune system. NK cells can also modulate the immune response through the 
release of pro- and anti-inflammatory cytokines like IFN-γ, TNF-α, GM-CSF, IL-10, RANTES, 
MIP-1α and -1β, and chemokines CCL5, CCL3/4, CXCL9, CXCL10 and others. 
 
NK cell activity depends on a tightly regulated balance between activating and inhibitory signals. 
In contrast to antigen specific T cells, they do not need priming for effector function, but depend 
on ligation of their activating and inhibitory receptors through target cells. Inhibitory receptors bind 
mostly HLA class I molecules, independently from presented peptides. This inhibition accounts 
for a NK cell “tolerance” of HLA class I-positive “self” cells.  
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Figure I-4 - Activation of NK cells through missing self recognition. Expression of HLA class I on target cells, inhibits the 
cytotoxic potential of NK cells through ligation of inhibitory receptors. Reduced or lost HLA class I expression on target cells, 
activates NK cells through ligation of NKG2D or DNAM-1, which then lyse their target cells. The basis for this activation 
however, is the presence of ligands for activating receptors on the target cell side. 
 
This concept of NK cell regulation was postulated as the “missing self” hypothesis by Klas Kärre 
[41]. Recent years have shown that this hypothesis alone can not account for NK-cell-self-
tolerance: HLA class I molecules (chromosome 6p) and corresponding inhibitory NK-receptors 
(chromosome 19q13.4) are inherited indepent of each other. Theoretically this should lead to NK 
cells without an inhibitory receptor for self-MHC-molecules, but there are no known autoimmune 
diseases, founded exclusively on this NK cell phenotype [42]. This is why the “at least one” 
concept has been postulated, which tries to explain this phenomen through a selection process of 
NK clones taking place in the bone marrow. This selection allows only NK cells with at least one 
inhibitory receptor for missing self MHC molecules to differentiate and develop into the periphery. 
This selection process is not yet explained on a molecular level, and part of controversial 
discussion in the field. Three models are possible: (i) According to the “disarming” model, NK 
cells without an inhibitory receptor are actively shut down during development through a surplus 
of activating signals, and enter an anergic state [43]. (ii) Yokoyama described the “licensing” 
model, which requires interaction of an inhibitory receptor with self MHC molecules in order to 
aquire an activating signal for NK cell development, and to “license” the cell for function [44]. (iii) 
Vivier postulated the need of NK cell “education” in order to complete NK cell development. 
According to this model, NK cells only reach their full competence if they get a signal of an 
inhibitory receptor binding to a self-MHC-molecule, arguing that this step is required to switch on 
efficient activating signal pathways in the NK cell [45]. 
Besides inhibition of NK cells, mainly through MHC-class-I molecules, activating receptors play 
an important role in shifting this balance towards NK cell activity. Transformed or virus-infected 
cells can lose their MHC-class-I expression and additionally upregulate NK receptor ligands. The 
NKG2D receptor represents one of the most important activating receptors and recognizes eight 
ligands, MICA/B and ULBP1-6 [46-48]. The second activating NK cell receptor of interest for this 
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thesis is DNAM-1, which binds two ligands, CD155 (polio-virus resptor, PVR) and CD112 (Nectin-
1). Since the ligands of these two receptors have been shown to be modulated by MAPK 
inhibition, I will focus on these molecules in this thesis. 
 
The activating receptor NKG2D is a homodimer, which binds the MHC-class-I-like molecules 
ULBP1-6 and MICA/B. The receptor is expressed on all NK cells, as well as on CD8+ αβ+ and γδ+ 
T-cells. Although it acts as an autonomous activating receptor on NK cells, NKG2D seems to 
have rather costimulatory function on T cells. NKG2D is of special interest in the human system, 
on the one hand, becasue many tumors express NKG2D ligands; on the other hand, tumor-
derived soluble NKG2D ligands can be detected in serum of tumorpatients, which impairs NKG2D 
expression and function, associated with a worse prognosis [49, 50] 
 
The polio virus receptor (PVR, CD155) is a transmembrane glucoprotein, which is widely 
expressed on normal cells, and overexpressed on many tumors, including melanoma. It acts as a 
ligand for the DNAX accessory molecule-1 (DNAM-1) receptor, which is involved in NK and T cell 
activation [51]. It has been shown that tumor-associated NK cells suffer from an impaired effector 
function, because DNAM-1 receptor expression is lower than in peripheral NK cells. The modified 
DNAM-1 expression is possibly due to chronic ligand exposure through the tumor cells, and 
supports the notion that tumor-induced alterations of activating NK cell receptor expression may 
hamper immune surveillance and promote tumor progression [52]. In case of melanoma, DNAM-
1/CD155 interactions have been shown to be relevant for tumor recognition by NK cells [53]. 
 
We have previously shown that MAPK inhibition, in a concerted effort with DNA 
methyltransferases, can lead to the reconstitution of HLA class I and NKG2D ligand expression in 
colon cancer cell lines [24]. A careful comparison between colon cancer lines and melanoma 
lines revealed that the effects of MAPK inhibition on expression of HLA and NK ligands differ 
substantially between these tumor entities. 
I.2 Integration of MAPK signaling, autophagy and apoptosis 
Of note, the effects of MAPK perturbations can not only be judged by their ability to inhibit ERK or 
MEK phosphorylation respectively. Building on our experience from colon cancer cell lines and 
MAPK inhibitor treatment, we aimed to comprehensively analyze the effects of MAPK inhibition in 
melanoma cells on (I) cell signaling, including the PI3K/Akt pathway, effects on NFκB signaling, 
p53 signaling, and some transcription factors, (II) proliferation of tumor cell lines, (III) HLA class I 
and NK ligand surface molecule expression on tumor cells, (IV) chemokine and growth factor 
secretion and (V) balance between apoptosis and autophagy. 
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Figure I-5 - MAPK pathway perturbations are likely to affect whole cell signaling processes. Due to its multiple 
connections to other pathways, alterations in cell signaling and gene expression are presumably visible well beyond 
downstream ERK effects. Changes in gene expression of e.g. p53, NFkB and c-Jun affect the secretion of chemokines and 
growth factors, as well as the expression of surface molecules on the tumor cell. The PI3K pathway is directly connected to the 
regulation of autophagy via mTOR. It is not yet fully understood, if induction or inhibition of autophagy is beneficial for tumor cell 
progression. 
 
Cell signaling and susceptibility to MAPK inhibitors can vary between different tumor cell lines, 
and most observed effects depend on the time period of treatment. We therefore decided to 
undertake a comprehensive approach for the analysis of a core set of melanoma cell lines. The 
A-375 melanoma cell line is a well-established tumor cell line that harbours the V600EBRaf 
mutation. Three primary melanomy cell lines have been established in the lab of Dirk 
Schadendorf (University Hospital, Essen), and carry the rare G469RBRaf mutation. Since those 
three primary melanoma lines originate from the same melanoma patient, they represent an 
excellent model system due to their limited genetic heterogeneity. It has been of special interest 
to me, to elaborate differences between the MAPK inhibitors Sorafenib, AZD6244 and U0126, as 
well as between the different cell lines with respect to signaling, autophagy and immune 
recognition by NK cells. I have made use of phosphoplex analysis, to evaluate cell signaling, 
measured chemokines and growth factor secretion with the Bio-Plex method, and used FACS 
analysis to determine changes on HLA class I and other surface molecule expression on tumor 
cells, and test those effects in the context of NK cell recognition of tumor cells.  
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I.2.1 MAPK inhibition and the balance between apoptosis and 
autophagy 
Autophagy is an evolutionary well-conserved eukaryotic response to degrade portions of the 
cytosol and cytoplasmic organelles. This material is sequestered in unique organelles, called 
autophagosomes, which then fuse to lysosomes to form the autolysosome, which is then 
degraded together with its content by proteases. “Basal autophagy” is a homeostatic process and 
part of protein metabolism, which recycles long-lived proteins and organelles. “Induced 
autophagy” is a survival mechanism to produce amino acids under starvation conditions, degrade 
damaged mitochondria or even act as a bactericide defense mechanism [54]. 
 
Autophagy is a multi-step process, regulated on several different levels (compare Figure I-6). It 
starts with an isolation membrane, also called phagophore. It is likely derived from lipid bilayer, 
contributed by the endoplasmatic reticulum (ER) and/or the trans-Golgi and endosomes [55, 56]. 
The exact origin is not yet known, and the existence of a pre-autophagosomal structure (PAS) in 
mammalian cells, like it has been discovered in yeast, is still a matter of debate [57]. The 
phagophore enlarges to engulf intracellular cargo, sequestering it in a double-membraned 
autophagosome. Loaded autophagosomes then fuse with lysosomes to degrade the content by 
lysosomal acid proteases. Amino-acids and other by-products of degradation are then 
transported back to the cytosol, where they can be re-used for building macromolecules and for 
metabolism [58].  
 
 
Figure I-6 - Process of autophagy. A double-layer membrane, called phagophore or isolation membrane enlarges to engulf 
long-lived proteins or organelles in the cytosol. The so-called autophagosomes then fuse with lysosomes to form the 
autophagolysosome (autolysosome), wherein the content is degraded by lysosomal acid proteases. Taken from Mizushima: 
Autophagy – process and function [58]. 
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I.2.2 Autophagy quantification and monitoring 
In the year 2000 Kabeya et al demonstrated that rat microtubule-associated protein 1 light chain 3 
(LC3) is associated with the autophagosome membranes after processing. LC3 exists in two 
forms: LC3-I is cytosolic, but LC3-II is autophagosome-membrane bound, found on the inside and 
outside of autophagosomes [59]. The fusion of LC3 with green fluorescent protein (GFP) marked 
an important step in autophagy quantification at single-cell levels. It provides the possibility to 
detect autophagosomes based on GFP-LC3 fluorescence, which appears punctuated for LC3-II 
attached to autophagosomes, in contrast to an even distribution in its cytosolic LC3-I form.  
Yet, precise quantification of autophagy is still a major problem in autophagy research. Among 
many different approaches, none of them yet proved to be sufficient [60, 61]. Western blotting is 
used to monitor the conversion of LC3-I to LC3-II, but lacks specificity, measures only population 
averages and gives semi-quantitative data. In contrast, high-resolution fluorescence microscopy 
allows for the examination of single cell autophagic activity, but its analysis is prone to subjectivity 
and the amount of cells usually analyzed is limited (≤300). It can only provide a snapshot of 
autophagic activity in a group of cells, which can not account for the amount of heterogeneity 
observed in populations of cells. In order to understand and further analyze regulation of 
autophagy on a molecular level, a method to accurately quantify autophagic activity is needed. 
 
In addition to limitations of the methods that have been used thus far to measure autophagy, the 
number of autophagosomes in fully functional autophagy can not be used as a good measure to 
evaluate autophagy. That is because the formation of autophagosomes is followed by the 
degradation step, during which autophagosomes fuse to lysosomes and become degraded. Cell 
images can only provide a snapshot of the current number of autophagosomes, from which it is 
impossible to infer how many autophagosomes have just been formed and degraded. These 
normal physiological conditions of fully functional baseline autophagy have therefore been termed 
“steady-state” conditions. A cell with increased numbers of autophagosomes under steady-state 
conditions can on the one hand undergo induced autophagy with an enhanced rate of 
autophagosome formation, and the image has been taken before their degradation. On the other 
hand, autophagosome degradation might be dysregulated, which also leads to an accumulation 
of autophagosomes, even though the cell undergoes only “basal autophagy”. Accordingly, in 
GFP-LC3 expressing cells, a population of cells undergoing basal autophagy will comprise 
images with dotted cells (depicting autophagosomes), as well as images with homogeneous GFP 
expression in the cytosol (Figure I-7). 
A possible solution to this problem is the use of lysosomal inhibitors. Bafilomycin A1 inhibits the 
fusion of autophagosomes and lysosomes and therefore artificially blocks degradation of 
autophagosomes. In addition, it reduces the quenching of acid-sensitive GFP-fluorescence, which 
otherwise occurs prior to the full degradation of autolysosomes. Conditions of lysosomal inhibiton 
have been termed “cumulative conditions”, because they lead to an accumulation of 
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autophagosomes. Accumulation of autophagosomes under cumulative conditions however will 
take place under “basal autophagy” as well as “induced autophagy”, only at different rates (Figure 
I-7). The comparison of steady-state conditions and cumulative conditions provides a good 
measure of true autophagic turnover, termed “autophagic flux”.  
The problems with autophagic turnover, and the need for true autophagic flux measurements are 
evident in autophagy research, still, many studies are still carried out under steady-state 
conditions only, which is probably a main cause of contradiciting and confusing reports on the 
regulation of autophagy [60, 61]. 
 
 
 
Figure I-7 - Autophagic flux measurements are necessary to determine autophagic turnover. Under steady-state 
conditions, the amount of autophagosomes is not a precise measurement of autophagic activity. Formed autophagosomes are 
immediately degraded upon fusion with lysosomes. Under “cumulative conditions”, lysosomal inhibitors like Bafilomycin A1 are 
used to block degradation of autophagosomes, leading to an accumulation of autophagosomes. Comparison of “steady-state” 
and “cumulative conditions” is necessary for the accurate assessment of autophagic activity.  
 
I.2.3 Regulation of autophagy 
Research over the past decade showed that regulation of autophagy is very complex. A proven 
central player in autophagy regulation is the mammalian target of rapamycin (mTOR). Amino acid 
and insulin/growth factor signaling seems to converge on mTOR, acting as a master regulator of 
nutrient signaling. mTOR is activated downstream of Akt, PI3K and growth factor receptor. When 
nutrients are available, this pathway signals to (I) promote growth through induction of ribosomal 
protein expression and increased protein translation and (II) to inhibit autophagy, even though it is 
not yet clear how this is carried out. Treatment with rapamycin effectively inhibits mTOR and 
promotes autophagic acitivity. Prior to the formation of the phagophore, the family of autophagy-
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related genes (Atg family) is involved. Atg’s have been discovered mainly in yeast, but the 
respective homologues have also been found in mammalian cells. Beclin-1 (Atg-6) is an essential 
protein for autophagy, it forms a complex with Vps34 (PI3K family), to control the formation of the 
phagophore, and in addition, it is also connected to the anti-apoptotic Bcl-2. Upon binding to Bcl-
2, Beclin-1 is inactivated, which leads to inhibited autophagy [62]. Bcl-2 is just one of many 
examples for proteins with defined roles in regulation of apoptosis, which have now been shown 
to be involved in regulation of autophagy too. Nutrient deprivation and death receptor activation 
can both positively and negatively regulate autophagy through dynamic interactions of not only 
anti-apoptotic Bcl-2 members, but also pro-apoptotic BH3-only proteins, JNK signaling, p53 and 
NFkB pathways. The dual role of the involved proteins caused much debate in recent years: 
Bcl-2 may directly [63] or indirectly [64, 65] suppress Beclin 1–mediated formation of 
autophagosomes. BH3-only proteins, sensors of cellular stress, are implicated in either the 
enhancement or activation of autophagy, presumably through the disruption of the Bcl-2:Beclin 1 
complex [66], via LC3 binding. JNK activation of autophagy in response to starvation [67] and 
ceramide addition [68] may involve inhibition of Bcl-2 via phosphorylation. Finally, the pro-survival 
IKK pathway can either inhibit so-called autophagic cell death (described as programmed cell 
death type II) [69, 70], increase autophagosome formation via NFκB signaling [71], or activate 
autophagy independent of NFκB [72]. In addition to its functions in regulation of cell-cycle 
progression and induction of apoptosis, p53 has been shown to inhibit autophagy if it is located in 
the cytosol [73, 74]. 
Recently autophagy has also been connected to cancer development and progression: It can be 
stimulated by the tumor suppressors PTEN, TSC1 and TSC2 [75]. It was also shown to be 
inhibited by proto-oncogenes PI3K and Akt [75]. There is proof that defects in autophagy can lead 
to tumor development and the controversial view of autophagy as a cell death mechanism has 
also been supportive of a tumor-suppressing role of this pathway. A more plausible explanation 
for the tumor-suppressive function of autophagy can probably be dervived from its role as a 
selective degradation pathway [76]. Yet, just like other cells in the body, tumor cells can depend 
on autophagy to survive starvation and stress. So autophagy is a double-edged sword in cancer 
development and it is unclear whether it should be inhibited or induced as part of therapeutic 
strategies.  
 
Autophagy is very likely to be affected by MAPK inhibition, not only due to oncogenic Ras 
signaling in tumor cells. Recently, hyperactivation of oncogenic BRaf (above “normal” oncogenic 
BRaf levels) was shown to induce growth inhibition and cell death by inducing autophagy, 
presumably through the inhibition of mTOR. The authors speculate, that the induction of 
autophagy might play a role in melanoma progression [77]. Contradictionary to this report, it has 
previously been shown, that high constitutive ERK phosphorylation found in many cancers, 
disrupts the maturation of autophagosomes and therefore may provide a malignant advantage, by 
impeding the tumor suppressive function of autophagy.  
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Many reports on autophagy regulation are contradicting each other. Autophagy is a vivid field of 
research and under heavy debate, yet a lot of ongoing discussion presumably stems from both, 
inaccurate measurements of autophagic activity, and from cell to cell variability which is not 
captured with population-average analyses, like Western Blot and FACS. Another reason for 
contradictory findings may be due to the assumption that autophagy regulation follows the same 
principles in each cell – from yeast to human tumor cells. Lessons from apoptosis and oncogenic 
MAPK signaling strongly suggest that the principles of cell survival, death and proliferation are 
significantly altered in tumor cells in particular, due to their oncogenic signaling status. These 
alterations may be specific for tumor entities as well as for the driver mutations that are 
responsible for their unlimited proliferative capacity. Since the role of autophagy in MAPK-driven 
tumor cells in not yet solved, one of the central aspects of my thesis was to establish a new 
method for the quantification of autophagy in the first place. Basing on this method, 
consequences of MAPK inhibiton could be addressed in detail.  
I.2.4 ImageStream-based method for the quantification of 
autophagy and apoptosis 
The ImageStream system is basically an imaging flow cytometer [78]. It integrates the features of 
flow cytometry and fluorosecence microscopy, allowing for the analysis of large numbers of cells, 
based on their fluorescent features, and providing the statistical power and analysis known from 
FACS. Additionally, the ImageStream allows the image analysis known from fluorescence 
microscopy for every measured single cell. This adds a new dimension of information to 
population analysis of cells. Simply stated, it combines the statistical power of FACS with the 
sophisticated analysis of high-resolution fluorescence microscopy, and uses advanced image 
analysis tools to extract single cell information for population level analysis. 
We wanted to make use of the ImageStream to establish a new method to monitor autophagy, 
and to counter the previously described problems of autophagy research. The challenge was to 
quantitatively measure and analyze phenotypic responses within a defined population of cells. I 
established the method with stably-transfected MCF7 GFP-LC3 breast cancer cells derived from 
a single colony, i.e. with a minimized genetic variability. MCF7 GFP-LC3 cells are commonly used 
in autophagy research and were therefore selected in the first place, to allow comparison of the 
ImageStream with commonly used methods. For each cell, the number of GFP-spots, 
representing autophagosomes, can be counted. Subpopulations with different autophagosome 
numbers (spots) were systematically identified for each condition. Primary flux metrics were 
derived from differences between measurements under “steady-state conditions” (w/o 
Bafilomycin A1), and “cumulative conditions” (in the presence of the lyososmal inhibitor 
Bafilomycin A1). Secondary multi-parametric flux metrics were calculated within each 
subpopulation to further characterize autophagic responses at the single cell level. These metrics 
could then be applied, to further evaluate the regulation of autophagy in MCF7 GFP-LC3 cells, 
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and the impact of MAPK inhibition on melanoma cells using stably-transfected A-375 GFP-LC3 
cells. We have combined our new method for autophagy quantification with an established 
ImageStream-based approach for quantification of apoptosis. Our method of simultaneous 
quantification of apoptosis and autophagy was used as a new powerful approach for the analysis 
of MAPK inhibition and its impact on the balance between apoptosis and autophagy. 
Aim of the thesis 
 
26 
Aim of the thesis 
The general aim of this thesis was to improve the current understanding of the impact of MAPK 
inhibition in melanoma cells, regarding recognition by natural killer cells, signaling via other 
pathways and induction of apoptosis and autophagy, respectively. 
 
In previous studies, our group has shown that inhibition of MAPK signaling in colon cancer cells 
altered the expression of several surface molecules relevant for T and NK cell recognition [24]. 
Although the MAPK pathway also represents an important pathway in melanoma, consequences 
of this oncogenic signaling differ substantially between different tumor entities. A set of well-
characterized cell lines, comprising the established A-375 melanoma cells with the V600EBRaf 
mutation and three primary melanoma lines from one patient carrying the G469RBRaf mutation, 
was used to determine the surface expression of HLA class I molecules and NK receptor ligands, 
and their respective modulation during treatment with a BRaf and two MEK-inhibitors. Among the 
different human ligand-receptor pairs, I focused on the ligands for the two most relevant activating 
receptors in the context of melanoma, NKG2D and DNAM-1. The functional consequences of a 
possible modulation of these surface molecules should be investigated with respect to recognition 
and lysis by NK cells. Furthermore, the effects of these inhibitors on the secretion of chemokines 
and growth factors by these melanoma cell lines should be determined in order to argue for 
alterations in the microenvironment.  
Using the novel phosphoplex technique, another aim was to investigate the effects of MAPK 
inhibition not only on the linear MAPK pathway, but also on various other interconnected 
pathways. Our panel included components of the PI3K, JNK and NFκB pathways. Tight kinetics 
were chosen for this pathway analysis, in order to demonstrate the importance of the dimension 
“time” for the regulation of cell signaling. The time-resolved analyses should help to improve our 
understanding of the impact on cell fate decisions like induction of apoptosis or autophagy.  
Since the regulation of apoptosis and autophagy is still controversially discussed in the literature, 
one of the most important aims of this thesis was to establish a novel technology for the 
simultaneous detection of these two processes at the single cell level. For this purpose, the novel 
ImageStream technology should be tested for its suitability to quantify apoptosis and autophagy, 
and to address the important question whether tumor cells possess a delicate balance between 
autophagy and apoptosis, and whether this balance can be modulated by MAPK inhibition. 
 
In the current literature, the rather simplistic view of identical effects of inhibitors within one 
“linear” pathway dominates the discussion – but for the long road to “individualized” therapy, 
detailed analyses of “side effects” will be necessary to improve future therapeutic approaches.  
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M. Materials and Methods 
M.1 Materials 
M.1.1 Cell culture 
DMEM was purchased from Sigma-Aldrich. RPMI 1640, FBS, L-glutamine, sodium-pyruvate and 
non-essential amino acids (NEAA) were purchased from Invitrogen. Cell lines have been tested 
for mycoplasma contaminations at least once a month. In case of mycoplasma contamination, 
cell lines were treated with Myco-3 (Calbiochem) for three weeks, and tested again. 
 
To isolate NK cells from peripheral blood of healthy donors, we used the NK cell negative 
isolation kits from Invitrogen. NK92 cells are human NK-leukemia cells that were originally 
derived by T. Tonn (Transfusion Medicine, DRK Frankfurt) and represent the most potent 
cytotoxic natural killer cell line. 
 
Cell medium Composition
TM RPMI 1640, 10% FBS, 2mM L-Glutamin, 1mM Na-Pyruvat, 1x NEAA 
RPMI III RPMI 1640, 2mM L-Glutamin, 1mM Na-Pyruvat, 1x NEAA 
DMEM DMEM, 10% FBS, 2mM L-Glutamin, 1mM Na-Pyruvat, 1x NEAA 
primary NK cell medium RPMI III, 500U IL-2/ml 
NK92 medium 
RPMI 1640, 5% T cell growth factor (AG Falk), 15% FBS, 10% human serum, 200 
U IL-2/ml 
MCF7 GFP-LC3 selection medium DMEM, 1mg/ml G418 
A-375 GFP-LC3 selection medium TM, 0,5mg/ml G418 
 
Name Origin Medium Source 
Ma-Mel-48a 
human primary melanoma line, patient ma-mel-48, 
established July 2002 from skin lesion 
TM D. Schadendorf 
Ma-Mel-48b 
human primary melanoma line, patient ma-mel-48, 
established January 2003 from lymph node metastasis 
TM D. Schadendorf 
Ma-Mel-48c 
human primary melanoma line, patient ma-mel-48, 
established July 2003 from lymph node metastasis, 
β2m-mutation, therefore HLA class I negative 
TM D. Schadendorf 
Ma-Mel-48c GFP LC3 Ma-Mel-48c, stably transfected with GFP-LC3 vector 
TM 0,25µg/ml 
Puromycin 
N.R. Brady/ 
Bartenschlager 
A-375 human malignant melanoma, skin-derived TM ATCC 
A-375 GFP-LC3 
A-375 GFP-LC3 cells, stably transfected with GFP-LC3 
vector 
TM 0,5mg/ml 
G418 
N.R. Brady 
MCF7 GFP-LC3 human, breast cancer cell line, Caspase-3 deficient 
DMEM 1mg/ml 
G418 
N.R. Brady 
K-562 human erythroleukemia line, HLA class I negative TM D. Schendel 
NK92 human NK cell leukemia line  NK92 medium M. Uhrberg 
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Name HLA/β2m NRas BRaf PTEN p53 p16/Arf 
Ma-Mel-48a HLA-A1, B8, Cw7 wt G469R wt wt wt 
Ma-Mel-48b* HLA-A1, B8, Cw7 wt G469R wt wt wt 
Ma-Mel-48c* HLA class I negative, β2m mutation wt G469R wt wt wt 
A-375 Cw06 (K80), Cw16 (N80)  V600E  wt  
MCF-7 GFP-LC3 HLA-A2, B18/44, Cw05   wt wt  
HLA-typing, and mutational status of selected cell lines. 
 
M.1.2 Antibodies 
Antigen Conjugation Isotype Clone Concentration Source
isotype control - IgG1 MOPC21  5 µg/ml Sigma 
isotype control - IgG2a UPC10  5 µg/ml Sigma 
isotype control - IgM MOPC104E  5 µg/ml Sigma 
HLA-Klasse-I - IgG2a W6/32 hybridoma supernatant J.Johnson 
HLA-A2 + B17 - IgG1 HB54 hybridoma supernatant ATCC 
HLA-A2 + A69 - IgG2b HB117 hybridoma supernatant ATCC 
HLA-A1 - IgM  20:1 BMT 
ULBP1 - IgG2a 170818 5 µg/ml  R&D  
ULBP2 - IgG2a 165903 5 µg/ml R&D  
ULBP3 - IgG2a JFY02 5 µg/ml R&D  
ULBP4 - IgG2a 7H7, Ratte hybridoma supernatant E.Kremmer 
MICA - IgG2b 159227 5 µg/ml R&D  
MICB - IgG2b 236511 5 µg/ml R&D  
ICAM-1 - IgG2a  hybridoma supernatant J.Johnson 
CD155 - IgG1 PV.404 5 µg/ml BC 
HLA-E - Rat IgG2 4D1 hybridoma supernatant E. Kremmer 
isotype control FITC IgG2b MOPC19 2 µl BD 
isotype control PE IgG2a 7T4-1F5 2 µl BC  
isotype control PerCP IgG2a X39 2 µl BD 
isotype control APC IgG2a X39 2 µl BD 
CD3 FITC IgG1 UCHT1 2 µl BC 
CD4 APC IgG1 13B8.2 2 µl BC 
CD8 PE IgG1 B9.11 2 µl BC 
CD14 FITC IgG1 M5E2 2 µl BD 
CD16 FITC, Pacific Blue IgG1 3G8 2 µl BC 
CD25 FITC IgG2a B1.49.9 2 µl BC 
CD44 FITC IgG1 37.51.1 2 µl BC 
CD56 APC, PE,  IgG1 NKH-1 2 µl BC 
CD107a FITC, PE IgG1 H4A3 10µl BD 
NKG2D  PE IgG1 149810 2µl R&D 
Primary antibodies used for direct or indirect flow cytometry. BD: Beckton Dickinson, BC: Beckman Coulter 
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Antigen Conjugation Species Concentration Source 
Maus-IgG PE goat 1:100 Jackson ImmunoResearch 
Maus-IgG/M PE, FITC goat 1:100 Jackson ImmunoResearch 
Secondary antibodies for flow cytometry 
 
Antigen Conjugation Clone Isotype Source 
Mouse anti-human p53  - DO-1 IgG2a Invitrogen 
Mouse anti-human β-actin - B11V08  Promokine 
Goat anti-mouse IgG Peroxidase   Jackson ImmunoResearch 
Antibodies used in Western blot analysis 
M.1.3 Buffers, chemicals, reagents, special machines 
Western Blot Components, Source
Cell lysis kit + protease inhibitors Bio-Rad 
Gel electrophoresis running buffer NuPage MOPS SDS running buffer 20x NP0001 
10x transfer buffer  120 mM Tris base, 960 mM glycine 
1x transfer buffer  10% 10x transfer buffer, 20% methanol, 70% water 
6x Laemmli buffer  
150 mM Tris-HCl, pH 6.8, 6% SDS, 30% glycerine, 0.15% 
bromphenolblue, 0.3 M DTT 
blocking buffer  
PBS, 0.1% Tween 20, 5% nonfat dried milk, AppliChem 
A0830 
wash buffer PBS, 0.05% Tween 20 
first Ab dilution buffer  PBS, 5% BSA fraction V, 0.2% Tween 20 
second Ab dilution buffer  PBS, 2.5% nonfat dried milk, 0.1% Tween 20 
Precision Plus Protein Standards All Blue  Bio-Rad 161-0373 
Super Signal West Dura Extended Duration Substrate Thermo Scientific 34075 
 
Cytokine multi-plex measurements Source 
Reagent Kit A (wash buffer, assay buffer, detection antibody diluents) Bio-Rad 
human cytokine tests: 
M-CSF, MIF, SCGF-b, SDF-1a (CXCL12), HGF, ICAM-1, IL-8 (CXCL8), VEGF 
Bio-Rad 
96-well filter plates Millipore 
 
Phosphoprotein multi-plex measurements Source 
Cell lysis kit + protease inhibitors Bio-Rad 
PMSF (Phenylmethylsulfonfluorid) Sigma 
phosphoprotein reagent kit Bio-Rad 
96-well filter plates Millipore 
total-protein tests: 
Akt, p53, IκB-α, ATF-2, c-Jun, ERK1/2, JNK, MEK1, p38 MAPK, CREB Bio-Rad 
phospho protein tests: 
Akt (Ser473), GSK-3α/β (Ser21/Ser9), p53 (Ser15), IκB-α (Ser32/Ser36), NF-κB p65 (Ser536), ATF-2 
(Thr71), c-Jun (Ser63), ERK1/2 (Thr202/Tyr204, Thr185/Tyr187), JNK (Thr183/Tyr185), MEK1 
(Ser217/Ser221), p38 MAPK (Thr180/Tyr182), CREB (Ser133) 
Bio-Rad 
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MAPK Inhibitors Source 
DMSO (solvent) Sigma 
U0126, MEK inhibitor Promega 
AZD6244 Lab D. Schadendorf 
Sorafenib (Nexavar, BAY 43-9006) Bayer 
 
Autophagy tools and pathway perturbation Source 
Earles balanced salt solution (EBSS) Invitrogen/Gibco 
Krebs-Henseleit solution Sigma 
Bafilomycin A1 Calbiochem 
Puromycin Sigma 
G418 Sigma 
SP600125 (JNK inhibitor, 50µM) Calbiochem 
QNZ (NFkB inhibitor, 10µM) Calbiochem 
HA14-1 (Bcl-2 inhibitor, 50µM) Calbiochem 
TNF-a (43ng/ml) Calbiochem 
 
Special machines Source 
xCELLigence system Roche Diagnostics 
Luminex/Bioplex system Bio-Rad 
ImageStream System Amnis corporation 
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M.2 Methods 
M.2.1 Cell culture 
All cells were grown at 37°C with 5% CO2 under sterile conditions. Adherent tumor cells were split 
every two to three days, cell culture flasks were changed at least once a week. In general, cells 
were frozen in 50% FBS/RPMI III / 10% DMSO at -80°C. Prior to use, FBS was inactivated by 
incubation at 56°C for 45 minutes.  
 
NK cell isolation 
We isolated NK cells from peripheral blood mononuclear lymphocytes (PBMC) using the 
magnetic Dyna-bead untouched human NK cells kit from Invitrogen/Dynal. In principle a mixture 
of biotinylated monoclonal antibodies against the non-NK cells is added to PBMC. During a short 
incubation time, depletion MyOne SA Dynabeads bind the non-NK cells. The bead-bound cells 
are then separated from NK cells with a magnet. Bead-bound cells are discarded, and the 
remaining untouched NK cells used. Purity of the NK cell fraction was checked by FACS with 
CD3 and CD56 stainings. 
 
Tumor cell treatment with MAPK inhibitors 
More then 60% of malignant melanomas carry activating mutations in the MAPK pathway, leading 
to uncontrolled proliferation. Therefore MAPK signaling in melanoma cell lines was inhibited using 
small molecule inhibitors, in order to study their effects on various signaling pathways, surface 
molecule expression and immune recognition by T and NK cells. 
U0126 is a MEK inhibitor, which binds the MAPK-kinase MEK1/2, inhibiting its catalytic activity 
and therefore activation of downstream kinases ERK1/2. It is solved in DMSO (stock solution, 
10mM), and used at a final concentration of 10µM. Sorafenib (Nexavar, BAY 43-9006) inhibits 
Raf-1, B-Raf and other receptor tyrosine kinases (e.g. VEGFR-2,3; PDFR-b, Flt-3 and c-KIT) [79] 
which also leads to inhibition of MEK/ERK signaling. One pill of Sorafenib was solved in 31,4ml 
DMSO (stock solution, 10mM) and used at a final concentration of 5µM. AZD6244 (Selumetinib, 
ARRY-142886) is a selective, non-ATP competitive inhibitor of MEK1/2 [80], solved in DMSO 
(stock solution, 10mM), and used at a final concentration of 3µM.  
To capture short-term as well as long-term effects of MAPK inhibition, the following timepoints 
were chosen for analysis: 30min, 6h, 12h, 24h, 48h, 72h and 96h. For Luminex and FACS 
analysis, 0,1x106 cells per sample were seeded in 6-well plates, one 6-well plate for each 
timepoint. Cells were seeded the day before treatment and allowed to adhere and grow over 
night. For treatment with MAPK inhibitors, the medium was discarded and cells washed with 2ml 
PBS per well, then the drug-containing medium was added. Since most of the inhibitors are not 
stable at 37°C, medium was changed after 48 hours of treatment. Cell culture medium 
supernatants were harvested for the detection of chemokines and growth-factors. For flow 
Materials and Methods 
 
32 
cytometry evalutation, cells were detached after their respective incubation time using Accutase 
(PAA, Germany). For phosphoplex and Western Blot analysis, we lysed the cells using the cell 
lysis kit for phosphoprotein detection from Bio-Rad, Germany.  
 
Flow cytometry (FACS) 
We used flow cytometry analysis to characterize melanoma cell lines surface expression of 
ligands of T and NK cells. In addition, subpopulations of cells within PBMC were defined as 
effector cells. HLA class I expression, CD155 expression and various other markers were used in 
indirect staining FACS assays to identify changes in surface expression following exposition to 
MAPK inhibitors. For cytotoxicity assays with NK cells, it was necessary to define the NK cell 
population, and other subpopulations within PBMC for specific analysis. CD107a staining, was 
used as marker for detection of degranulating effector cells following contact with target cells. 
Measurements were performed with BD FACSCalibur or BD LSR II and analyzed using the BD 
CellQuest software and BD FACS Diva software respectively. 
 
Indirect staining protocol with secondary antibodies 
At least 10000 cells per well in 96-well plates were resuspended in 50µl FACS-buffer. 50µl of 
primary antibody (hybridoma supernatant) was then added (5µg/ml) to the cell suspension, and 
incubated on ice for 45 minutes. Following a washing step with FACS-buffer, secondary anti-
mouse goat PE antibody was added in 50µl FACS-buffer. After a further incubation period of 20 
minutes on ice, cells were washed in FACS-buffer and measured immediately, or fixed with 1% 
PFA/PBS. Isotope control monoclonal antibodies were used to determine nonspecific background 
staining. 
 
Direct staining of cells and FACS analysis 
Direct antibody staining was performed in 96-well u-bottom plates. At least 50000 cells per 
sample were resuspended in 50µl FACS-Buffer, and respective antibodies in different 
combinations were added. After incubation on ice and in the dark for 45 minutes, cells were 
washed with 150µl FACS-buffer, and if necessary, cells were fixed using 1% PFA/PBS. Isotope 
controls for each color were used to determine background staining.  
 
CD107a Degranulation Assay 
If NK cells and T cells recognize their specific target cells, they release cytotoxic granules into the 
immunological synapse, in order to induce programmed cell death in target cells. With the fusion 
of lysosomes to the cell membrane, lysosomal-associated protein-1 (LAMP-1, CD107a), which is 
associated with the granula membrane, becomes transiently detectable at the cell surface of 
activated NK cells and T cells [81]. During co-incubation of NK cells and/or T cells with target 
cells, specific antibodies were used to detect CD107a expressing effector cells as a marker for 
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target cell-induced cytolytic activity. This marks effector cells which have released granula in 
order to kill their taget cells.  
Isolated NK cells from PBMC were stimulated for 24h with 500U IL-2. In 96-well plates target and 
effector cells were mixed in a 1:1 ratio in 200µl medium, and 10µl CD107a antibody (PE-labeled) 
per well was immediately added. After 1h of incubation, Monensin was added (2mM, BD 
Bioscience) to minimize the internalization of CD107a during incubation. Monensin prevents the 
acidification of endocytic vesicles, thus avoiding the degradation of reinternalized CD107a 
proteins from the surface, and allowing for the visualization of this marker following stimulation 
[81]. 3h later, after a washing step, further antibody staining was used to characterize the effector 
cell population, with e.g. DNAM-1 FITC, CD3 PerCP, CD56 APC and CD16 Pacific blue, as 
described previously.  
M.2.2 Protein biochemistry 
SDS-Polyacrylamid gel-electrophoresis (SDS/PAGE) 
We denaturated the samples in Laemmli buffer, and put them on ice after boiling them for 5 
minutes at 95°C. Next, we separated the samples on NuPage gels, running at 150V constant for 
50-90 minutes in 1x MOPS buffer. 
 
Western Blot 
After SDS/PAGE proteins were transferred to a polyvinylidene difluoride (PVDF) membrane for 
90 minutes at 200mA in Western Blot transfer buffer. Prior to use, the PVDF membrane was 
activated in methanol and washed in transfer buffer. After blotting, we placed the membrane in 
blocking buffer for 2h at RT or over night at 4°C. Primary antibody was then added and incubated 
over night at 4°C. After rinsing the membrane in wash buffer, we incubated the blot with 
horseradish peroxidase (HRP)-conjugated secondary antibody for 1 hour at RT, and following a 
washing step, we developed the blot in SuperSignal Substrate Working Solution for 
approximately 5 min. 
 
M.2.3 ImageStream system 
The ImageStream Multispectral Imaging Cytometer combines the advantages of high-resolution 
microscopy and flow cytometry in one system (www.amnis.com). It is a flow-based system like 
FACS, but collects multisprectral fluorescence images of every collected cell [82, 83]. I used it to 
establish a solid monitoring technique of autophagic activity, and to further elucidate the complex 
regulation of autophagy. In principal, cells labeled with 405, 488 or 658nm excitable 
fluorochromes are hydrodynamically focused, excited with laser light and imaged on a time dealy 
integration (TDI) CCD camera (Figure M-1). Light passes through a spectral decomposition 
element that directs different spectral bands to spatially distinct channels on the TDI CCD 
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detector. A single cell image is optically decomposed into a set of sub-images, each 
corresponding to a different color component.  
 
 
Figure M-1 - Operation principle of the ImageStream (www.amnis.com) 
 
 
Quantification of apoptosis 
Experimental procedure and analysis 
The method of detecting apoptotic cells has previously been established [84]. We have 
established the quantification of apoptosis in A-375 wild-type cells. Cells were seeded in 6-well 
plates to ~90% confluency and treated with DMSO (solvent control) and high-dose Sorafenib 
(20µM) for 24 hours. After detaching the cells with Accutase, cells were fixed in 1,5% PFA for 
10min at RT, and permeabilized in 0,1% Saponin/PBS. DNA was then stained with Hoechst, and 
afterwards washed and imaged with the ImageStream. The identification of apoptotic cells relies 
on detection of fragmented DNA in apoptotic cells. This is quantified using the two features (I) 
“Bright detail intensity threshold” to quantify nuclear fragmentation and (II) “area threshold” to 
quantify nuclear condensation. We have imaged 10000 cells per sample. This method was 
applied to quantify apoptosis in A-375 GFP-LC3 cells in response to MAPK inhibition. 
  
  Materials and Methods 
 
  35 
Quantification of autophagy 
 
Experimental procedure 
The ImageStream System was applied to establish a new method for the monitoring of 
autophagy. For sample preparation, stable GFP-LC3-expressing cells were seeded in 6-well 
plates and grown to 90% confluency. Following a wash step with PBS, the cells were incubated in 
EBSS and drug cocktail, with or without lysosomal inhibitor Bafilomycin A1 (100 nM). Following a 
3h treatment period, cells were detached using 2% Trypsin/EDTA, then diluted in ice-cold PBS, 
and fixed in 4% paraformaldehyde (PFA) for 20 minutes at 37°C. For ImageStream 
measurements, cells were then resuspended in 50µl PBS. 
 
Analysis principle 
Side scatter, bright-field and GFP fluorescence were collected. For all image analysis and 
classification steps, the Amnis Software IDEAS© 3.0.233 was used, which contains a large 
amount of features and masks for combinatorial analyses. To discriminate single cells from cell 
aggregates and cells out of focus, a dot plot of the features “aspect ratio” versus “area” was 
created. Aspect ratio is the minor axis divided by the major axis, and therefore describes the 
extent to which an object is round or oblong. The area feature is equal to the number of square 
microns within a mask. The dot plot clearly separates a single cell population from cell 
aggregates that are either too large or too elongated to be included in the single cell gate (Figure 
M-2, A). 
 
 
Figure M-2 - ImageStream workflow. A Gate on single cells, using the object features area and aspect ratio. Using the single 
cell population, cells in focus were determined with the gradient RMS and contrast features to filter out cells out of focus. B Cells 
in focus analyzed for autophagosomal content. Based on the number of detected spots we created populations of low (0-4 
spots), medium (5-12 spots) and high (more than 12 spots) autophagic activity. 
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The contrast feature and the gradient RMS calculation were then used to determine the focus 
quality of images in the single cell population. The contrast feature measures the image 
sharpness by detecting large changes in pixel values. For every pixel the slopes of the pixel 
intensities are computed from the surrounding 3x3 pixel block. The Gradient RMS feature was 
computed using the average gradient of a pixel normalized for variations in intensity levels. This 
is similar to the contrast calculation with differently weighted assignments to the pixel arrays. The 
combination of gradient RMS and contrast allowed the detection of cells in focus (Figure M-2, A) 
[78].  
The population of “cells in focus” was analyzed to measure autophagic activity, which can be 
determined because LC3-II binds to the membrane of autophagosomes. Once LC3 is fused to 
GFP and stably expressed, autophagosomes become visible as GFP-labeled spots. The ‘spot 
mask’ feature was used to determine spots and the ‘count’ feature utilized to measure the number 
of spots, i.e. individual and clustered GFP-labeled autophagosomes. After manual inspection of 
more than 100 cells, the spot to background ratio was set to 6 and the radius of spots to 2, to 
achieve comparable results between manual inspection and automated analysis. Depending on 
autophagosomal content three states of autophagic activity were defined: Low, (0-4 spots, I) 
medium (5-12 spots, II) and high (more than 12 spots, III). An example subpopulation distribution 
for spot count measurements is shown in Figure M-2B. 
 
Compared to high resolution fluorescence microscopy the resolution of the ImageStream system 
is still low. Sometimes, clusters of autophagosomes were observed, that count as just a single 
spot. To overcome this misinterpretation, the differences between autophagosome clusters and 
single autophagosomes were incorporated into our analysis: Clusters of autophagosomes are 
bigger than single autophagosomes, and the GFP intensity in autophagosome clusters is higher 
compared to single autophagosomes. Therefore, secondary metrics were added, to take into 
account the area of spots within a cell as well as the intensity of spots compared to the total GFP 
intensitiy of a cell. I called those secondary metrics “normalized area” and “normalized intensity”. 
For the calculation of both - normalized area and normalized intensity a tight object mask on the 
bright field pictures was used to determine the extent of the whole cell. For normalized area the 
area of this tight object mask was calculated, as well as the total area of all spots within this cell. 
Normalized area then calculates as the ratio of area of spots and area of the object. For 
normalized intensity the ratio of intensity of spots divided by the intensity of the whole cell was 
calculated (determined as mean fluorescence GFP intensitiy of the object mask). Clusters of 
spots show higher normalized area and normalized intensity values compared to single spots. 
Importantly, there was a positive correlation between normalized area and spot count, indicating 
the validity of our metrics (Figure M-2, B). 
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M.2.4 Luminex-based multiplex system 
The Luminex/Bioplex technique 
The Luminex/Bioplex system allows for the simultaneous detection of several proteins, like 
cytokines, chemokines or kinases in cell culture supernatants or cell lysates respectively. This 
method uses a panel of up to 100 fluorescence-labeled-beads, which can be differentiated from 
another due to their color by the Luminex machine (Figure M-3, A). The bead sets are colored in 
different ratios of red dye and infrared dye. 10 different levels of fluorescence intensity for each 
dye creates a panel of 100 beads which can be distinguished from another by the classifier laser. 
This bead set allows the simultaneous detection of different proteins within one sample: 
Differently colored beads are specific for different proteins because of their coating with specific 
antibodies. Each bead carries thousands of capture antibodies for one specific protein. 
Quantification of the protein of interest occurs by the addition of a second biotinylated specific 
antibody, which binds to another epitope of the protein, and thus addition of SAPE enables 
quantificiation according to fluorescence intensity (Figure M-3 C). The Luminex reader is 
equipped with two lasers, a classification laser (635nm) which excites the beads and allocates 
them into specific regions, and a reporter laser (532nm) which excites the molecular tags, i.e. PE. 
The amount of fluorescent intensity (reporter laser) is proportional to the amount of the captured 
molecule. With default settings, the system is calibrated to analyze 25-100 beads for each region, 
and reports the median fluorescence intensity of these beads. 
 
 
Figure M-3 – the Luminex technique. A The bead set is internally dyed with combinations of two spectrally different 
fluorophores. 10 different levels of fluorescence intensity for each fluorophore create a panel of 100 distinguishable beads. B 
Thousands of capture antibodies are bound to each bead; different beads carry different capture antibodies. C bead-bound 
antibodies collect proteins in the sample; reporter biotinylated secondary antibodies bind to sample molecules. D The 
classification laser excites the beads, fluorescence of the beads identifies the region (E). The reporter laser excites molecular 
tags, i.e. SAPE. The amount of fluorescence intensity is proportional to the amount of analyte captured. 
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Cytokine detection and quantification from culture supernatants 
We used the Luminex technique to create a cytokine and chemokine secretion profile for 
melanoma cell lines, and to determine the effects of MAPK inhibiton on this profile. Following 
MAPK inhibitor treatment as described in 0, cell culture supernatants were collected, and stored 
at -80°C until the measurement. Bio-Plex assays (Bio-Rad) contain standard concentrations of 
each analyte, and the calculation of respective standard curves allows calculation of protein 
concentrations in the culture supernatants of treated melanoma cells. 
 
We performed the assay according to the manufacturers protocol. Lyophilized cytokine standard 
was resuspended in 500µl RPMI III, and incubated on ice for 30 minutes. Serial dilution series to 
generate standard curves of each chemokine/growth factor of interest were performed. The bead 
mixture, specific for the analyzed chemokines and growth factors was incubated with 50µl 
supernatant in a 96-well filter plate for 30 minutes at RT. This incubation step, as well as all 
following incubation steps, have been carried out on a plate shaker in the dark, to avoid bead 
aggregations, as well as bleaching of the beads and SAPE-labeled detection antibodies. Wells 
which contained only medium served as background controls. Several washing steps were 
performed with 100µl wash buffer, to remove unbound proteins. We used a vacuum pump for all 
washing steps to remove the fluid in the wells. Since the beads are bigger (5nm) than the filter 
pores, they remain in the wells. After addition of secondary biotinylated antibody mix for 30 
minutes at RT, and three more washing steps SAPE was added for 10 minutes at RT (1:125 
dilution). After three final washing steps and addition of 125µl assay buffer, standards and 
samples were analyzed for bead and SAPE fluorescence. 
 
Analysis of standard curves and samples 
We used the Bio-Rad Manager 5.0 and 6.0 software for analysis. Standard curves are 
automatically calculated by the software using a 5 parameter logistic plot formula, which allows 
the calculation of protein concentrations in the samples (pg/ml), according to the linear 
relationship between FI and concentration. The software permits the definition of two outliers, 
which differ strongly from the standard curves. Usually this only occurs at very high or low 
standard concentrations. Only values within the linear regression range of the standard curves 
were qualified as concentrations. Linear concentration range was between 1-50000pg/ml. 
 
Phosphoplex measurements 
Besides chemokine detection assays, the Multiplex technology was also used to determine the 
phosphorylation status of kinases and transcription factors from whole cell lysates. The technique 
was applied to analyze the effects of MAPK inhibition by small molecule inhibitors in melanoma 
cell lines on various signaling pathways, in addition to the Ras/Raf/MEK/ERK pathway. On 
separated plates, the total content of kinases as well as the phosphorylated protein fraction in our 
samples was determined. 
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Preparation of cell lysates 
We used the cell lysis kit from Bio-Rad for the preparation of tumor cell lysates, because this lysis 
procedure maintains the binding site for both, capure and detection antibody. The treatment with 
different small molecule inhibitors of the MAPK pathway was performed as described in 0. After 
treatment, the supernatant was collected for chemokine detection, and cells were washed with 
2ml icecold PBS per well. After adding 150µl cold lysis-buffer to each well, cells were detached 
with a cell scraper and lysates were transferred to 1,5ml Eppendorf tubes. Next, the tubes were 
incubated during gentle rotation at 4°C for 20 minutes, and then shock-frozen at -80°C to 
increase cell digestion. After thawing the lysates on ice, they were centrifuged at maximum speed 
for 25 minutes at 4°C. The supernatant was transferred to a new tube, and stored at -20°C. 10µl 
lysate aliquots were stored in separate tubes for detection of total protein concentrations.  
 
Detection of lysate protein concentrations and adjustment to assay concentrations 
For the quantification of total protein, we used the Pierce BCA Protein Assay Kit (Thermo 
Scientific). 10µl of each sample was pipetted into a 96-microplate well. 200µl of the working 
reagent were added to each well, and mixed with the sample on a plate shaker for about 30 
seconds. The plate was covered and incubated at 37°C for 30 minutes. After the incubation 
period, the absorption was measured at 562nm with an Elisa reader. The use of a standard 
dilution series and the calculation of standard curves, allowed for the exact determination of 
protein concentrations in each sample.  
Protein concentrations were set to the lowest necessary concentration amongst all lysates within 
one group, diluted with assay buffer: To allow for the comparison of drug perturbations as well as 
comparison between cell lines, we detected the lowest protein concentration within this set of 
samples, and adjusted all other sample concentrations accordingly. 50µl of lysates were 
incubated on a plate shaker at RT in the dark with bead mixtures over night. The following day 
biotinylated detection antibodies were added after three washing steps, and plates were 
incubated at RT for 30 minutes. For quantification SAPE was added, and after three further 
washing steps plates were measured and analyzed in 125µl assay buffer with the Luminex 
machine and the Bio-Rad Manager 5.0 and 6.0. 
 
Phosphoplex analysis 
For phosphoprotein detection, Bio-Rad does not provide standards with defined protein 
concentrations, but positive control lysates to test for general assay performance. We collected at 
least 50 beads for each analyte region. Reported median fluorescence intensity values for each 
analyte are a measure for the total or phosphorylated protein content in the samples. It is 
important to quantify changes in phosphorylated kinase protein in comparison with corresponding 
total protein content. Usually total-kinase levels are used to prove correct protein quantifications, 
e.g. in Western Blotting, where they serve as loading controls. Due to the higher sensitivity of the 
phosphoplex assay, changes in total kinase content are also detected.  
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M.2.5 xCELLigence system 
The xCELLigence system monitors cellular events in real time without incorporation of labels or 
dyes. It measures electrical impedance across interdigitated micro-electrodes integrated on the 
bottom of tissue culture E-plates. The impedance measurement provides quantitative information 
about the biological status of the cells, including cell number, viability and morphology 
(adherence) [85, 86]  
The presence of cells on top of the electrodes affects the local ionic environment at the interface 
between electrode and solution, leading to an increase in the electrode impedance. The gold 
electrodes at the bottom of E-plates cover about 80% of the bottom of the wells. The more cells 
attached to the electrodes, the larger the increases in electrode impedance. In addition, the 
impedance depends on the quality of the cell interaction with the electrodes. For example, 
increased cell adhesion or spreading will lead to a larger change in electrode impedance. Thus, 
electrode impedance, which is displayed as cell index (CI) values, can be used to monitor cell 
viability, cell number, morphology, and degree of adhesion (Figure M-4), it is however not 
possible to discriminate between these events. 
 
 
Figure M-4 - xCELLigence technology and derivation of Cell Index (CI). Cell Index is a relative metric, and requires a 
background measurement as a starting point for evaluation. Changes in impedance by cell adhesion and proliferation lead to 
higher impedance and higher values of CI. Image used from Roche Diagnostics. 
 
CI is a dimensionless parameter derived as a relative change in measured electrical impedance 
to represent the status of cells in the wells. When cells are not present or are not well-adhered on 
the electrodes, the CI is zero. Under the same physiological conditions, when more cells are 
attached on the electrodes, the CI values are larger. Thus, CI is a quantitative measure of cell 
number present in a well. Additionally, change in cell status, such as cell morphology, cell 
adhesion, or cell viability will lead to changes in CI. 
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We used the real-time cell analyzer dual plate (RTCA DP) instrument to perform proliferation 
assays, measure the effects of drug perturbations and the extent of NK cell killing. We placed the 
instrument in an incubator set to 37°C and 5%CO2, and used this incubator only for xCELLigence 
analysis. This minimizes temperature and CO2 changes during cell incubation times, and 
therefore reduces artificial changes in Cell Index values.  
 
Proliferation assays 
For proliferation tests over 96 hours, we seeded between 1250 to 10000 cells in duplicate wells 
for each cell line. Control wells contained only TM, and the initial background measurement was 
performed with 100µl TM only in each well. After addition of the cells, they were allowed to sink 
for 30 minutes at RT, before initiating the measurement. Incubation of the cells occurred at 37°C 
and 5% CO2 for the indicated times. In the absence of inhibitors or other drugs, increasing 
impedance correlates with cell proliferation. As shown in Figure M-5, higher cell numbers at 
timepoint 0 resulted in increased curves. 
 
 
Figure M-5 - Example of real-time monitoring of proliferation with xCELLigence system. Electrode impedance is displayed 
and recorded as Cell Index (CI). It reflects the biological state of monitored cells, including cell number, cell viability, morphology 
and adhesion degree. Ma-Mel-48a was tested with 10000, 5000 and 2500 cells per well. Values shown are averages of 
duplicate measurements. TM served as negative control without cells. 
 
MAPK inihibition and effects on cell status and proliferation 
One of the features of therapeutic agents like MAPK inhibitors can be detected as reduced 
proliferation of tumor cells and possibly the induction of cell death. The real-time monitoring 
technique of the xCELLigence system is especially suited to continuously analyze the effects of 
MAPK inhibition on cell status and proliferation without any further intervention over long 
incubation periods. 
Cells were seeded one day before addition of inhibitor or solvent control. After adjusting the 
background measurement, 5000 cells were added in a total volume of 100µl TM per well, and 
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rested for 30 minutes at RT. Then the E-plate was placed in the RTCA instrument and the 
measurement was started. On Day 0, MAPK inhibitors were diluted in 20µl TM and added to the 
E-Plate wells. Final concentrations in these wells were 10µM for U0126, 3µM AZD6244 and 5µM 
for Sorafenib. These concentrations were chosen on the basis of prior flow cytometry 
experiments, in order to utilize concentrations with high biological activity, but without immediate 
induction of cell death. The measurement was immediately continued for 96 hours. 
 
NK cytotoxicity assays 
The xCELLigence system can also be used for cytotoxicity assays, since lysis of adherent target 
cellx by killer cells results in decreasing values of CI. Suspension cells like lymphocytes do not 
influence CI values, because their adherence to the E-plates is to low to interfere with the 
impedance of tumor cells. After the background measurement, melanoma cell lines were added 
in a total volume of 100µl, containing 5000 cells per well. Adhesion of the tumor cells was allowed 
for 4-6 hours, before primary NK cells were added in a 5:1 effector:target ratio in 50µl TM per 
well. NK cells were either isolated from PBMC the day before use, stimulated for 24h in RPMI III 
supplemented with 500 U IL-2/ml; or NK92 NK leukemia cells were used.  
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R.Results 
R.1 Melanoma and MAPK pathway 
R.1.1 Characterization of melanoma cell lines 
For the analysis of MAPK inhibition in melanoma cell lines we used a core set of cell lines for all 
experiments. This set includes A-375 cells, a well-established melanoma cell line, carrying the 
V600E BRaf mutation (V600EBRaf), and three primary melanoma lines: Ma-Mel-48a, -48b and -
48c, carrying the G469R BRaf muation (G469RBRaf). Importantly, the Ma-Mel-48 cell lines have 
been established from different melanoma lesions of one patient, one skin lesion and two from 
lymph node metastases. 
The set of melanoma cell lines was characterized using FACS analysis, using different antibodies 
to test for HLA class I expression (W6/32, B9.12), HLA-A1, HLA-A2 (HB54), β2-microglobulin 
(HB28) and HLA-E (4D1), as shown in Figure R-1. 
 
 
Figure R-1 - FACS characterisation of Ma-Mel-48 W6/32 recognizes only correctly folded HLA/β2m/peptide complexes; B9.12 
recognizes HLA-Classe-I heavy chain alone, HB28 recognizes β2m which is non-covalently associated with HLA class I heavy 
chains. HB54 binds specifically to HLA-A2, 4D1 antibody binds the non-classical HLA molecule HLA-E. 
 
Ma-Mel-48a and -48b cells show strong expression of HLA class I (W6/32 and B9.12) with β2-
microglobulin surface expression recognized by HB28 antibody. Ma-Mel-48a and -48b are HLA-
A1 positive, HLA-A2 negative and show a little background expression of HLA-E. In contrast, Ma-
Mel-48c cells show a complete loss of HLA class I expression (negative for W6/32, B9.12, HLA-
A1) probably due to a loss of β2-microglobulin, as seen with HB28 staining. This assumption has 
been confirmed by A. Paschen (Lab D. Schadendorf, University hospital Essen), who identified a 
deletion combined with a mutation in the β2m gene (unpublished results). HLA-E expression is 
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comparably low in both, Ma-Mel-48a and -48b. Without β2-microglobulin, HLA-peptide/ β2m-
complexes can not be expressed at the cell surface.  
A-375 cells are HLA class I positive, HLA-A2 positive and do not show any defects in β2m 
expression. HLA-E is expressed similarly low to Ma-Mel-48 cells. We have summarized the 
characterization of melanoma cell lines in Table R-1. In addition to HLA expression, we have 
investigated the expression of ligands for the activating NK cell receptors NKG2D and DNAM-1. 
 
Surface molecule General expression Weighting
HLA class I ++ 48a=48b>A-375<48c; (48c are negative) 
ULBP2 + A-375>48a>48b>48c 
MICA (+) A-375>48a>48b>48c 
CD155 + 48b>48a>48c>A-375 
ICAM-1 +++ 48a>48b>48c>A-375 
ULBP1 -  
ULBP3 -  
ULBP4 -  
MICB -  
Table R-1 - Evaluation of important ligands for NK cells in melanoma cell lines. In addition to HLA class I, we have tested 
the expression of ULBP1-4, MICA/B, CD155 and ICAM-1 using FACS analysis. In addition to general expression levels, we 
have classified these expression levels in a descending direction. 
 
Remarkably, especially the expression of ULBP1-4 and MICA/B, which bind to NKG2D, is low in 
all melanoma cell lines. Only ULBP2 and MICA are expressed, we could not find any expression 
of ULBP1,3,4 and MICB. CD155 is expressed by all melanoma cell lines. 
Loss of HLA class I expression is a common phenomenon in tumor cells. HLA class I negative 
cells can not be recognized by cytotoxic CD8+ T cells, and therefore, loss of HLA class I is often 
postulated to be a survival benefit for tumor cells. Then again, loss of HLA class I can also lead to 
loss of NK cell inhibition, which in turn can lead to enhanced NK cell cytotoxicity. 
Therefore, a loss of HLA class I expression should render Ma-Mel-48c cells, compared to Ma-
Mel-48a, -48b, and A-375 cells, more sensitive to cytolysis by NK cells, since no inhibition of NK 
cells can be achieved in Ma-Mel-48c, but could work in Ma-Mel-48a, -48b and A-375.  
The xCELLigence system is a real-time monitoring system for cell proliferation and adhesion in 
vitro. Impedance measurements allow the analysis of proliferation, adhesion, morphological 
changes and also cell death. Cell death, induced either through drugs or killer cells, ultimately 
leads to detachment of cells from the well bottom, which leads to decreasing impedance. 
Therefore, I utilized the xCELLigence system to perform NK cell cytotoxicity assays, whereby 
melanoma cells were seeded in E-plates, and afterwards NK92 cells were added at an effector to 
target ratio of 5:1. NK92 is used as killer cell because of its high cytotoxic activity, due to its high 
expression of many activating receptors. In contrast to classical 4 hour chromium release assays, 
the xCELLigence method does not directly show lysis of cells but indirectly quantifies decreasing 
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adherence to the plate as a consequence of being killed. The advantage of this system is that 
slow lysis processes can be monitored for >24 hours. 
 
 
Figure R-2 - NK92 lyse melanoma cells slowly and independent of target HLA class I expression. A Raw cell index values 
for A-375 cells in NK92 and medium control wells. After addition of NK92 cells, cell index values decrease rapidly. B Calculation 
of % Kill values (division of “treated” cell index through control cell index, and substraction from 100) reveals different kinetics 
and extents of cell lysis.  
 
Figure R-2A shows the raw curves of cell index values for A-375 cells after addition of NK92 cells 
and in medium control wells. Obviously, the addition of NK92 cells led to a rapid decrease in cell 
index values, corresponding to cell lysis. Figure R-2B integrates the relation between NK92 and 
control wells, showing %lysis values, which are calculated by division of “treated” cell index 
through control cell index, and substraction from 100. This graph shows that relative to control, A-
375 cells were killed efficiently and to a high level of 80% within 24 hours. Ma-Mel-48a cells 
showed the smallest changes and were killed slowly by NK92 only to a degree of 30% within 24 
hours. 48b cells have been killed to a similar extent as A-375 but not as quickly in the beginning, 
and the kill of Ma-Mel-48c ranges between 48a and 48b. Surprisingly, Ma-Mel-48c cells were not 
killed more effectively than Ma-Mel-48b cells, even though are HLA class I negative. Although all 
melanoma lines express at least some ligands for activating NK receptors, this seems to be 
insufficient to increase NK lysis in the absence of HLA class I molecules. 
 
In conclusion, this experiment showed that inhibition of NK cell activity through HLA class I 
expression of melanoma cells is not the only mechanism that regulates NK cell cytotoxicity. The 
absence of NK cell inhibition does not necessarily lead to enhanced activation of NK cells, which 
also depends on the expression of ligands for activating receptors. Melanoma cells have been 
killed with different kinetics and to a different extent by a highly cytotoxic NK line, arguing that 
they activate NK cells to different levels.  
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R.1.2 MAPK inhibiton limits melanoma cell proliferation 
We have shown in a previous study of MAPK inhibition in colon-cancer cell lines, that MAPK 
signaling perturbations can have immediate effects, like inhibition of phosphorylation of 
downstream targets, but also longterm effects like alterations in HLA class I expression and DNA-
methyltransferase activity [24]. Therefore, I was interested in the evaluation of this situation 
melanoma cells. In order to allow for treatment periods of up to 96 hours, the concentrations of 
the inhibitors had to be titrated for each cell line. Our goal was to find concentrations of each 
inhibitor that could be used for all cell lines, with maximum biological activity, but limited 
occurrence of cell detachment and cell death in longterm experiments. As expected, these effects 
proved to be dose-dependend and different between the cell lines. For a treatment period of 96 
hours, concentrations of 10µM for U0126, 3µM for AZD6244 and 5 µM for Sorafenib were chosen 
for all cell lines. These concentrations showed pronounced biological activity with limited toxic 
effects, like detachment of dead cells in cell culture experiments and FACS analysis (data not 
shown). Since the BRaf inhibitor Sorafenib and the two MEK inhibitors U0126 and AZD6244 
target the MAPK pathway at two kinases that are directly connected in the signaling cascade, it 
was of interest to see whether differences in proliferation and adhesion could be detected 
between inhibitors and between cell lines respecetively. 
 
The xCELLigence system is especially suited to analyze basic effects of MAPK inhibition on 
melanoma cell lines, because the effects of treatment are followed in real time. Figure R-3 shows 
the effect of MAPK inhibition for Ma-Mel-48a, -48b, -48c and A-375. The xCELLigence system 
measures effects on proliferation, morphology changes, adhesion and cell death. Graph analysis 
shows the effects of drug treatment relative to DMSO control, which was set to 100% living cells. 
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Figure R-3 - Sensitivity of melanoma cell lines to MAPK inhibitors. Cell index values were normalized at the starting point of 
treatment. Percent living is then calculated as the ratio between treatment and control, times 100. Control DMSO-treated cells 
were set to 100% living cells. Cells have been treated with U0126 [10µM], AZD6244 [3µM] and Sorafenib [5µM] for the indicated 
times. In Ma-Mel-48c and A-375 cells, the experiment was stopped earlier, due to 100% confluency in control wells. 
Ma-Mel-48a and -48c show decreased proliferation as an effect of U0126, AZD and Sorafenib 
treatment, the three drugs acted very similar. i.e. compared to DMSO, proliferation decreased to 
~70%. Ma-Mel-48b showed a similar trend, but AZD6244 and Sorafenib affected the cells more 
than U0126. A-375 cells generally reacted more sensitive to MAPK inhibition. After 16h of 
treatment, cell proliferation in all treated wells decreased significantly. Sorafenib and U0126 lead 
to strong decreases in cell index compared to DMSO. While AZD6244 reduced the cell index 
level further to 25% of DMSO control cells after 70 hours.  
The susceptibility of melanoma cells to MAPK inhibition has previously been linked to the state of 
BRaf mutations. A-375 cells are the only cells in our set which carry the V600EBRaf mutation, while 
Ma-Mel-48 cells carry the “gate-keeper” mutation G469R. If the mutation of BRaf is responsible 
for the different susceptibililty to MAPK treatment, this opens up a lot of questions regarding the 
functional concequences of BRaf mutations, and especially V600EBRaf. What are the differences in 
oncogenic signaling between G469RBRaf and V600EBRaf, and how does it affect the expression of 
surface molecules or the secretion of cytokines, chemokines and growth factors? To answer 
these questions, I analyzed several parameters in the course of MAPK inhibition. 
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R.1.3 Influence of MAPK inhibition on HLA, CD155 and NKG2D 
ligands expression 
The effects of MAPK inhibition on cell proliferation could not be determined immediately after the 
beginning of treatment. Differences between the inhibitors U0126, AZD6244 and Sorafenib 
appeared later than 30 hours after treatment. Due to the proliferation rate of melanoma cells, this 
might not be surprising, because differences between normal proliferating cells and cells with 
induced cell-cycle arrest or inhibited proliferation may arise only after a whole cell cycle. But it 
also holds the possibility that the effects of MAPK inhibition can not only be captured within short 
periods of time. To capture short-term as well as longterm effects of MAPK inhibition in FACS and 
multiplex analysis, we decided to include early measurements of 30min, 6h and 12h, and then 
continued monitoring of our cell lines after 24h, 48h, 72h and 96h.  
As shown in Figure R-2, HLA class I expression on Ma-Mel-48a, -48b, -48c and A-375 does not 
provide a sufficient explanation for different levels of NK cell lysis. NK cell cytotoxicity against 
these melanoma lines can also be due to a lack of NK cell activation. Thus, I focused on ligand 
expression of the activating receptor NKG2D, including MICA/B and ULBP1-4, as well as CD155 
expression, which can activate NK cells via the DNAM-1 receptor (compare Table R-1). 
Additionally, effects of MAPK inhibition on these cell surface molecules were addressed by 
monitoring ligand expression over 96 hours of treatment. Figure R-4 demonstrates the time and 
inhibitor-dependent alterations of CD155 surface expression.  
 
 
Figure R-4 - CD155 is expressed on all melanoma cells, and modulated through MAPK pathway perturbations. Cells 
were treated with MAPK inhibitors (U0126 10µM, AZD6244 3 µM, Sorafenib 5µM) and analysed in FACS staining after 30’, 6h, 
12h, 24h, 48h, 72h and 96h. Graphs show the mean fluorescence of CD155 antibody stainings for Ma-Mel-48a, -48b, -48c and 
A-375 melanoma cell lines.  
  Results 
 
  49 
Ma-Mel-48a and A-375 show identical patterns: Stable expression of CD155 within the first 12 
hours of treatment: At 24 hours, U0126 and AZD6244 treated cells show decreased levels of 
CD155 expression, compared to DMSO control treatment and Sorafenib. Later timepoints show 
that the decrease of CD155 in U0126 and AZD6244 samples is sustained over 96 hours. DMSO 
control expression levels are stable over 96 hours. Surprisingly, Sorafenib treatment strongly 
increased CD155 expression, peaking at 72 hours of treatment. Ma-Mel-48b cells showed similar 
effects but to a limited extent. After 48 hours, Sorafenib samples show a slightly higher 
expression of CD155 than DMSO control samples, and U0126 and AZD6244 again seem to 
slightly inhibit CD155 expression levels. I could not detect a modulated expression of CD155 in 
Ma-Mel-48c cells, where the expression level was generally lower than in Ma-Mel-48a and -48b, 
but remained stable over 96 hours for all treatments.  
 
The analysis of HLA class I expression over a timecourse of 96 hours also reveals differential 
modulating effects of MAPK inhibition (Figure R-5). In Ma-Mel-48a and A-375 cells, U0126 and 
AZD6244 treatment led to a slightly upregulated HLA class I expression after 48 hours, which 
decreases again to baseline levels after 72 and 96 hours. Since this upregulation in HLA class I is 
also seen in DMSO treated cells, but not to the same extent, it seems to be cell cycle-associated. 
Ma-Mel-48b cells, show a similar effect, but the increase after 48 hours is not as pronounced as 
in Ma-Mel-48a and A-375. Sorafenib seems to have an inhiting effect on HLA class I expression 
in all three HLA class I positive cell lines. Ma-Mel-48a and -48b show a more pronounced 
inhibition with Sorafenib than A-375 cells. The HLA class I negative Ma-Mel-48c show of course 
no influence of MAPK inhibition, since HLA class I is not expressed.  
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Figure R-5 - HLA class I is modulated by MAPK pathway perturbations. Treatment effect of melanoma cells with U0126 
(10µM), AZD6244 (3µM) and Sorafenib (5µM) was analyzed for HAL class I expression using W6/32 and goat α mouse 
antibodies. 
 
We have also tested the expression and modulation of NKG2D ligands MICA/B and ULBP1-4. 
Expression of these ligands on Ma-Mel-48 and A-375 cells turned out to be generally very low 
(Table R-1) and does not show any substantial modulating effects of MAPK inhibition (data not 
shown). 
 
In conclusion, we could show that MAPK inhibition by these drugs in melanoma cell lines 
surprisingly leads to different expression levels of CD155, an important ligand for the NK cell 
activating receptor DNAM-1. Additionally, U0126, AZD6244 and Sorafenib proved to modulate 
this expression differently, showing even opposing effects of increased CD155 expression in 
Sorafenib treated cells and decreased levels of CD155 expression in U0126 and AZD6244 
treated cells (Ma-Mel-48a and A-375). Interestingly, the modulation of HLA class I surface 
expression by the three MAPK inhibitors follows a mirror image of CD155. In contrast to CD155, 
U0126 and AZD6244 treated cells displayed increased HLA class I levels and Sorafenib-treataed 
cells showed decreased expression. Therefore, CD155 and HLA class I seem to be regulated by 
different mechanisms that are differentially influenced by BRaf (Sorafenib) and MEK (U0125, 
AZD6244) inhibition.  
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R.1.4 Consequences of altered HLA and NK ligand expression for 
NK cell degranulation 
I have shown that untreated melanoma cell lines were killed slowly by NK92 cells independently 
from their HLA class I expression (Figure R-2). Additionally, I observed changes in cell surface 
molecule expression in response to treatment with MAPK inhibitors. The modulation of CD155 
expression (Figure R-4) was of special interest, as it might induce changes in NK cell recognition 
by binding to the DNAM-1 receptor. Since the xCELLigence system showed a strong influence of 
the inhibitors on cell proliferation, this assay was not suited to address NK cell cytotoxicity to 
treated cells, due to indistinguishable overlapping effects. Therefore, we performed CD107a 
degranulation assays with NK cells from PBMC, co-cultured with treated melanoma cell lines 
(Figure R-6A). NK cells, which recognize their targets and get activated, release cytotoxic granula 
into the immunological synapse. During this process, lysosomes, containing granzymes and 
perforin, fuse with the NK cell plasma membrane, and lysososmal associated protein-1 (LAMP-1, 
CD107a) becomes transiently visible on the surface of NK cells. NK cell degranulation assays 
make use of this mechanism to identify active NK cell subsets. Since NK92 are leukemic cells 
with a constant high turnover of vesicles and permanent high levels of surface CD107a 
expression, they are not useful for degranulation assays. Therefore, PBMC were used as effector 
cells, and degranulation of NK cells was determined by gating on the CD3-/CD56+ population 
only. In order to lower the degranulation threshold, PBMC were pre-activated for 24 hours with IL-
2, which did not alter their phenotype, but allowed stronger degranulation in response to target 
cells. 
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Figure R-6 - In A-375 cells, CD155 expression correlates with NK cell cytotoxicity. Degranulation of NK cells is detected as 
CD56bright and CD56dim CD107a+cells (Q2-1 and Q4-1), and calculated from 100% NK cells. A Shows an representing dot plot of 
FACS analysis, and a quantification of percent CD107a+ NK cells targeting MAPK inhibited A-375 cells. B Shows a 
quantification of corresponding target FACS analysis to detect HLA class I and CD155 expression levels. C Quantification of 
CD107a+ NK cells in blocking experiments with mAb binding to MOPC21 (Isotype), NKG2D and DNAM-1 receptors. 
 
In A-375 melanoma cells treated for 48 hours with MAPK inhibitors, a modulated NK cell 
degranulation was observed. DMSO and Sorafenib treated samples showed 30% of CD107a 
positive NK cells. Degranulation was substantially decreased in U0126 and AZD6244 treated 
melanoma cells. Simultaneously to the degranulation assay, A-375 cells were tested for their 
modulation of HLA class I and CD155 expression in inhibitor-treated cells, as shown in Figure 
R-6B. In DMSO and Sorafenib treated cells, CD155 expression was relatively stronger than HLA 
class I expression. Whereas HLA class I expression remains stable in U0126 and AZD6244-
treated samples, a decrease in CD155 was observed. Thus, CD155 expression correlates well 
with the lower NK cell recognition of U0126 and AZD6244-treated samples (compare Figure R-6A 
and B). This suggests CD155 as a possible regulator of NK cell activity in A-375 melanoma cells. 
Its expression is modulated in response to MAPK inhibitor treatment, which seems to influence 
NK cell cytotoxicity. 
To further assess the regulatory role of CD155, blocking experiments were performed. To avoid 
ADCC (antibody-dependent cytotoxicity) by binding of CD155-antibodies to the Fc-receptor 
CD16, blocking antibodies against the relevant receptors DNAM-1 and NKG2D as control were 
used. Before co-culture with A-375 target cells, NK cells were incubated with blocking antibodies 
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against (I) DNAM-1 (receptor for CD155), (II) NKG2D, as control receptor, to inhibit activation 
through NKG2D ligands, and (III) compared to the isotype antibody (MOPC21), and untreated NK 
cells respectively. As shown in Figure R-6C, the experiment confirmed the inhibited NK cell 
cytotoxicity in U0126 and AZD6244 treated samples. In the presence of DNAM-1 specific mAb, 
degranulation was slightly decreased by ~10-15% which resembles an inhibition of ~30% in all 
samples. NKG2D-specific mAb had only a minor effect on degranulation, indicating that DNAM-1 
is more involved in the recognition of melanoma cells than NKG2D. This hierarchy follows nicely 
the higher expression of DNAM-1 ligand CD155, compared to NKG2D ligands. 
 
Although they were slowly killed by the NK line NK92, Ma-Mel-48 cells, in contrast to A-375, 
activated NK cells only to a very limited extent (Figure R-7). Ma-Mel-48a, -48b and -48c primary 
melanoma cells were treated for 48 hours with MAPK inhibitors, and co-cultured with pre-
activated NK cells from three different PBMC for 4 hours. K-562 cells were used as positive 
control for NK cell activity, because K-562 cells are HLA class I negative and strongly activate NK 
cells. Figure R-7 shows that with K-562 target cells all three NK cell populations from different 
PBL show high values of CD107a degranulation, ranging from 60% to 75%. Negative control 
samples without target cells show a baseline degranulation in less than 10% of NK cells. 
Interestingly, NK cells from PBL I-III show different amounts of CD107a degranulation with Ma-
Mel-48a, -48b and -48c target cells, but in comparison to K-562 cells, only a small subpopulation 
of CD107a positive NK cells was induced. For all target cells, PBL I NK cells show highest 
amounts of activity, PBL III NK cells the lowest amount of activity, and PBL II NK cells range in 
between.  
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Figure R-7 - Ma-Mel-48 cells induce limited NK cell cytotoxicity. NK cells were isolated from three different PBMC of healthy 
donors, preactivated and then co-cultured with Ma-Mel-48a, -48b and -48c cells in CD107a degranulation experiments. The HLA 
class I negative cell line K-562 was used as a positive control for NK cell recognition, and shows high amounts of CD107a 
positive NK cells for all three PBL. Ma-Mel-48 cell all induced only limited amounts of NK cell degranulation, but where 
recognized to different extents by the PBL. PBLI showed the highes NK cell degranulation, followed by PBL II and PBL III.  
 
Treatment of melanoma cells with U0126, AZD6244 and Sorafenib did not have strong effects on 
NK cell cytotoxicity for all Ma-Mel-48 cell lines. Even though Ma-Mel-48c cells are HLA class I 
negative, again primary NK cells do not display higher degranulation compared to HLA class I 
positive Ma-Mel-48a and -48b cells. This observation confirms the previous finding that the 
absence of HLA class I alone, is insufficient to increase NK activity, probably due to low NK 
ligand expression, especially of CD155. 
 
In conclusion, I could show that the modulating effects of MAPK inhibitors on CD155 
expression, can result in effects on NK cell recognition as seen in U0126 and AZD6244-treated 
A-375 samples, which show downregulation of CD155, and decreased NK cell cytotoxicity 
accordingly. Blocking the interaction between CD155 and DNAM-1 was shown to slightly inhibit 
cytotoxicity of primary NK cells. Importantly, the effects of the different MAPK inhibitors are not 
consistent, e.g. in A-375 cells, U0126 and AZD6244 treatment led to reduced expression of 
CD155, while Sorafenib induced CD155 expression.  
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R.1.5 Influence of MAPK inhibitors on secretion of chemokines and 
growth factors 
Transformation of tumor cells does not only include changes in tumor cells themselves, but also 
impacts the tumor microenvironment, which is composed of various cell types, e.g. fibroblasts, 
blood vessels, infiltrating immune cells and growth factors, chemokines and cytokines. Immune 
cell infiltration of tumors strongly depends on the chemokine and cytokine milieu in the tumor. 
Since many growth factors and chemokines are produced by tumor cells, the secretion of 
chemokines, cytokines and growth factors of Ma-Mel-48 cells was analyzed to determine 
changes in their secretion profile in response to MAPK inhibition. Cell culture supernatants 
following treatment were therefore stored before subjecting the cells to lysis for Phosphoplex or 
Western Blot analyses. The secretion of M-CSF, MIF, HGF, ICAM-1, SCGF-β, SDF1-α, IL-8 and 
VEGF, in Ma-Mel-48a, -48b and -48c cells after 48 hours of treatment with DMSO, U0126, 
AZD6244 and Sorafenib was determined. In Bio-Plex measurements these factors are quantified 
simultaneously. Remarkably, the three melanoma lines differed substantially in their secretion 
profile. HGF (hepatocyte growth factor), IL-8 (CXCL8), M-CSF and SDF-1α (CXCL12) were 
highly secreted by Ma-Mel-48a cells, and to a fractional amount by Ma-Mel-48c. In contrast, Ma-
Mel-48b does not produce these factors at all. Treatment of MAPK inhibitors inhibited secretion of 
these factors almost completely. In contrast, VEGF was produced by all three cell lines to a 
different extent and was almost completely inhibited following treatment with the MAPK inhibitors. 
A similar picture was seen with soluble ICAM-1, which is procued by the three lines and strongly 
decreased by MAPK inhibitors. The observation that SCGF secretion by Ma-Mel-48a and -48c 
was not influenced by the inhibitors demonstrates that the strong inhibition of the other factors 
was not due to a general suppression of protein secretion. Thus, only factors that are presumably 
MAPK-dependent were influenced by inhibition of this pathway. Interestingly, MIF was the only 
factor out of 50 tested that showed an increased release in Ma-Mel-48b cells following treatment 
with Sorafenib. Since MIF is involved in several resistance pathways of tumor cells, this effect 
may be responsible for resistance of tumor cells to MAPK inhibition in vivo.  
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Figure R-8 - Cytokine, chemokine and growth factor profile of Ma-Mel-48 cells in response to MAPK pathway 
perturbations. Supernatants of Ma-Mel-48a, -48b and -48c cells were harvested following 48 hours of treatment with MAPK 
inhibitors, and subjected to multiplex analysis. Cells have been treated with U0126 [10µM], AZD6244 [3µM] and Sorafenib 
[5µM]. 
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Macrophage inhibitory factor (MIF) was produced in large amounts by Ma-Mel-48b cells, and 
treatment with Sorafenib increased the secretion to more than 15.000pg/ml. Ma-Mel-48a and -48c 
did not show any secretion of MIF. ICAM-1 and VEGF show secretion profiles similar to each 
other: In DMSO controls, we could detect substantial amounts of ICAM-1 and VEGF in cell 
culture supernatants of all three cell lines. But ICAM-1 and VEGF are both efficiently 
downregulated with U0126, AZD6244 and Sorafenib treatment. SCGF-β in contrast to that did 
prove to be unaffected of MAPK inhibition. We detected substantial amounts of SCGF-b in Ma-
Mel-48a and -48c, and low amounts in Ma-Mel-48b. The secretion remained stable after MAPK 
inhibition.  
 
In conclusion, the secretion profiles can be grouped into four different schemes. M-CSF, HGF, 
SDF-1α and IL-8 are only produced by Ma-Mel-48a, and decreased in response to treatment. 
Since these chemokines and growth factors represent important factors for the tumor 
microenvironment, the inhibition of the MAPK pathway results in a substantial alteration. ICAM-1 
and VEGF are secreted by all three cell lines in substantial amounts, and treatment with MAPK 
inhibitors leads to efficient downregulation of ICAM-1 and VEGF. VEGF was shown to be of 
prognostic relevance in melanoma patients. Thus, the decrease in VEGF secretion following 
MAPK inhibition may be of clinical relevance. MIF was only produced by Ma-Mel-48b cells and 
upregulated with Sorafenib. SCGF-b is secreted by primary Ma-Mel-48a and -48c cell lines, and 
production remained stable over 48 hours of treatment with U0126, AZD6244 and Sorafenib. 
Taken together, secretion of VEGF, M-CSF, IL-8, SDF1-α, HGF and M-CSF is highly dependent 
on MAPK signaling in melanoma cells. 
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R.2 Kinetics of phosphorylation patterns during MAPK 
pathway inhibition 
The perturbation of MAPK signaling with U0126, AZD6244 and Sorafenib is the basis for all 
observed effects – i.e. alterations in surface molecule expression, NK cell cytotoxicity and 
secretion profiles. Notably, substantial differences in some of these read-out systems were 
observed between the BRaf inhibitor Sorafenib, and the MEK-inhibitors U0126 and AZD6244. 
Therefore, we aimed to elucidate the effects of MAPK inhibitor treatment on MAPK signaling 
itself, but also on various connected pathways, e.g. JNK and Akt signaling or p53 stabilization. In 
order to capture the effects comprehensively and to possibly find explanations for the observed 
phenomena, we chose to utilize the Luminex system to perform phosphoplex analysis, which 
allows the simultaneous measurement of several different proteins in one sample. We quantified 
phosphorylated and total content of ERK1/2, MEK1, CREB, Akt, NFκB, IkB-α, JNK, c-Jun, p38 
MAPK, GSK3α/β, Atf-2 and p53. Using this technique we were able to monitor the effect of MAPK 
inhibitors on various pathways over a time course of 96h.  
 
R.2.1 Effects of MAPK inhibition on MEK/ERK proteins 
R.2.1.1 Modulation of MEK1 and ERK1/2 phosphorylation in response to 
MAPK inhibition 
A commonly used readout for the performance of MAPK inhibitors is the inhibition of 
phosphorylation of downstream kinases. Inhibition of MEK or Raf impairs their own kinase 
activities, which are involved in the kinase cascade that finally leads to phosphorylation of ERK, 
which then signals to various transcription factors to control cell proliferation. Thus, inhibited 
activity of Raf (by Sorafenib) or MEK (by U0126 and AZD6244) leads to dephosphorylation of 
MEK and ERK respectively. Due to the assumed linear signaling within the MAPK pathway, 
dephosphorylation of MEK with Sorafenib, should also lead to dephosphorylation of ERK. 
Therefore, all three inhibitors are supposed to mediate inhibition of ERK phosphorylation. The 
antibody that has been used in Phosphoplex analysis binds to both, ERK1 and ERK2 
(Thr202/Tyr204, Thr185/Tyr187). Figure R-9 shows the effects of treatment of Ma-Mel-48a, -48b, -48c 
and A-375 with U0126, AZD6244 and Sorafenib for 96h, on phoshpo-ERK1/2 levels. 
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Figure R-9 - ERK phosphorylation inhibited with all MAPK inhibitors Melanoma cells were treated with U0126 (10µM), 
AZD6244 (3µM) and Sorafenib (5µM) or DMSO as solvent control.  
 
Ma-Mel-48a, -48b and -48c show a very similar kinetic of ERK phosphorylation in response to 
treatment. ERK1/2 is constitutively phosphorylated in all three cell lines in large amounts. In 
DMSO control samples, phospho-ERK levels increased over the treatment period of 96 hours, 
probably due to cell-cycle dependent signals. The treatment with all three MAPK inhibitors led to 
a rapid and sustained inhibition of p-ERK1/2 in Ma-Mel-48a, -48b and 48c. In A-375 cells, DMSO 
control samples showed a more constant phospho-ERK level compared to Ma-Mel-48 cells. 
U0126 and AZD6244 achieved a rapid and sustained inhibition of ERK acitivity, but Sorafenib 
treatment could only partially inhibit ERK1/2 phosphorylation. 
 
The read-out of ERK phosphorylation proved effectiveness of all three drugs in our set of 
melanoma cell lines. The substantial inhibition of phospho-ERK levels was achieved within 30 
minutes of treatment, and was sustained over 96 hours. Since Ma-Mel-48a cells carry the 
G469RBRaf mutation, and A-375 cells the V600EBRaf mutation, the mutation status of BRaf seems to 
be irrelevant for MEK inhibitors. In A-375 cells, Sorafenib showed only a partial inhibition of 
phospho-ERK acitivity, which might be dependent on their V600EBRaf mutation. 
 
The analysis of p-MEK1, upstream of ERK1/2, revealed more pronounced differences between 
the inhibitors and cell lines (Figure R-10). Sorafenib is the only inhibitor, which inhibits Raf 
activity, directly upstream of MEK. U0126 and AZD6244 are both MEK inhibitors, which are 
supposed to inhibit kinase activity of MEK, although they bind at different sites. MEK inhibition is 
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not necessarily associated with a decrease MEK phosphorylation itself. This difference depends 
on the mutation status, as e.g. V600EBRaf has been shown to suppress p-MEK in AZD6244-
treated cells. Along those lines, differences in p-MEK levels between both MEK inhibitors, U0126 
and AZD6244 were observed. U0126 inhibited p-MEK1 levels in all four melanoma cell lines 
tested, in Ma-Mel-48c cells not as strongly and sustained as in 48a, 48b and A-375. 
 
 
Figure R-10 - p-MEK1 expression varies between different inhibitors and cell lines. Cells have been treated with U0126 
[10µM], AZD6244 [3µM] and Sorafenib [5µM] for 96 hours, and subjected to phosphoplex analysis. 
 
In contrast, AZD6244 treatment – even though shown to be very effective in inhibition of ERK 
activity before, resulted in increased p-MEK1 levels compared to DMSO in Ma-Mel-48a and -48c 
lines. This increase in p-MEK1 levels was suppressed in V600EBRaf A-375 cells. Surprisingly, only 
in Ma-Mel-48b cells, AZD6244 treated samples showed phospho-MEK levels lower than in 
DMSO control cells. Sorafenib, as expected, effectively inhibited p-MEK1 expression in all cell 
lines, due to its upstream inhibition of Raf.  
 
In conclusion, the analysis of p-MEK levels reveals different mechanisms of action of the two 
MEK inhibitors. U0126 binds to MEK1/2 proteins to inhibit their activity, and obviously blocks 
phosphorylation of MEK1 at Ser217/Ser221. AZD6244, which is a non-ATP competitive inhibitor, 
does not block phosphorylation sites of MEK1, but somehow inhibits dephosphorylation of MEK1, 
which leads to increasing levels of phospho-MEK1. For obvious reasonsm this underlines the 
necessity to test downstream ERK phosphorylation to assess the effectiveness of MEK inhibitors. 
Sorafenib proved to be very effective at inhibition of MEK activity, due to the directly upstream 
inhibited kinase activity of Raf, which normally functions to phosphorylate MEK.  
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R.2.1.2 Modulation of total ERK1/2 and MEK1 protein levels in response to 
MAPK inhibition 
Total protein concentrations of the lysates have been equalized between all cell lines and 
treatments before phosphoplex analysis, to ensure that total protein changes are not due to 
different amounts of lysate. Therefore, changes in total protein levels observed with Phosphoplex 
analysis can either be due to degradation processes in case of reduction of total protein levels, or 
stabilization of proteins and increased metabolism in the case of increasing total protein levels. 
Short and long term kinetics strengthen the interpretation of drug-induced effects on total kinase 
levels. Figure R-11 shows the course of total ERK1/2 protein levels in the four cell lines. There is 
no evident correlation between the inhibition of phosphorylation and the amount of total ERK1/2 
proteins.  
 
 
Figure R-11 - Heterogenous levels of total ERK1/2 protein in response to MAPK inhibition. Total protein concentrations 
across all cell lines and treatments were adjusted to 150µg/ml before analysis. Cells have been treated with U0126 [10µM], 
AZD6244 [3µM] and Sorafenib [5µM] for 96 hours and subjected to phosphoplex analysis. 
 
A-375 cells show homogenious levels of t-ERK1/2 for the different treatments, which 
demonstrates the correct adjustment of the lysates. After 24h, DMSO samples show an 
increasing amount of t-ERK1/2, that is not visible with MAPK inhibitor treatment. Such changes 
are likely to be cell cycle-dependent since they often occur after 24 hours of treatment. For Ma-
Mel-48a, -48b and -48c cells, the total ERK1/2 curves are less homogeneous, which raises the 
question whether protein concentrations were adjusted correctly. This problem could be excluded 
by the analysis of total protein levels of e.g. c-Jun (Figure R-14). Thus, total ERK1/2 curves in 
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Ma-Mel-48 cells most likely reflect fluctuations of the kinases during cell-cycle progression. While 
Sorafenib seems to stabilized these fluctuations, U0126 causes a strong increase in t-ERK1/2 in 
Ma-Mel-48a and -48c. In contrast, Ma-Mel-48b show the highest t-ERK1/2 in DMSO samples, 
and rather decreased levels with the inhibitors. Remarkably, these t-ERK1/2 fluctuations occur 
independently from the constant and sustained inhibition of phosphorylated ERK1/2. It is also 
important to mention that the changes in kinase concentrations are basically not detected by 
Western Blot analyses, because they are balanced by different exposure times in case of high or 
low signals.  
 
The evaluation of total MEK1 levels reveals a unique feature of AZD6244 treatment (Figure 
R-12). Across all cell lines, AZD6244 effectively decreases t-MEK1 levels, which is in contrast to 
the increased or sustained MEK1 phosphorylation we have detected (Figure R-10). So binding of 
AZD6244 to MEK1 leads to the disappearance of total protein on the one hand, and increasing 
levels of phosphorylated MEK1 on the other hand. Since U0126 has a different binding site, and 
does not show similar effects, the binding site may be responsible for these opposing AZD6244-
specific effects on p-MEK1 versus t-MEK1. This hypothesis is currently investigated using a third 
MEK inhibitor. 
 
 
Figure R-12 - Only AZD6244 reduced total MEK1 content. Total protein concentrations across all cell lines and treatments 
were adjusted to 150µg/ml before analysis. Cells have been treated with U0126 [10µM], AZD6244 [3µM] and Sorafenib [5µM] 
for 96 hours and subjected to phosphoplex analysis. 
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U0126 and Sorafenib seem to lower total MEK1 levels in Ma-Mel-48b cells a bit, but do not show 
clear inhibiting or activating characteristics in Ma-Mel-48a, -48c, and A-375 cells. Overall MEK1 
total protein levels are high for all cell lines, supporting the role as a driving signaling force. 
 
In conclusion, within MAPK signaling, the inhibitors U0126, AZD6244 and Sorafenib all inhibit 
ERK phosphorylation effectively. The inhbiting effect is achieved within minutes, and sustained 
over a treatment period of 96 hours. Sorafenib achieved only a partial inhibition of phospho-
ERK1/2 in A-375 cells, but showed full inhibition in Ma-Mel-48 cells. AZD6244 showed a striking 
characteristic with elevated levels of phosphorylated MEK1 in Ma-Mel-48a and -48c cells, 
together with decreasing levels of total MEK1 protein in all cell lines. Generelly, phosphorylated 
MEK or ERK can be stabilized while total kinase levels are decreased during inhibitor treatment, 
suggesting that phosphorylated and unphosphorylated kinases can be regulated independently. 
Both specific MEK inhibitors, U0126 and AZD6244, showed two different mechanisms of action, 
but both achieved the goal of inhibited ERK phosphorylation. 
 
R.2.2 JNK, Akt and p53 phosphorylation and stabilization are 
affected by MAPK inhibition 
R.2.2.1 JNK and c-Jun signaling is altered in response to MAPK inhibition 
C-Jun N-terminal kinases (JNK) were first characterized as stress-activated members of the 
MAPK family, and are involved in the regulation of cell-cycle progression and induction of 
apoptosis, through the control of various downstream substrates, e.g. c-Jun and p53. Phospho-
JNK levels in Ma-Mel-48 and A-375 cells were constantly low over the timecourse of 96 hours of 
MAPK treatment (Figure R-13). Ma-Mel-48a and Ma-Mel-48b show a slight inhibition of JNK 
phosphorylation with the three MAPK inhibitors.  
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Figure R-13 - Phosphorylation of JNK and c-Jun is modulated in response to MAPK inhibition. Cells have been treated 
with U0126 [10µM], AZD6244 [3µM] and Sorafenib [5µM] for 96 hours and subjected to phosphoplex analysis. 
 
Downstream of p-JNK, p-c-Jun levels showed more pronounced effects. In Ma-Mel-48a, p-c-Jun 
levels in DMSO-treated control cells steadily increase after 12 hours and peak at 72 hours. This 
effect is efficiently suppressed by U0126, AZD6244 and Sorafenib treatment. Ma-Mel-48b cells 
show similar effects: Phospho-c-Jun levels in DMSO-control cells remain at high values over 96 
hours and are strongly inhibited in response to inhibitor treatment. In Ma-Mel-48c we detected an 
increase in phospho-c-Jun only in U0126-treated cells; DMSO as well as Sorafenib and AZD6244 
show low c-Jun phosphorylation levels. In A-375, phospho-c-Jun levels seem to be upregulated 
early (6h) and after 24 hours with MAPK inhibitors. DMSO control cells show decreasing levels of 
phospho-c-Jun.  
The parallel analysis of total JNK and c-Jun protein content revealed two important aspects of this 
highly sensitive quantificiation method: First, MFI values for total-c-Jun were much lower than 
those of phosphorylated-c-Jun (Figure R-14). We have made similar observations for Akt and 
some other proteins. This puzzling observation was clarified based on our data with the 
manufacturer (Bio-Rad). While the capture mAb on the bead is identical for phospho- and total-
assays, the phospho-specific detection mAb always detects all isoforms of the kinase or 
transcription factor, while the total-specific detection mAb sometime only binds to some but not all 
isoforms. In the case of total-c-Jun, only c-Jun and not its other variants like junB is detected in 
the total assay. In the case of total Akt, only Akt1 but not Akt2/3 are detected (Figure R-16). 
Second, JNK and c-Jun nicely display a direct correlation between phosphorylated and 
unphosphorylated proteins (compare Figure R-13 and Figure R-14), supporting the interpretation, 
that the relationship between phosphorylated and total kinases and transcription factors follows 
an individual regulation.  
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Regarding JNK, only a small portion occurs in its active phosphorylated state, and here total JNK 
levels are generally higher than phospho-JNK levels (Figure R-14), confirming that all JNK 
isoforms are detectable.  
 
 
 
Figure R-14 - Total amounts of JNK and c-Jun follow the observed modulation in phospho JNK and c-Jun. Cells have 
been treated with U0126 [10µM], AZD6244 [3µM] and Sorafenib [5µM] for 96 hours and subjected to phosphoplex analysis. 
 
In Ma-Mel-48a and -48b the picture of total JNK regulation looks very similar to the 
phosphorylation pattern of JNK. DMSO control samples show increasing levels of total JNK after 
24 hours, which are reduced with MAPK inhibitors. Even though the JNK-phosphorylation 
patterns of A-375 cells were different from Ma-Mel-48a and -48b, total JNK seems to be regulated 
the same way, i.e. DMSO control cells show an increase in total JNK content, which was 
prevented in U0126, AZD6244 and Sorafenib samples effectively. 
 
The analysis of total c-Jun levels revealed that the patterns of c-Jun phoshporylation and total 
protein content correlate nicely. The increase in phospho c-Jun in DMSO-treated Ma-Mel-48 cells 
is accompanied by a parallel increase in total c-Jun protein that was suppressed by the three 
inhibitors. Obviously, inhibition of the MAPK pathway has consequences for the natural regulation 
of the transcription factor c-Jun. This may be one of the reasons for the decreased secretion of 
growth factos and chemokines in Ma-Mel-48 cells, since VEGF and CXCL8, for example, 
possess AP-1 binding sites in their promoters. 
 
R.2.2.2 Degradation of total protein levels is independent of caspase activity 
One of the big surprises was the extent to which total protein levels were regulated in response to 
MAPK inhibition. While c-Jun was an example in which the kinetic of an increase in total and 
phospho c-Jun over 96 hours was suppressed, other kinases were clearly degraded in MAPK 
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inhibitor-treated cells, p38 MAPK for instance. We wondered, whether this degradation is protein 
specifically regulated, or if it occurs in the context of apoptosis and caspase activity. In order to 
test this, I have used the pan-caspase inhibitor zVAD fmk in further phosphoplex experiments, to 
inhibit caspase activity in addition to treatment with MAPK inhibitors for 48 hours. The results 
clearly show that caspase activity is not responsible for protein degradation, because neither in 
phospho-protein levels, nor in total protein levels, inhibition of caspase activity could reverse the 
effects of MAPK treatment. Figure R-15A shows that total c-Jun levels are unaffected by the 
addition of zVAD FMK, in A-375 cells as well as in Ma-Mel-48a. Besides c-Jun, we have also 
checked phosphorylated and total amounts of Akt, Atf-2, IκB-α, p38MAPK, p90RSK, ERK1/2, p53 
and MEK1 for the influence of caspase inhibition. None of these proteins showed changes in 
response to addition of zVAD fmk. Figure R-15B exemplarily shows the kinetic of total p38 MAPK. 
All three inhibitors lead to a strong degradation of total p38 MAPK, which is unaffected by the 
addition of zVAD, as tested for the timepoint of 48 hours of treatment. Additionally, this data 
nicely shows that even though the amount of fluorescence changes between different 
phosphoplex assays, the tendency remains the same between measurements (compare 
fluorescence between left and right graph in Figure R-15B). 
 
 
Figure R-15 - Caspase inhibition does not alter protein degradation levels. zVAD fmk was added additionally to the 
respective wells, in a final concentration of 40µM. For the zVAD assay, we have used U0126 and Sorafenib in final 
concentration of 10µM. Total p38 MAPK kinetic included the treatment with U0126 (10µM), AZD6244 (3µM) and Sorafenib 
(5µM).  
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R.2.2.3 Influence of MAPK inhibition on PI3K/Akt signaling 
Akt signaling, alongside p53, plays a central role in controlling cell fate decisions. MAPK signaling 
is tightly connected to Akt, since Ras signals also activate PI3K, which signals via PIP3 to 
phosphorylate and activate Akt. On the one hand, Akt signals to inhibit apoptosis, e.g. via 
inhibition of BAD, or via regulation of pro-survival transcription factors. On the other hand, Akt 
activates the mammalian target of rapamycin (mTOR), which controls cell metabolism, and is a 
central regulator of autophagy. In its active phosphorylated state, mTOR inhibits autophagy, via 
yet unclear mechanisms.  
 
Even though the MAPK inhibitors we use inhibit MAPK signaling downstream of Ras, it seems 
likely that dysregulation of MAPK signaling also alters PI3K/Akt signaling. Indeed, our evaluation 
of phosphorylated and total amounts of Akt protein implicates that MAPK perturbations can lead 
to dysregulation of Akt signaling (Figure R-16), presumably via feedback-loops from Akt/mTOR to 
the MAPK pathway [87]. The observation that all cells possess a weak baseline phosphorylation 
of Akt (<500 MFI), is an indicator for a non-mutant PI3K pathway, since PI3K-mutated cells are 
characterized by much higher intrinsic Akt levels, e.g. PI3K-mutated MCF7 cells (Appendix Figure 
1).  
 
 
 
Figure R-16 - Total and phosphorylated amounts of Akt are altered in response to MAPK inhibitor treatment. Kinetics 
include the treatment with U0126 (10µM), AZD6244 (3µM) and Sorafenib (5µM). 
 
In Ma-Mel-48a and -48b cells, phosphorylated Akt (Ser473)  levels increase in DMSO controls 
cells at 24 hours of MAPK inhibitor treatment, and remain stable. However, this increase is 
suppressed by the three inhibitors in Ma-Mel-48 cells. The phosphorylated picture is partially 
reflected in corresponding total Akt levels of Ma-Mel-48a and -48b. Ma-Mel-48c seem to follow 
the trend of Ma-Mel-48a and -48b cells, but the increase in phosphorylated Akt is not as 
pronounced in Ma-Mel-48c. A-375 show a different regulation of Akt: Phosphorylated levels first 
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seem to increase with U0126 and Sorafenib treatment, in contrast to Ma-Mel-48 cells. In DMSO-
treated cells, phospho-Akt levels slightly increase after 12 hours, but return to baseline levels 
after 24 hours of treatment. In sharp contrast to Ma-Mel-48 cells, Sorafenib treatment in particular 
results in late Akt-phosphorylation that peaks at 48 hours and 72 hours respectively. Total levels 
of Akt in A-375 cells are low and stable across all samples. Of note, the observation of lower total 
Akt levels than phospho-Akt values can be explained by the detection of total Akt1 only. However, 
like in most melanoma cells, Akt3 is primarily expressed but not detectable (personal 
communication by A. Paschen, University Hospital Essen).  
 
In conclusion, the primary melanoma lines Ma-Mel-48 and the established A-375 line differ in 
their kinetics of phosphorylated and total levels of JNK, c-Jun and Akt, despite the fact that 
homogeneous inhibiton of ERK1/2 is achieved  by all three inhibitors. In addition, there is 
variability between the three melanoma lines although they carry the same G469RBRaf mutation 
and were derived from one single patient. Thus, inhibition of phospho-ERK1/2 is a common 
denominator of MAPK inhibition at BRaf or MEK, but it is not at all reflecting individual reactions 
to other kinases or transcription factors.  
 
R.2.2.4 Influence of MAPK inhibition on phosphorylated and total amounts of 
p53 
P53 signaling and transcriptional activity results in three major outputs; cell cycle arrest, cellular 
sensescence and/or apoptosis. The tightly regulated p53 protein is not only under control of JNK 
signaling, but also induced by a number of stress signals, including DNA damage, oxidative 
stress and activated oncogenes. Therefore, dysregulation of p53 through MAPK inhibition could 
have major effects on cell fate. Figure R-17 shows the kinetics of phophorylated and total protein 
p53 levels (phosphorylation at Ser15). In all cell lines, and for phosphorylated as well as total 
protein levels, an upregulation of p53 during the first 12 hours is detectable, which then 
decreases again to initial levels after 24 hours. This is probably due to a cell cycle dependent 
stabilization of p53. As we have shown in Figure R-3, inhibition of proliferation in comparison to 
DMSO controls starts to be visible as early as 20 hours after the start of treatment, some effects 
are dependent on the cell cycle, and become detectable only in thight kinetics.  
 
  Results 
 
  69 
 
 
Figure R-17 - Phosphorylated and total amounts of p53 are tightly connected and modulated with MAPK inhibitors. 
Cells have been treated with U0126 [10µM], AZD6244 [3µM] and Sorafenib [5µM] for 96 hours and subjected to phosphoplex 
analysis. 
 
All Ma-Mel-48 cells show a similar regulation of p53 in response to treatment with MAPK 
inhibitors. During the first 24 hours of treatment, a transient increase in both, phospho- and total-
p53 levels is detectable that can be somewhat stronger in the presence of inhibitors. After 24 
hours, phosphorylated levels in DMSO controls further increase substantially. Remarkably, this 
effect is not seen in MAPK inhibitor treated samples. In this setting, the comparison of 
phophorylated and total protein levels shows a strong correlation for all three cell lines. In contrast 
to Ma-Mel-48 cells, A-375 cells shows a different behavior. After 24 hours, only Sorafenib-treated 
cells show a strong upregulation of p53 phosphorylation and to a lesser extent total p53 too.  
 
In conclusion, the analysis of Phosphoplex data shows a strong impact of MAPK inhibition on 
various pathways, which play central roles in the control of cell fate, like p53, Akt, and JNK. In 
addition, the use of MAPK inhibitors has to be thoughtfully evaluated before treatment, on the one 
hand because the inhibitors U0126, AZD6244 and Sorafenib showed different effects on the 
regulation of phosphorylated and total amounts of proteins, which in conclusion means that the 
choice of inhibitor does matter - even small differences in mechanisms of action or target 
specificity can lead to large changes. On the other hand, the target cells have to be evaluated as 
well, because the effects of treatment varied between cell lines, even if the genetic heterogeneity 
is as limited as in Ma-Mel-48 cells. Our approach also reveals the need for analysis of immediate 
as well as long-term effects of MAPK inhibition. 
This comprehensive approach of pathway analysis underlines the interconnectivity of the MAPK 
pathway with JNK, PI3K/Akt and p53 signaling. Even specific inhibition of single proteins, as seen 
with U0126 and AZD6244, has widespread effects on cell signaling, which have to be taken into 
account. 
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R.2.2.5 Western Blots confirm Phosphoplex findings 
Phosphoplex assays are a newly established and improved method to analyze cell signaling. In 
order to confirm our Phosphoplex findings, we performed Western blots from the same lysates 
which have been used for Phosphoplex analysis. We picked A-375 cells and p53 protein to test 
the reproducibility of our findings, and tested all lysates from 0-96 hours in response to MAPK 
treatment. Figure R-18 shows that the results of Western blot (Figure R-18A) and phosphoplex 
analysis (Figure R-18B) correlate well. 
 
 
Figure R-18 - Western Blot analysis confirms Phosphoplex analysis of total p53. The same lysates which have been used 
in Phosphoplex analysis were used to confirm our results in Western Blot experiments. The comparison of Western Blot and 
Phosphoplex analysus reveals a strong correlation between both methods. Phosphoplex analysis proves to be more sensitive 
and quantifiable than Western Blot measurements. 
 
Phosphoplex analysis shows low fluorescence values for p53 within 30 minutes. Accordingly, 
there is no detectable p53 in Western Blot analysis at this timepoint. After 6 hours we see 
increases in p53 content for U0126, AZD6244 and Sorafenib treated cells, and only a slight band 
of p53 in the DMSO control sample. This fits nicely to Phosphoplex analysis, with low amounts for 
DMSO, and higher amounts for MAPK inhibitor treated cells. The correlation of Western Blot and 
Phosphoplex data remains tight over the course of 96 hours. At 12h and 24h, a high amount of 
p53 is detectable in all 4 samples. After 48 hours, until the end of treatment, p53 is reduced in 
U0126 and AZD6244-treated samples, and even increased in the Sorafenib-treated sample, 
compared to DMSO. In Western Blots, p53 becomes undetectable from 72 hours to 96 hours in 
inhibitor-treated cells. DMSO levels of p53 remain stable in Western Blot until the end of 
treatment; Sorafenib is still detectable after 72 hours, but not anymore at 96 hours of treatment. 
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In conclusion, the comparison of Western Blot and Phosphoplex analysis shows a perfect 
correlation of protein levels for all samples and timepoints. Phosphoplex analysis is more 
sensitive than Western Blot analysis, and thus, even slight differences between the samples are 
easily visible and quantified. 
 
R.3 MAPK inhibition influences balance between 
apoptosis and autophagy regulation 
P53, Akt and JNK play dual roles in the critical regulation of autophagy and apoptosis. P53, 
known as the guardian of the genome, controls cell-cycle progression and the induction of 
apoptosis in response to DNA damage, and other cell stress signals. It has also been shown that 
cytoplasmic p53 inhibits autophagy induction, whereas nuclear p53 does not [73]. Akt was shown 
to inhibit apoptosis, as well as autophagy, and JNK was shown to induce apoptosis, as well as 
autophagic cell death [88]. In addition, other proteins well-known for their role in regulation of 
apoptosis, e.g. Bcl-2, have been implicated in autophagy regulation. 
The role of autophagy as such, is proposed to have cytoprotective functions, but in parallel, 
dysregulation of autophagy can lead to cell death, described as programmed cell death type II. 
These discrepancies are controversely and intensively discussed in current research in this field. 
As autophagy is currently limited by the established methods to quantifiy its activity, I wanted to 
develop an approach that allows the simultaneous monitoring of apoptosis and autophagy at 
single cell levels. I took advantage of the ImageStream System, which is a flow-based imaging 
cytometer. Like FACS analysis, it provides high content measurements with high statistical 
significance, and combines this with the advantages of single cell inspection in fluorescence 
microscopy.  
 
R.3.1 Monitoring apoptosis with the ImageStream 
The approach of monitoring apoptosis with the ImageStream system is based on DNA staining, 
and the occurrence of DNA fragmentation and nuclear condensation in response to induction of 
apoptosis, and has previously been established for the ImageStream [84]. Measurements of 
nuclear fragmentation correlated with secondary methods of detection of apoptosis over time, 
which indicated that it is also an early marker for apoptosis. I used this method to establish the 
quantification of apoptosis in A-375 cells, following treatment with Sorafenib, which induced 
apoptosis more efficiently compared to AZD6244 and U0126. Therefore, A-375 cells have been 
treated with DMSO and Sorafenib for 24 hours, and then analyzed with the ImageStream system. 
 
Nuclear fragmentation (Bright detail intensity threshold) and nuclear condensation (area 
threshold) analysis of 10000 cells per sample identified only a small population of apoptotic cells 
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after DMSO treatment (Figure R-19A). With high-dose [20µM] Sorafenib treatment however, we 
observed a large shift in distribution towards apoptotic cells, with a total of 67%.  
 
Figure R-19 - Identification of apoptotic cells based on nuclear condensation and nuclear fragmentation with the 
ImageStream. A total of 20000 cells have been collected per sample. Apoptosis was induced through Sorafenib (20µM) 
treatment for 24 hours. A Quantification of apoptotic cells based upon DNA staining with Hoecht 55432, and the detection of 
fragmented DNA and nuclear condensation. B Example pictures for living and apoptotic cells. Note the occoring DNA 
fragmentation in the Hoechst channel. Additionally to Hoechst, we have staind HLA class I. SSC= Side-ward scatter, BF= 
brightfield, Merge and Merge2 contain merges of Hoechst, BF and HLA class I channels. C Quantification of apoptotic cells 
upon treatment with Sorafenib (20µM) for 24 hours.  
 
Corresponding pictures for living and apoptotic cells are shown in Figure R-19B, which clearly 
shows the extent of nuclear fragmentation in Hoechst-channel images. Also displayed are side 
scatter (SSC), brightfield (BF), HLA class I staining (HLA-I) as homogeneous surface staining, 
and merges of these channels. Figure R-19C shows a quantification of gated apoptotic cells for 
DMSO and Sorafenib treatment, showing more than 60% of apoptotic cells for Sorafenib 
treatment, and less than 5% for DMSO.  
 
In conclusion, the ImageStream provides a new and improved method to identify apoptotic cells 
based on single cell analysis, but for large populations of cells. 
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R.3.2 Monitoring autophagy with the ImageStream 
Autophagy is a well-conserved response of eukaryotic cells to degrade portions of the cytosol and 
cytoplasmic organelles. During autophagy, they are sequestered in characteristic 
autophagosomes and delivered to lysosomes, where they are degraded by proteases, for the 
recycling of amino acids for instance. 
Monitoring autophagy depends on the autophagosome-specific marker LC3 [59]. LC3 exists in 
two forms, the cytosolic LC3 I, and LC3-II, bound to autophagosome membranes. Upon induction 
of autophagy, LC3 I is converted to LC3 II by the attachment of Phosphatidylethanolamin (PE) 
and is then recruited to autophagosome membranes by the atg5-atg12 complex [89]. LC3 II 
remains attached to the membrane of autophagosomes until its degradation in the lysosome. 
Commonly used methods to monitor autophagy are (i) Western blot experiments, which detect 
conversion of LC3I to LC3II; (ii) FACS which uses mean fluorescence of GFP-LC3 signals as a 
read-out of autophagic activity, and (iii) fluorescence microscopy through detection of GFP-
labeled autophagosomes. These established methods all are insufficient in terms of either lack of 
specificity and quantification, or lack of statistical significance: Western Blot analysis is relatively 
unspecific in detection of the conversion of LC3, and hard to quantify [90] as shown in Figure 
R-20A. The addition of BafA1 leads to enhanced conversion of LC3-I to LC3-II, as seen in both, 
full medium as well as starvation medium. Under cumulative conditions in starvation medium we 
observed the strongest expression of LC3-II. 
 
 
Figure R-20 - Comparison of established methodologies for autophagy monitoring. A Western Blotting shows the 
increased capture of LC3II under cumulative conditions (with Bafilomycin A1) after 3h, in full medium (FM) as well as starvation 
medium (KH). B High resolution fluorescence microscopy visualizes GFP-LC3 under starvation conditions for 3h. Notice the 
large increase of LC3-GFP dots under cumulative conditions. Western Blots and fluorescence microscopy were performed in 
the lab of N.R. Brady (Bioquant, Heidelberg).  
 
FACS analysis provides statistical significance due to the large number of analysed cells but 
lacks specificity, because it does not provide any spatial information in the cellular distribution of 
the GFP-LC3 signal. In addition, both methods suffer from the finding that population average 
analysis is unable to account for occurring heterogeneity within cell populations in autophagic 
responses. Fluorescence microscopy provides the required sensitivity for specific detection of 
autophagosomes (Figure R-20B), but lacks statistical significance due to the limited number of 
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cells that can be analysed per sample and simultaneously. Analysis of fluorescence micrscopy 
involves manual inspection of acquired images and is therefore prone to subjectivity. In 
monitoring of autophagy, the challenge then was to develop a method which combines both 
needs: an integration of high-content analysis, and highly specific analysis on single-cell levels. 
We hypothesized that the ImageStream provides the possibility to establish such a new and 
improved method to quantify autophagy under different conditions with statistical significance.  
 
In order to establish the method, the breast cancer cell line MCF7 was stably transfected with a 
vector encoding the GFP-LC3 fusion proteins. MCF7 cells do not carry activating Ras or Raf 
mutations, but possess a E545KPI3K mutation and are caspase-3 deficient. The activating PI3K 
mutation was confirmed in phosphoplex analysis, displaying constitutively high phosphorylated 
levels of Akt (Appendix figure 1). As in fluorescence microscopy, images acquired with the 
ImageStream show a cytosolic distribution of GFP-LC3 in non-autophagic cells, because under 
these conditions, LC3 is in its cytosolic LC3-I form. Upon induction of autophagy, for instance by 
starvation, LC3-II is recruited to autophagosomal membranes and then appears punctuated 
(compare Figure R-21). The amount of LC3-II is closely related to the number of 
autophagosomes, serving as a good indicator of autophagosome formation. Following fusion of 
autophagosomes with lysosomes, LC3-II is degraded and additionally, acidification in 
autolysosomes leads to an early quenching of the GFP signal, so the interpretation of results can 
be difficult [90]. Lysosomal inhibitors, e.g. Bafilomycin A1, inhibit the degradation of 
autophagosomes and therefore the loss of the GFP-LC3-II signal, but leaves LC3-I unaffected. 
The comparison of steady-state conditions (without lysosomal inhibition) and cumulative 
conditions (addition of Bafilomycin A1) is widely accepted as necessary for the quantification of 
true autophagic flux [60]. 
 
We analysed MCF7 GFP-LC3 cells under steady-state and cumulative conditions in full medium, 
as well as starvation medium in order to set up an automated detection of GFP-LC3 spots within 
cells. For each sample, we collected 10000 cells. Based on the manual inspection of cells with 
GFP-labeled autophagosomes, we created a “spot mask” to objectively detect autophagosomes. 
Based on our settings, measurements of 0 to 40 spots per cell, for full medium and starvation 
medium, under steady-state and cumulative conditions were obtained. Example pictures of cells 
and the application of the spot mask are shown in Figure R-21A. These findings underline the 
heterogeneity of autophagic responses within a population of cells, which is ignored using 
population average analyses like Western Blots and simple FACS analysis. In order to account 
for this heterogeneity, subpopulations of autophagic activity were defined: First, we gated on cells 
with 0-4 spots which show a rather cytosolic distribution of GFP-LC3 and therefore LOW 
autophagic activity. Second, we gated on cells with 5-12 spots, which show increased spot 
formation alongside a large decrease in cytosolic GFP-LC3 expression and therefore MEDIUM 
autophagic activity. Third, we defined a population of cells with HIGH levels of autophagic activity, 
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comprising cells with more than 12 spots, which show no more cytosolic GFP-LC3 expression. 
Figure R-21A shows respective pictures for each subpopulation, and Figure R-21B shows the 
gating of the respective populations. 
 
 
Figure R-21 - Example pictures of MCF7 GFP-LC3 cells showing LOW, MEDIUM and HIGH autophagic activity. A Shows 
MCF7 GFP-LC3 fluorescent cells, after 3h starvation under cumulative conditions. The response is heterogenic, and 
categorized in subpopulations of low, medium and high activity. B Definition of subpopulations, according to spot count 
numbers.  
 
The defined subpopulations were used to further analyze the autophagic response of MCF7 GFP-
LC3 cells, and introduce the metric of “autophagic flux”. After 3 hours in starvation medium and 
steady-state conditions (w/o BafA1), 73% of cells belong to the population of low activity, 26% to 
medium, and 1% to high autophagic activity (Figure R-22A). With the addition of BafA1, which 
inhibits the degradation of newly formed autophagosomes, the subpopulation distribution shifts 
accordingly: Only 22% of cells show low activity, 63% of cells show medium activity and 15% of 
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cells fall into the gate of high activity. The corresponding results for full medium are displayed in 
Figure R-22C.  
 
Figure R-22 - Subpopulations of autophagic activity shift under cumulative and steady-state conditions. MCF7 cells 
were cultured for three hours in starvation medium (A and B) or full medium (C and D) under steady-state and cumulative 
conditions. Autophagic flux was calculated from the substration of steady-state levels from cumulative levels for each 
subpopulation, integrating both conditions (B and D).  
 
With measurement of steady-state as well as cumulative conditions, autophagic flux can be 
calculated by substracting steady-state from cumulative conditions for each subpopulation (Figure 
R-22B and D). This integration of steady-state and cumulative conditions leads to values of -51, 
37 and 14 (low, medium and high) for EBSS, and -55, 44 and 11 for full medium. 
 
The resolution of the first-generation ImageStream is 0.5µm2 per pixel. The size of 
autophagosomes varies between different cells, with values ranging from 150nm to 1µm [91]. 
Therefore it is possible, that the software detects clusters of autophagosomes as single spots, 
because of insufficient resolution. Our method was further improved by taking into account the 
size and intensity of detected spots through the introduction of the secondary metrics “normalized 
spot intensity” and “normalized spot area”. They are normalized at the single cell level, by 
calculating the ratio of “spot area/intensity” and “cell area/intensity”. I created a tight object mask, 
based on the brightfield signal of the whole cell, to comprise the size of the cell. The GFP 
intensity and the area of this mask was calculated as “area object” and “intensity object”. The 
same was calculated for the spots within a cell, named “area spots” and “intensity of spots”. 
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“Normalized spot area” is the area of spots divided by the area of the object, and “normalized 
spot intensity” calculates as the intensity of spots divided by the intensity of the object. These 
secondary metrics can be additionally used to describe and analyze autophagic responses for 
each subpopulation, as shown in Figure R-23. 
 
 
Figure R-23 - Normalized area and intensity support spot detection analysis. Secondary metrics account for the relative 
size and intensity of detected GFP-LC3 spots, to further characterize the autophagic response.  
 
“Normalized spot area” shows large increases from steady-state to cumulative conditions, for 
EBSS as well as FM. (Figure R-23, A). The difference between basal autophagy (FM) and 
starvation-induced autophagy (EBSS) displays as a 2-fold increase in total normalized area, best 
seen with the comparison of flux between EBSS (0,03 – 0,05 – 0,06) and FM (0,01 – 0,03 – 
0,02). “Normalized spot intensity”-analysis underlines these findings. (Figure R-23, B) 
 
Valid detection of autophagosomes depends on the specificity of the GFP signal to LC3, because 
unspecific GFP fluorescence could lead to false-positive detections of autophagosomes. In order 
to validate my analysis of autophagic activity, MCF7 GFP-LC3 cells were treated with the PI3K 
inhibitor Wortmannin [92]. Wortmannin-mediated inhibition of PI3K has been shown to inhibit 
autophagy [93] and should therefore decrease spot numbers and lower the values of normalized 
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spot area and intensitiy. Respective cells were treated for 3h in full medium and starvation 
medium, under steady-state and cumulative conditions with Wortmannin [50µM] (Figure R-24).  
 
 
Figure R-24 - ImageStream analysis shows inhibition of autophagy following Wortmannin treatment. The data is 
summarized with the depiction of % changes between autophagic flux values of Wortmannin-treated MCF7 cells and control 
samples. From left to right, quantifications of spot count analysis, normalized area and normalized intensity. All conditions and 
metrics show large inhibiting effects of Wortmannin treatment. 
 
The effects of PI3K-inhibition are depicted as percent changes. The percent changes are based 
on autophagic flux measurements to integrate cumulative and steady-state conditions, and the 
change of Wortmannin treatment is calculated relative to control treatment (same conditions 
without Wortmannin). Subpopulation distribution shows substantial decreases in the medium and 
high subpopulations and a strong increase in the low subpopulation in starvation medium (EBSS) 
as well as in full medium (Figure R-24). Wortmannin treatment shifted subpopulation distributions 
towards low and medium, showing a strong inhibition of autophagic activity. Normalized area and 
normalized intensity emphasize this inhibition, by displaying large decreases for all 
subpopulations and treatments. 
 
In conclusion, we have established a new ImageStream-based method to monitor autophagy. It 
combines large sample sizes with the identification of autophagic activity on single-cell levels. 
After manual inspection of cells, we were able to set up an objective automated analysis of 
autophagic activity, using the definition of spot masks to identify autophagosomes and a count 
feature. The definition of subpopulations for low, medium and high autophagic activity based on 
autophagosome numbers, captures the observed amount of heterogeneity in autophagic 
responses. Measurements of steady-state and cumulative conditions allow for the calculation of 
autophagic flux. This integrated metric is a valuable read-out for true autophagic activity.  
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R.3.2.1 Identification of JNK and NFkB as key regulators of autophagy 
The ImageStream-based method is superior to common methods of autophagy monitoring. 
Therefore one of the goals of my thesis was to define the roles of JNK, NFkB, Bcl-2 and TNFα in 
the regulation of autophagy by using this technology. These proteins are controversely discussed 
in autophagy research. Therefore, small molecule inhibitors were selected to target JNK 
(SP600125), NFκB (QNZ) and Bcl-2 (HA141), or to activate TNFRI signaling through the addition 
of TNFα. To focus on starvation-induced autophagy, and immediate effects of pathway 
perturbations, MCF7 GFP-LC3 were cultured cells for 3h in starvation medium in the presence of 
the respective drugs. Surprisingly, addition of TNFα had no effect on subpopulations distributions, 
indicating that the TNFRI signal alone, in not one of the driving forces in autophagy induction of 
these cells. In contrast, inhibition of JNK or NFκB resulted in striking shifts in subpopulation 
distributions, that were clearly detectable under cumulative conditions of starvation-induced 
autophagy: Inhibition of JNK by SP600125 leads to an increase in the high activity spot count 
population (16%25%), and a corresponding decrease in the low activity spot count population 
(22%15%; both Figure R-25 - cumulative). Medium populations remain at ~60%. In contrast to 
JNK inhibition, NFkB inhibition has a strong inhibitory effect on autophagy, that becomes nicely 
visible under cumulative conditions. The low spot count activity population increases to 52%, from 
22% under control conditions, which is accompanied by decreases in medium and high activity 
populations. Similar to TNFα treatment, Bcl-2 inhibiton had only minor effects.  
 
 
Figure R-25 - Pathway perturbation reveals autophagy regulation under starvation conditions. The regulative potential of 
TNFR, JNK, NFκB and Bcl-2 was evaluated in MCF7 GFP-LC3 cells, during 3h treatment periods in starvation medium. The 
data summarizes at least 5 experiments for each condition. NFκB inhibition leads to strong inhibition of autophagy, JNK 
inhibition induced autophagy above control conditions.  
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Steady-state conditions (w/o BafA1) show only minor changes in subpopulation distributions for 
all treatment conditions, underlining the need for careful evaluation of cumulative and steady-
state conditions to assess regulated autophagic activity. The high amount of “low” detected 
activity in steady-state conditions, also assures, that increased numbers of spots under 
cumulative conditions are not due to a block in the degradation of autophagosomes, as this would 
be also visible in steady-state conditions. Because of the constant levels in steady-state 
measurements, the calculation of autophagic flux and corresponding percent changes of 
treatment analysis primarily reflects the changes observed under cumulative conditions: It shows 
a 54% increase in the high spotcount subpopulation with the JNK inhibitor, and a 48% increase in 
the low spotcount subpopulation with inhibited NFkB.  
 
In conclusion the ImageStream-based method was useful to clarify the role of JNK, NFκB, 
TNFRI and Bcl-2 in autophagy in MCF7 breast cancer cells. Surprisingly, neither TNFRI nor Bcl-2 
seem to play a major role in the regulation of starvation induced autophagy, since addition of 
TNFα, or inhibition of Bcl-2 had no significant effect on the subpopulation distribution. In sharp 
contrast, JNK was identified as a negative regulator of autophagy, because JNK-inhibition 
increased autophagic activity under starvation conditions. Remarkably, NFκB seems to be 
required for the induction of autophagy since addition of an NFκ inhibitor suppressed autophagy 
substantially.  
 
R.3.2.2 Sorafenib inhibits autophagy in MCF7 GFP-LC3 cells 
The MAPK pathway has been proposed to be tightly connected to autophagy regulation. Highly 
active ERK signaling has been reported to disrupt autophagosome formation [94]. On the 
contrary, it was recently shown that hyperactivated ERK signaling, as a consequence of BRaf 
mutation, leads to induction of autophagy and inhibition of melanoma growth. [77]. To clarify 
whether these discrepancies arise from the different mutation status in tumor cells, the V600EBRaf-
mutated A-375 melanoma cells were compared to PI3K-mutated MCF7 cells. Therefore, a stably 
GFP-LC3 transfectant of A-375 was established and analyzed with the ImageStream-based 
approach. 
 
As seen in Phosphoplex analysis with BRaf-mutated melanoma cells, BRaf or MEK perturbations 
also led to changes in phosphorylation of Akt, p53 and JNK pathways which are all involved in the 
regulation of autophagy as well as apoptosis. In order to see whether PI3K-mutated MCF7 cells 
are sensitive to BRaf or MEK inhibition with respect to autophagy induction, these cells were 
treated with Sorafenib, U0126 and AZD6244 and analyzed with the ImageStream. The effects on 
phosphorylation status of MEK, ERK, Akt and p53 were analyzed by phosphoplex experiments 
that confirmed the constitutively active phospho-Akt status and inhibition of MEK/ERK 
phosphorylation following treatment with MAPK inhibitors in MCF7 cells (Appendix figure 1). 
  Results 
 
  81 
MCF7 GFP-LC3 cells are caspase-deficient and were therefore analysed for autophagy only, not 
for the induction of apoptosis. To analyze the effects of MAPK treatment on autophagic activity, 
MCF7 GFP-LC3 cells were treated for 24 hours with MAPK inhibitors and controls in full medium. 
The evaluation of steady-state conditions in Figure R-26 shows no autophagic activity for all 
treatments, indicating that MAPK inhibition does not affect the process of autophagy. Under 
cumulative conditions however, a substantial increase in the low activity spotcount population of 
Sorafenib-treated cells became visible. Compared to full medium only, the low population 
increases from 63% to 95% gated cells, and accordingly the high spotcount population virtually 
disappears.  
 
 
Figure R-26 - Sorafenib inhibits autophagy, unlike U0126 and AZD6244. MCF7 GFP-LC3 cells were treated for 24 hours in 
full medium with the MAPK inhibitors U0126 [10µM], AZD6244 [3µM] and Sorafenib [5µM]. The analysis reveals strongly 
inhibiting effects of Sorafenib on the induction of autophagy.  
 
While U0126 and AZD6244 had no effect on autophagic flux, Sorafenib suppressed autophagy 
completely. Along this line, the calculated percent change analysis shows a 91% increase in the 
low subpopulation of Sorafenib-treated cells, accompanied by 89% and 95% decreases in 
medium and high subpopulations respectively. This strong inhibiting effect of Sorafenib on 
autophagy by far exceeds the effects of NFkB inhibition observed before. 
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In conclusion – U0126 and AZD6244 had no significant effects on subpopulation distribution of 
autophagic activity. In contrast, Sorafenib completely inhibited the formation of autophagosomes, 
exceeding levels of inhibition we observed before with NFκB inhibitors. 
R.3.2.3 MAPK inhibition in melanoma cells shifts the balance between 
apoptosis and autophagy 
One of the most important differences to the MCF7 system is the constitutively active MAPK 
pathway in BRaf-mutated melanoma A-375 cells. In an effort to simultaneously quantify apoptosis 
and autophagy, I combined the ImageStream-based approaches to monitor autophagy and 
apoptosis. First, the responsiveness of stably transfected A-375 GFP-LC3 to starvation-incuced 
autophagy and specificity of GFP-LC3 were tested, and the achieved results of subpopulation 
distributions showed to be comparable to MCF7 GFP-LC3 cells (data not shown).  
In order to evaluate the immediate effects of MAPK-inhibitor treatment, A-375 GFP LC3 cells 
were cultured for 3h in full medium and starvation medium, under steady-state and cumulative 
conditions and in the presence of MAPK inhibitors. Figure R-27 shows the impact of MAPK 
inhibitor treatment on the regulation of autophagy. Steady-state conditions of starvation-induced 
autophagy (EBSS) show slight increases in the medium population of U0126 (22%), AZD6244 
(27%) and Sorafenib (31%) compared to DMSO treatment (17%). In cumulative conditions and 
starvation medium, we observe an increase in the low population of cells with Sorafenib treatment 
(26,6%) compared to DMSO (20,2%), along with a decrease of the high population.  
 
 
Figure R-27 - In A-375 GFP-LC3 cells, Sorafenib shows inhibiting effects on autophagy under starvation conditions 
within 3 hours. Analysis of MAPK inhibition on the induction of autophagy in A-375 GFP-LC3 cells, in full medium as well as in 
starvation medium. Cells have been treated for 3h with U0126 [10µM], AZD6244 [3µM] and Sorafenib [5µM].  
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The calculation of autophagic flux and the corresponding calculation of percent change of 
treatment shows that in starvation medium, Sorafenib has the strongest impact on autophagy 
regulation. The low population increased by 37%, while the medium population decreased by 
52%, and the amount of high cells was recuced by 23%. Notably, under full medium conditions, 3 
hours of treatment with MAPK inhibitors did not result in any immediate effects on autophagy 
regulation.  
Simultaneously to the analysis of autophagy, the amount of apoptotic cells in response to MAPK 
treatment was quantified by DNA staining with Hoechst, and occurring DNA fragmentation and 
nuclear condensation. Figure R-28A shows that under steady-state levels (fully functional 
autophagy), starvation for 3 hours induced apoptosis to a limited extent in all samples. Among all 
inhibitors, Sorafenib showed the highest amount of apoptotic cells (14%). In full medium under 
steady-state conditions, we observed only background levels of apoptotic cells, indicating that in 
full medium the cells protected against the immediate toxic effects of MAPK inhibition. 
 
 
Figure R-28 - Sorafenib treatment induces apoptosis after 3 hours, esspecially under cumulative conditions. 
Simultaneous to the analysis of autophagy, A-375 GFP-LC3 cells were analyzed for the induction of apoptosis with the 
ImageStream. In starvation medium, under steady-state conditions we detected 14% apoptotic cells in Sorafenib samples. 
Under cumulative conditions, this amount increased to 35%. In full medium, we observed less than 5% apoptotic cells in steady-
state as well as cumulative conditions. 
 
However, in starvation medium under cumulative conditions (Figure R-28B), an increase in 
apoptosis induction was observed. While DMSO treated samples showed comparable amounts of 
apoptotic cells, U0126 and AZD6244 treated samples showed somewhat increased amounts of 
17,8% and 19,7% respectively. Sorafenib treated cells, showed an even stronger induction of 
apoptosis with 35,4% apoptotic cells, compared to 9,5% in DMSO-treated control cells. In full 
medium samples, only background amounts of apoptotic cells were detectable, similar to steady-
state conditions. For the analysis of long-term effects of MAPK inhibition, I focused on full 
medium conditions only, because most cells died from starvation conditions within 24 hours. 
Additionally, Sorafenib was selected for this analysis, because it was implicated twice as a strong 
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regulatior of autophagy. As a positive control for autophagic activity, the DMSO- and Sorafenib-
treated cells (24 hours), were compared with a 3 hour starvation medium control sample. 
As seen in Figure R-29A, after 24 hours of treatment, Sorafenib in full medium achieves complete 
inhibition of autophagic activity in A-375 GFP-LC3 cells, whereby under cumulative conditions, 
the low population comprises 99,7% of cells. Since DMSO-treated cells show normal, basal levels 
of autophagic acitivty, the integration of steady-state and cumulative conditions reveals 
substantial differences between DMSO control and Sorafenib-treated cells, that are reflected in 
100% changes for all subpopulations. 
 
Figure R-29 - Within 24 hours of treatment Sorafenib achieves full inhibition of autophagic activity in A-375 GFP-LC3 
cells in full medium. A-375 GFP-LC3 cells have been treated for 24h Sorafenib [5µM] and DMSO as a solvent control. EBSS 
samples were starved for only 3 hours as a positive control for autophagy induction. A Quantification of autophagy, reveals that 
Sorafenib completely inhibited autophagic activity upon 24h of treatment with Sorafenib. B Simultaneous quantification of 
apoptotic cells, shows largely increased amounts of apoptotic cells in comparison to DMSO-treated samples.  
 
As shown in Figure R-29B, the parallel quantification of apoptosis by Hoechst staining revealed a 
strong induction of apoptosis following treatment with Sorafenib, in steady-state as well as 
cumulative levels. DMSO treatment showed only 0,1% of apoptotic cells in both conditions, which 
increased in response to Sorafenib treatment to 9,9% and 6,5% respectively.  
 
In conclusion, we have identified Sorafenib as a strong inhibitor of autophagy, in MCF7 GFP-
LC3 cells as well as in A-375 GFP-LC3 cells. In addition, Sorafenib treatment, induced a 
simultaneous strong induction of apoptosis in A-375 GFP-LC3 cells. Possibly, this underlines the 
cytoprotective function of autophagy. It seems that through inhibition of autophagy, the cells are 
more prone to undergo apoptosis. The dysregulation of autophagy and apoptosis implicates 
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strong effects on cell fate in response to Sorafenib treatment. In contrast to Sorafenib, neither 
U0126 nor AZD6244 showed significant effects on the regulation of autophagy or induction of 
apoptosis. 
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D.Discussion 
The frequently-mutated MAPK pathway in melanoma is a main focus in the search of therapeutic 
possibilities for metastatic melanoma patients. Several small molecule inhibitors have been 
developed to inhibit the MAPK pathway through inhibition of Raf or MEK. In an attempt to 
comprehensively analyize the effects of MAPK inhibition on melanoma cells, we have used 
U0126, AZD6244 (both MEK inhibitors) and Sorafenib (multi-kinase inhibitor with BRaf activity) 
for the treatment of melanoma cell lines. The major focus was on (I) cell surface molecule 
expression of melanoma cells involved in NK cell recognition, (II) the effects of treatment on 
cytokine/chemokine and growth factor secretion, (III) comprehensive analyses of cell signaling, 
and (IV) evaluation of the effects of MAPK inhibition on cell fate decisions regarding induction of 
apoptosis and autophagy.  
D.1 Modulation of immune cell recognition following 
MAPK inhibition 
The development of new inhibitors for MAPK inhibition usually involves tests in melanoma cell 
lines, as well as in preclinical mouse models. A commonly featured melanoma cell line is A-375, 
which carries the most frequent V600EBRaf activating mutation, and was therefore included in our 
set of melanoma cell lines. In contrast to A-375 cells, I included three primary melanoma lines, 
Ma-Mel-48a-c, which have been established from one patient over a timeperiod of one year, from 
different tumor sites. Ma-Mel-48a was established from a skin lesion, Ma-Mel-48b and -48c are 
both established from lymph node metastases. All three Ma-Mel-48 cells heterozygously carry the 
G469RBRaf mutation, which affects a region closest to the gate keeper domain in exon 11 of the 
BRaf gene.  
The evaluation of these melanoma lines revealed a loss of HLA class I expression in Ma-Mel-48c 
cells in FACS and WB characterization, comfirmed through the detection of a mutation in β2-
microglobulin in RT PCR (Figure R-1, and personal communication Annette Paschen, University 
Hospital Essen). In light of the evaluation of NK cell recognition of melanoma cells, Ma-Mel-48 
cells provide three different cell lines with the same mutation of BRaf, identical genetic 
background, but different levels of HLA class I expression. Since HLA class I expression on target 
cells is the main mechanism of NK cell inhibition in theory, the loss of HLA class I expression in 
Ma-Mel-48c cells should render them more susceptible for NK cell recognition and killing. I have 
therefore been surprised by the finding that Ma-Mel-48c cells are not killed more efficiently by the 
highly cytotoxic NK cell line NK92 than Ma-Mel-48b cells (Figure R-2). Interestingly, highly HLA 
class I positive Ma-Mel-48a cells seemed to be the most resistant cells to NK92-cytotoxicity. This 
experiment underlined that loss of HLA class I alone does not guarantee increased NK cell 
cytotoxicity against melanoma cells. This observation was confirmed by independent experiments 
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and melanoma lines by Annette Paschen (University Hospital Essen). Besides inhibition, NK cell 
activation also depends on the expression of ligands for activating receptors. Since this set of 
melanoma cell lines has been killed with different kinetics and to different extents by NK92 cells, 
this suggests that they activate NK cells to different levels, which could be related to individual 
expression of NK ligands. It has to be considered however, that the NK cell kill measured with the 
xCELLigence system included a time frame of 30 hours, in contrast to immediate kill assays like 
chromium release assays or CD107a degranulation assays. Thus, killing of melanoma cells by 
NK92 cells is an evaluation of rather slow and late effects of NK cell recognition. Nevertheless, 
the analysis led to the hypothesis, that Ma-Mel-48 cells may have low levels of ligands for the 
activating NK cell receptors NKG2D and DNAM-1, the two most relevant NK receptors in 
melanoma [51]. This was indeed shown to be the case and will be discussed in the context of the 
MAPK-inhibition-mediated alteration of the DNAM-1 ligand CD155 in particular. 
In order to visualize the effects of different MAPK inhibitiors on melanoma cell growth, we have 
made use of the xCELLigence system, which provides real-time quantification of tumor cell 
proliferation over time periods of several days. In these long-term proliferation tests, the four 
melanoma lines showed different susceptibility to MAPK-inhibition. I have detected reduced levels 
of proliferation in the presence of inhibitors in all cell lines, but A-375 cells were more susceptible 
to the treatment with U0126, AZD6244 and Sorafenib than Ma-Mel-48 cells (Figure R-3). This 
difference may be due to the different mutations of BRaf in A-375 and Ma-Mel-48 cells. A-375 
cells carry the strongly activating V600EBRaf mutation, which has been shown to enhance BRaf 
activity 500-fold compared to wild-type [16]. The “gate-keeper-like” mutation G469RBRaf in Ma-Mel-
48 cells in contrast, does not result in a comparably activated state of BRaf, which became visible 
by the lower starting levels of phospho-MEK (Figure R-10). This renders A-375 cells more 
sensitive to inhibition of MAPK signaling, as many studies have previously shown [95, 96]. 
Previous findings [24] as well as initial experiments have shown the need for short-term as well 
as long-term analyses of MAPK inhibition effects. Immediate events (30min-12h) primarily affect 
phosphorylation and stabilization of kinases, early events (12h-24h) rather affect cell cycle 
progression, and late events (>24h) affect surface expression of HLA and NK ligands. Hence, 
inhibition of the MAPK pathway in colon cancer cell lines revealed modulated cell surface 
molecule expression in response to treatment after 24 hours, depending on protein synthesis and 
transcriptional effects. Besides real-time monitored xCELLigence assays, I have therefore 
decided to analyze a defined kinetic, at the timepoints of 0’, 30’, 6h, 12h, 24h, 48h, 72h and 96 
hours in an effort to comprehensively capture different effects of treatment. 
 
The examination of various surface molecules on melanoma lines showed that CD155 was 
affected the most. The ligand for the activating NK cell receptor DNAM-1 was opposedly 
regulated: On the one hand by U0126 and AZD6244, which inhibited CD155 expression, and on 
the other hand by Sorafenib, which enhanced CD155 expression in Ma-Mel-48a and A-375 cells, 
and to a limited extent in Ma-Mel-48b cells (Figure R-4). This opposing alteration in CD155 
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expression became detectable at 24 hours with a further increased effect at 48, 72 and 96 hours, 
indicating that these changes are not directly connected to the immediate MAPK pathway 
inhibition. The occurrence of this effect in Ma-Mel-48a cells and A-375 cells hints that this effect is 
independent of the BRaf mutation. With MEK inhibitors going in one, and Raf inhibition going in 
the other direction, it seems more likely that the point of inhibition in the MAPK signaling cascade 
is critical for this effect. Additionally, Sorafenib, as a multi-kinase inhibitor, inhibits other targets 
besides Raf, which might be involved in expression of CD155. HLA class I expression is also 
affected in response to MAPK inhibition but in the opposite direction (Figure R-5). This 
modulation did not show to be important in the regulation of NK cell function. In addition, MICA/B 
and ULBP1-4, all ligands for the activating NK receptor NKG2D, showed very low expression 
levels in all melanoma lines, and have not been modulated in response to treatment. 
Functional consequences of this CD155 and HLA regulation in response to MAPK inhibition were 
examined in CD107a degranulation asssays (Figure R-6). The over-expression of CD155 
following Sorafenib treatment did not prove to further enhance NK cell activation, and showed 
levels of NK cell activation similar to DMSO control samples. But downregulation of CD155 led to 
reduced levels of NK cell degranulation, which implies the dependence of NK cell activation on 
the activating interaction between CD155 and the DNAM-1 receptor. The interaction of CD155 
ligand expression on tumor cells and activation of NK cells through DNAM-1 signaling has been 
described before. A challenge of DNAM-1 deficient mice with transplantation of CD155-positive 
sarcoma cells, showed increased tumor development and metastasis in these deficient mouse-
models, and increased occurrence of CD155 positive tumor cells. [97]. Further evaluation 
described the dependence of NK cells on activation through DNAM-1 for natural or cytokine 
suppression of tumor metastases, in the absence of NKG2D, or NKG2D ligands respectively. 
However, DNAM-1 was shown to be dispensable, if the tumor cells expressed ligands for 
NKG2D. [51]. Tumor cells have also been shown to downregulate DNAM-1 expression through 
chronic ligation [52]. In light of the importance of CD155 epxression for NK cell targeting of tumor 
cells, our results provide new insights with the modulation of CD155 by MAPK inhibition, which 
results in impaired NK cell-targeting of A-375 cells in the case of CD155 downregulation. 
Taken together, our results reveal a special role of CD155 in the context of MAPK inhibition in 
melanoma cell lines, resulting in differential modulation of CD155, and the implications for NK cell 
cytotoxicity. This raised several questions: Why is CD155 in this context more crucial than HLA 
class I or NKG2D-ligand expression for NK cell cytotoxicity regulation? Why do the MEK inhibitors 
have opposing effects on the expression of CD155 compared to the BRaf inhibitor Sorafenib? 
CD155 (PVR) is an immunoglobulin-like molecule, and was first described as the cellular receptor 
for poliovirus [98]. CD155 has been reported to be involved in cell-cell adhesion via a heterophilic 
trans-interaction with nectin-3 and stimulation of this receptor has been shown to inhibit cell 
adhesion and enhance cell migration [99, 100]. CD155 is also over-expressed in many human 
cancers [100-102]. The cytoplasmic domain of human CD155α contains a conserved 
immunoreceptor tyrosine-based inhibitory motif (ITIM), which is tyrosine-phosphorylated by Src 
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kinase family members (SrcK), and recruits SH2-containing tyrosine phosphatase-1 (SHP-1) and 
SHP-2. SHP-2 is a likely mediator of the cellular functions of CD155, since dominant negative 
SHP-2 inhibits cell migration and FAK dephosphorylation after stimulation of cellular CD155 in 
fibroblasts [103]. Furthermore, it has been reported in 2004, that mouse Necl-5 enhances cell 
proliferation by serum- or PDGF-stimulation through the MAPK signaling pathway [104]. 
Prompted by the structural and functional similarities of Necl-5 with human CD155, Tokuyuki et al 
have shown that CD155 also signals to enhace the proliferation of Ras-mutated cells [105]. They 
demonstrated that expression of a truncated version of CD155, lacking the cytoplasmic domain 
(CD155ΔCP), resulted in decreased levels of serum responsiveness in ras3T3 and DLD-1 
carcinoma cells, compared to wild-type CD155 expression. This suggests, that the cytoplasmic 
domain of CD155 containing an ITIM has a pivotal role in the growth support by CD155. 
Additionally, a dominant-negative effect of CD155ΔCP expression on cell proliferation in ras-
mutated DLD-1 cells was observed and hence, they speculate that CD155 expression might 
enhance the recruitment of SHP-2, which may then somehow activate the MAPK cascade, to 
facilitate the enhancement of serum-stimulated cell growth (compare Figure D-1). 
 
 
Figure D-1 - A model of the signal transduction from CD155 upon ligation. CD155 is tyrosine phosphorylated by members 
of the Src kinase family (SrcK) and recruits SHP-2 to the plasma membrane. In Ras-mutated cells, SHP-2 leads to enhanced 
cell proliferation through activation of the MAPK pathway. 
 
On the basis of this model, I hypothesize that the connection of CD155 with MAPK signaling is 
the main reason for the divergent effects on CD155 expression patterns. Additionally, I suggest 
that the link between SHP-2 recruitment and MAPK signaling probably can be postulated to lie 
between Raf and MEK, since inhibition of these kinases results in opposing effects. The situation 
in Ras-mutated cells furthermore implies an important role for CD155 in the regulation of 
proliferation in melanoma cells. We are planning to further study the role of CD155 in cell growth 
in an extended set of melanoma cell lines, to further elucidate this situation.  
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Nevertheless, NK cell recognition of Ma-Mel-48 cells showed to be very low, probably due to the 
low expression of NKG2D and natural cytotoxicity receptor (NCRs) ligands in particular. Even 
fresh pre-activated NK cells showed only low CD107a subpopulations in corresponding 
degranulation assays (Figure R-7). These findings suggest, that the relatively frequent loss of 
HLA class I molecules can be covered by NK cell because of their higher anti-tumor activity in the 
absence of HLA class I. However simultaneous downregulation of NK ligands via several 
mechanisms may counteract this opportunity. 
 
D.2 MAPK inhibition leads to changes in tumor 
microenvironment 
In an effort to comprehensively identify downstream targets of oncogenic BRaf V600E/MEK 
signaling, Marais et al found CXCL1 and CXCL8 (IL-8) downregulated in response to inhibition 
with the V600EBRaf-specific inhibitor PLX4720 [106]. Our analysis of cell culture supernatants of 
melanoma cell lines underlined and expanded these findings to more chemokines and growth 
factors. CXCL8 is produced by Ma-Mel-48a cells, but after 48 hours, MAPK treatment resulted in 
efficient downregulation. Since IL-8 (CXCL8) expression is driven by an AP-1 site, among other 
promotor sites, the suppression of c-Jun phosphorylation after 24 hours of MAPK inhibitor 
treatment could be involved in the suppression of IL-8 secretion in Ma-Mel-48 cells. Accordingly, 
Marais et al showed that the downregulation of IL-8 is mediated transcriptionally. Loss of IL-8 
secretion of Ma-Mel-48 cells could provide a survival benefit for disseminating cells, because this 
chemokine usually attracts granulocytes, T and NK cells. However, IL-8 is a double-edged sword 
in tumor biology, since it has also been shown to act as a growth promoter in tumor cells [107]. 
Similar to IL-8 - HGF, SDF-1α (CXCL12) and M-CSF have only been strongly secreted by Ma-
Mel-48a cells, and secretion was effectively down-regulated with all three inhibitors. This implies 
that their expression is at least in part driven by MAPK signaling. In addition, the chemokines IL-8 
and SDF-1α share with growth factors like VEGF, HGF, and M-CSF the transcriptional regulation 
by AP-1 sites in cooperation with NFκB and/or SP-1 and p53 sites. Therefore, this concerted 
action of MAPK inhibition of these factors may be due to the suppression of c-Jun and 
subsequent missing AP-1 dependent transcription of these genes. HGF, also known as scatter 
factor, is a pleiothrophic growth factor, stimulating motility and invasion of several cancer types 
via its receptor c-Met, and has also been shown to induce angiogenesis. Downregulation of HGF 
should therefore be desirable in tumor treatment. SDF-1α belongs to the CXCL chemokine family 
and acts as a strong attractant for T, B, and NK lymphocytes. Macrophage colony-stimulating 
factor (M-CSF) is a cytokine that primarily acts in hematopoiesis by controlling the production, 
differentiation and function of granulocytes and macrophages. The downregulation of these 
factors therefore provides beneficial as well as counterproductive effects of MAPK inhibition 
regarding tumor treatment.  
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Vascular endothelial growth factor (VEGF) has been shown to play an important role in 
angiogenesis. Secretion of VEGF was detected in all three Ma-Mel-48 cell lines, and was almost 
completely down-regulated following MAPK inhibition. In contrast to early reports of VEGF 
expression in melanoma [108], VEGF expression has recently been repeatedly related to 
melanoma progression serving as a negative prognostic factor for melanoma therapy responses 
[109-111]. Our findings suggest, that inhibition of MAPK signaling can lead to reduced expression 
levels of VEGF in melanoma patients and this is currently analyzed in a melanoma phase I 
clinical trial (personal communication D. Schadendorf, University Hospital Essen).  
In light of several changes in tumor immunology in response to MAPK inhibition, and NK cell 
recognition of treated melanoma cell lines, the secretion of macrophage migration inhibitory factor 
(MIF) was of special interest to us. In tumor biology, MIF has been proposed as a biomarker for 
prostate cancer [112]. Furthermore, MIF plays a critical role for angiogenesis, stimulates tumor 
cell migration, and suppresses p53 activity [113, 114]. Wischhusen et al showed that MIF may 
contribute to the immune escape of ovarian carcinoma by transcriptionally down-regulating 
NKG2D in vitro and in vivo which impairs NK cell cytotoxicity towards tumor cells [115]. Due to its 
potent tumor-promoting and escape properties, it would be very interesting to unravel the role of 
MIF expression in melanoma. As a known counterpart to p53, it might inhibit induction of 
apoptosis, and additionally influence NK cell recognition of melanoma cells. If MIF presents an 
important escape mechanism for melanoma cells, a correlation of responders and non-
responders with MIF expression levels in clinical studies, e.g. of Sorafenib treatment in metastatic 
melanoma, could provide an early opportunity to identify the potential benefit of treatment. Our 
data shows that MIF is only secreted by Ma-Mel-48b cells, and is strongly upregulated with 
Sorafenib, in contrast to all other factors that are downregulated. Through this sole role of Ma-
Mel-48b cells, and the strong impact of Sorafenib treatment, we hold a unique situation in our 
hands, to further elucidate the effects of MIF expression and over-expression with Sorafenib in 
context of melanoma immunology, and NK cell recognition. The possible escape mechanism via 
MIF will also be further investigated in our lab. 
Finally, SCGF-β turned out to be the only growth factor which was secreted from all Ma-Mel-48 
cell lines, but was not affected by MAPK inhibition. For the evaluation of chemokine and growth 
factor secretion profiles, this non-modulated expression pattern of SCGF-β is very important, 
because it shows that the observed inhibiting or increasing effects of MAPK treatment are specific 
and not due to some general impairment in protein synthesis. In addition, SCGF-β itself may act 
as an autocrine growth factor through its binding to the c-Kit receptor that is mutated often in non-
sun-exposed mucosal melanoma. Therefore, the inability of Sorafenib to suppress SCGF-β 
secretion may also contribute to the poor, non-existing effectiveness of this drug in melanoma. 
Taken together, the analysis of melanoma cell culture supernatants reveals strong effects of 
MAPK inhibition on the composition of the tumor microenvironment, which could have strong and 
far-reaching effects on tumor metastasis and tumor escape mechanisms.  
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Without accounting for our specific findings, Figure D-2 tries to give an overview of MAPK 
signaling, and its connections to surface molecule expression, chemokine and growth factor 
secretion, surrounding pathways and the induction of apoptosis and autophagy. The various 
effects of MAPK inhibition occur in a time-dependent manner. Surface molecule expression and 
the tumor microenvironment are longterm effects of treatment, whereas signaling events and the 
corresponding impact of pathway perturbations can occur immediately. 
 
 
Figure D-2 - Summarizing scheme of the multiple impacts of MAPK inhibition. Due to the interconnectivity of the MAPK 
pathway, inhibition has far-reaching effects on cell signaling, surface molecule expression, micrenvironment and the induction of 
apoptosis and/or autophagy. 
 
D.3 Surrounding effects of MAPK inhibition on other 
critical cell signaling pathways 
It is becoming increasingly clear that cell fate decisions in most mammalian cells are not 
regulated by one pathway alone. Rather, the combinatorial and quantitatively regulated activation 
of signalling pathways seems to determine the cellular response. The MAPK pathway is one of 
the most and best studied pathways in human normal and oncogenic cell signaling. Still, the 
systemic effects of MAPK inhibition in malignant and non-malignant cells are poorly understood. It 
is currently unclear, what the best method to study the widespread effects of MAPK inhibition 
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would be. We have applied Phosphoplex analyses to investigate the directly and indirectly 
connected pathways in regulation of cell fate decisions, which included JNK and c-Jun signaling, 
p53 activation and stabilization and Akt signaling, amongst others I did not report on in this work. 
As expected I have shown, that the three inhibitors show downstream inhibition of phospho-ERK 
within 30 minutes of treatment, and inhibition was sustained constantly for up to 96 hours. A-375 
cells have only been partially inhibited with Sorafenib (Figure R-9).  
ERK inhibition is achieved over different mechanisms of action. Sorafenib inhibits BRaf, upstream 
of MEK and ERK, and therefore achieves dephosphorylation of both, MEK and ERK. U0126 
binds to MEK, and inhibits phosphorylation of the kinase itself. AZD6244, in contrast, inhibits 
MEK function effectively, as we have shown complete inhibition of ERK phosphorylation, but 
surprisingly leads to a stabilized or even increased phosphorylation of MEK (Figure R-10). 
Presumably, it binds to MEK independent of its phosphorylation state, and thereby prevents 
dephosphorylation. Besides the different effects of U0126, AZD6244 and Sorafenib on MEK 
phosphorylation, our analyses also revealed a large difference between Ma-Mel-48 cells and A-
375 cells. All Ma-Mel-48 cells show relatively low amounts of p-MEK at starting points. In 
contrast, A-375 cells have large amounts of p-MEK at the start of treatment. This allows for some 
conclusions about the involvement of the different BRaf mutations. The G469RBRaf mutation, which 
is closely located to gate-keeper mutations, obviously does not lead to constitutively active MAPK 
signaling, because the downstream target of mutated Raf shows relatively low phosphorylation 
levels. In contrast, V600EBRaf leads to a strong constitutive MEK-activation as proposed before. 
This observation might contribute to the different susceptibility of Ma-Mel-48 cells and A-375 cells 
to MAPK treatment, as I have shown in xCELLigence analyses. The perturbation of constitutively 
active oncogenic V600EBRaf signaling through MAPK inhibitors in A-375 cells probably showed the 
largest impact, because oncogenic MAPK signaling plays a major part in transformation of these 
cells. Ma-Mel-48 cells instead, carry a gate-keeper-like mutation, and have probably acquired 
other mutations to drive transformation of these cells forward, which explains the smaller 
dependence on oncogenic BRaf signaling. These co-existing mutations possibly target PTEN, 
since a strong correlation of PTEN with BRaf and p53 with N-Ras has been described previously 
[116, 117] 
 
The analysis of phosphorylation proves ERK to be a good read-out for inhibitor activity. 
Surprisingly, not only phosphorylation of ERK and MEK was changed in response to MAPK 
inhibitors, but in addition, total protein amounts have been modulated. Total ERK levels showed 
little variation in Ma-Mel-48 cells. In A375 cells though, I have observed stable total ERK levels in 
MAPK inhibitor treated samples, but DMSO control lysates showed increasing total ERK levels 
(Figure R-11). Examination of total MEK levels again proved the different mechanisms of action 
of AZD6244 and U0126, since AZD6244 treatment led to the degradation of total MEK, whereas 
U0126 did not (Figure R-12). Such decreased total kinase levels become more visible in 
Phosphoplex assays, due to the more sensitive quantification in terms of MFI of more than 50 
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beads per sample and analyte, instead of density evaluation in Western Blots, where degradation 
of proteins can easily be mistaken as variations in loaded protein, or overlooked due to longer 
exposure times of the WB membrane. This technical reason may be responsible for the 
underestimation of total kinase changes in control samples and during MAPK inhibition. 
Therefore, direct comparisons between Phosphoplex and WB were performed for p53. These 
analyses used the same lysate and reveased an almost perfect correlation of phosphoplex 
analysis with Western Blot analysis, but higher sensitivity of the phosphoplex technique (Figure 
R-18). 
 
In light of our findings in the linear MAPK pathway, I decided to concentrate on JNK, p53 and Akt 
signaling to evaluate the effects of MAPK inhibition on other pathways involved in cell fate 
decisions. The JNK signaling pathway belongs to the superfamily of MAPK pathways and was 
originally described to be activated by stress signals like UV and gamma radiation, chemokines 
and interleukins. JNKs are also called stress activated phospho kinases (SAPK), and got their 
original name of “c-Jun n-terminal activating kinases” through their ability to activate and 
phosphorylate c-Jun. C-Jun regulates gene expression in combination with c-fos as the AP-1 
complex in the nucleus, and targets proteins involved in cytosceletal function, microenvironment 
and chemokines and regulates proteins of the BH3-only family involved in apoptosis.  
The anti-apoptotic Bcl-2 protein is inhibited through phosphorylation of JNK, while pro-apoptotic 
Bax is activated. Therefore JNK signaling is regarded as a pro-apoptotic pathway. Recently the 
view on JNK signaling has changed quite substantially, since Alexaki et al have provided 
evidence that JNK, in particular JNK1, supports the growth of melanoma cells, acting either 
through the control of cell cycle by regulating the expression of p21Cip1/Waf1, or by controlling 
apoptosis [118]. The controversial involvement in the regulation of autophagy will be discussed in 
the next section. In our melanoma lines, little influence of MAPK inhibiton on phosphorylated 
levels of JNK was shown, in fact phosphorylation levels of JNK are constantly very low (Figure 
R-13). The antibody used in phosphoplex analysis is supposed to recognize JNK1 and JNK2, yet 
in total there are ten isoforms of JNK existing in humans. The abundance of these isoforms might 
explain the low phosphorylation levels of JNK, because not all JNK isoforms are detected in this 
assay. Phosphorylation of c-Jun, which is directly regulated through JNK was strongly 
suppressed in the presence of MAPK inhibitors in Ma-Mel-48a and-48b (Figure R-13). In contrast, 
Ma-Mel-48c cells show increased levels of c-Jun phosphorylation at Serine 63 by Sorafenib 
treatment. This difference is very interesting based on the fact, that the Ma-Mel-48c cells, which 
are so closely related to Ma-Mel-48a and -48b, show different phosphorylation patterns. Along 
this line, A-375 cells show a JNK/c-Jun regulation again different from all Ma-Mel-48 cells. In 
inhibitor-treated samples an increase in c-Jun phosphorylation was observed, indicating that in A-
375 cells, AP-1 complex dependent transcription could be induced upon MAPK inhibition, which 
is further inverstigated.  
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The PI3K pathway is linked to the MAPK pathway via several signaling nodes, e.g. PI3K p110α 
[119]. Therefore, it was of interest to determine possible consequences of MAPK inhibition for Akt 
signaling. Phosphorylation of Akt at Serine 473 has previously been suggested to be regulated by 
Akt autophosphorylation in a PI3 kinase dependent kinase 1(PDK-1) dependent manner. 
Additionally, it has been shown that integrin-linked kinase (ILK) is also involved in 
phosphorylation of this site, and critical for kinase activity [120]. Recently, Akt Ser 473 has also 
been shown to be regulated through mTOR complexes 1 and 2 [121], leading to autophagy 
activation and other cellular responses. Its pleiotropic functions render Akt a critical player in 
autophagy and apoptosis activation which is discussed in detail in the next chapter.  
PI3K signaling can be dependent on Ras activation and since Ras is upstream of the inhibitors I 
used, it can only be altered as a result of feedback loops in Ras-Raf-MEK-ERK signaling. Our 
results implicate such feedback loops by showing that Akt phosphorylation, similar to c-Jun, is 
reduced in MAPK inhibitor treated samples in Ma-Mel-48a, -48b and -48c cells (Figure R-16). 
Again, A-375 cells show a different pattern of Akt regulation, especially because treatment with 
Sorafenib led to increased phosphorylation of Akt at Serine 473. Analogously to t-JNK, total levels 
of Akt are low in our analyses, and of special note, lower than phosphorylated levels. As the 
antibody for total protein should recognize phosphorylated as well as unphosphorylated protein, 
this appeared unlikely and I therefore assumed, that the effect is probably due to different 
specificity of Akt antibodies. Indeed, it turned out that the phospho-Akt antibody recognizes Akt 1-
3, whereas the total protein antibody only recognizes Akt1. The data suggests, that Ma-Mel-48 
cells express all three Akt isoforms, whereas A-375 cells, which show surprisingly low levels of 
total Akt, assumingly possess Akt2 and/or Akt3, a feature described for many melanoma lines 
[122]. Our analyses of components of the JNK/c-Jun and PI3K/Akt pathways revealed that BRaf 
as well as MEK inhibition, also affects other pathways, in part by a cell-specific manner. Thus, 
MAPK inhibition should be addressed in the future in the context of the JNK/c-Jun and PI3K 
pathway to get a more comprehensive view on possible links between signaling cascades. 
 
p53 functions primarily as a transcription factor, where cellular stress serves to activate and target 
p53 to genes that initiate accelerated DNA repair, inhibit cell cycle progression, or lead to 
senescence or apoptosis [123]. Since p53 plays a vital role in preserving the genetic integrity of a 
cell, it is not surprising that regulation of its activity is complex [124], by integrating several 
positive and negative feedback loops that either promote or reverse the stress response. One of 
these negative regulators, MDM2, binds to Serine15-non-phosphorylated p53, blocking its 
transcriptional activity and targeting it for ubiquitin-mediated proteasome degradation. P53 itself 
positively regulates MDM2 transcription, thus creating a negative autoregulatory feedback loop. In 
Ma-Mel-48 cells we observed reduced levels of phosphorylated and total amounts of p53 in 
MAPK-inhibitor-treated samples compared to DMSO (Figure R-17). In DMSO controls, p53 was 
obviously stabilized, which was detectable by increasing amounts of phosphorylated and total 
protein, whereas in U0126, AZD6244 and Sorafenib samples, the levels remained low. The 
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kinetics of Ma-Mel-48 cells display a biphasic curve with peaks at 6-12 hours and 72 hours 
respectively, and a valley at 24 hours. This time-dependent distribution of p53 indicates a close 
link to cell cycle and proliferation. In contrast to Ma-Mel-48 cells, A-375 cells show late p53 
stabilization in response to Sorafenib treatment only, preceeded by an early peak at 12 hours that 
was supported by MEK inhibition. The strong correlation of phosphorylated and total amounts of 
p53 underlines the strict regulation of active p53 via Serine 15 phosphorylation, which protects 
p53 from immediate degradation. The modulation of this regulation in Sorafenib treated A-375 
cells is of great interest, and could account for enhanced levels of apoptosis in A-375 cells, 
compared to Ma-Mel-48 cells.  
 
Altogether, the analysis of this phosphoplex data set is not intuitive, first of all due to the huge 
amount of data. Four phosphorylation profiles over 8 timepoints for 12 proteins, the same for total 
protein levels, and that across 4 cell lines, makes up for a total of 3072 datapoints. Secondly, the 
data is quite complex in terms of interactions and non-linear effects. We have therefore decided 
to use a systems biology approach, in order to establish off-target effects, interactions that 
contribute to the cellular response and to select the best procedure to inhibit tumor proliferation. 
Our computational modeling approach uses a data-driven “fuzzy logic” approach. Once we have 
established this analysis in cooperation with Nathan Brady and Marti Bernardo Faura (Bioquant, 
Heidelberg), it will hopefully enable us to comprehensively compare the response of our 
melanoma cells to MAPK inhibition, and unravel differences between the inhibitors themselves, 
as well as between cell lines. The model system will also be connected to functional responses, 
in order to identify protein kinases that are most likely responsible for variations in cellular 
reactions at the surface. The first response we are going to add is the modulated expression of 
CD155 on melanoma cells during MAPK inhibitor treatment. Subsequently, we can also relate it 
to induction of autophagy or apoptosis, which could help to further understand the observed 
variations in patient response to MAPK inhibitor treatment. In the future, such approaches could 
pave the way to predictions of patient responses, depending on the phosphorylation profile of the 
patient. 
 
D.4 MAPK inhibition modulates the balance between 
apoptosis and autophagy 
As our phosphoplex analysis has shown, even the specific inhibiton of a single protein kinase 
(MEK, U0126, AZD6244) can lead to cellular reactions apart from the linear signaling cascade. 
Therefore, I focused on pathways which are involved in the regulation of apoptosis and 
autophagy.  
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D.4.1 ImageStream-based approach for the quantification of 
autophagy 
Even though autophagy is a tremendeously expanding research field, it lacks an elegant and 
practical “go-to” method for correct quantification of autophagic activity. Common measurements 
of autophagic activity report an average or a typical response of a population, or changes to a 
pre-defined population, yet do not account for cell-to-cell variation. This is particularly relevant in 
the context of autophagy measurements using the macroautophagy-specific marker LC3 [59]. 
Typically GFP-LC3 is used to determine the number of cells displaying autophagosomes, or 
numbers of autophagosomes per cell based on manual counting. While fluorescence microscopy 
provides the necessary resolution for the detection of single autophagosomes per cell, 
classification is neither standardized, nor fully quantitative and objective. Moreover, steady-state 
autophagosome numbers, the most commonly reported autophagy metric, are not indicative for 
autophagic activity and can therefore not be considered a reliable indicator of autophagic flux 
[125]. 
I hypothesized, that an ImageStream-based method could provide a new and improved approach 
to address the methodological constraints in detecting autophagy by integrating high resolution 
imaging, the high-sampling capacity of flow cytometry and rich feature extraction for population-
level statistical analyses. In order to establish the new method for autophagy quantification, I 
have used MCF7 GFP-LC3 cells, which are commonly used in autophagy research. First steps in 
establishing the method were performed in starvation medium to induce autophagy, and imaged 
under steady-state versus cumulative conditions. This comparison is necessary, because the full 
process of autophagy involves the turnover of formation and degradation of autophagosomes, 
giving rise to punctuated as well as non-punctuated cells. Under cumulative conditions, I use the 
lysosomal inhibitor Bafilomycin A1, which inhibits fusion of autophagosomes to lysosomes, and 
therefore inhibits degradation of newly-formed autophagosomes, and the acid-induced quenching 
of GFP fluorescence. For a correct analysis of autophagic activity, it is necessary to compare 
steady-state levels to cumulative levels. The integrating metric “autophagic flux” is calculated by 
the substraction of steady-state levels from cumulative levels. First evaluations of autophagic 
activity in response to starvation supported the assumption of heterogenic responses within 
populations of cells. Thus, I observed non-spotted as well as spotted cells (Figure R-21), and 
sought to capture this heterogenic response with the definition of subpopulations of autopagic 
activity according to the spot count per cell. We have clustered cells with 0-4 spots as “low” 
autophagic activity, 5-12 spots as “medium” and more than 12 spots as “high” autophagic activity. 
The subpopulation distribution shifts significantly between steady-state and cumulative levels 
(Figure R-22). Of note, even after a 3 hour starvation period, which strongly induces autophagy, 
subpopulation distributions of around 20% low, 65% medium and 15% high autophagic activity 
were found under cumulative conditions. In this situation, without the degradation of 
autophagosomes, the high cell-to-cell variability in autophagic responses becomes visible, which 
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can not be evaluated by other methods based on population-average analyses. Besides the 
quantification of autophagy by the number of detected spots, I introduced the secondary metrics 
of normalized spot area and intensity to further characterize the cellular reactions. These metrics 
are secondary, because a priori, they depend on the identification of spots. Both metrics 
supported our findings based on spot count analysis, and proved to be valuable additional metrics 
to characterize the autophagic response (Figure R-23). 
 
D.4.2 Modulation of autophagy by TNFR, JNK, Bcl-2 and NFκB 
signaling 
Although I have not reported extensively on our findings regarding the regulation of autophagy in 
MCF7 cells in this thesis, they show that the autophagic response is highly tunable, und critically 
dependent on JNK and NFκB [Maßen et al, in preparation. Compare Figure D-3]: TNFα has been 
implicated in activation of autophagy in T-lymphoblastic cells [126], and has been used to induce 
autophagy in rat Ewing sarcoma cells [69]. We have therefore added TNFα to study the 
regulatory effects of TNF receptor I activation on autophagy. Our results reveal that TNFα 
treatment under starvation conditions showed only minor effects on induction of autophagy 
(Figure R-25), and full medium experiments did not show any significant activation of autophagy 
(data not shown), contradiciting previous findings. On the one hand, this might be due to the 
analysis of only steady-state levels in previous studies, and on the other hand on differences 
between cell systems. 
Moreover, direct inhibition of Bcl-2 using the BH3 mimetic HA14-1 protein tended to decrease 
autophagic activity (Figure R-25). Although these results are not consistent with the proposed 
paradigm of a Bcl-2 mediated inhibition of Beclin 1, they suggest the co-existence of pro-survival 
activities of both Bcl-2 and autophagy [127]. Furthermore, these results are consistent with earlier 
flux measurements of Beclin 1 lacking the Bcl-2 domain, which indicated a decreased Beclin 1 
activity in the absence of Bcl-2 binding [128] and further supports a more complex relationship 
between Beclin 1 and Bcl-2 [129, 130]. 
During nutrient deprivation-induced autophagy the pharmacological inhibition of the NFκB 
pathway reduced levels of autophagy in my experiments (Figure R-25). This is in contrast to 
previous findings [69], which established that NFκB activation, associated with TNF and nutrient 
deprivation, blocks the autophagic response. However, our findings are consistent with a recent 
report that NFκB directly activates autophagy by increasing Beclin 1 expression [131], as well as 
consistent with the survival role of autophagy in nutrient deprivation, as NFκB inhibition has been 
shown to enhance starvation-induced cell death [132].  
Importantly, results from pharmacological perturbations indicated that in our model system, 
autophagy is negatively regulated by JNK (Figure R-25). JNK inhibition during nutrient 
deprivation-induced autophagy further increased autophagic activity above nutrient deprivation 
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levels. Importantly, the sensitivity of the autophagy detection method described here evidenced 
an increase from “medium” to “high” cumulative autophagosome levels, demonstrating that a 
large percentage of cells up-regulated autophagy, and thus had maintained an extra capacity in 
terms of both autophagosome formation and degradation which is pharmacologically responsive. 
These results strongly suggest that JNK acts in our experimental model to inhibit autophagy, 
which is in contrast to other reports that state that inhibition of JNK with SP600125 inhibited the 
induction of autophagy [133-137]. 
Building on our findings, I have further elucidated the mechanism of action behind the inhibiting 
role of JNK, and activating role of NFκB in cooperation with Nathan Brady (Bioquant, Heidelberg). 
Using Western Blots experiments, transfection of dominant-negative JNK, and TAT-delivered 
JNK inhibitor peptide, it was possible to identify JNK as a critical negative regulator of autophagy 
induction. JNK was phosphorylated upon induction of autophagy and with addition of Bafilomycin 
A1, and inhibition of NFκB lead to increased phosphorylation of JNK. Together with the 
confirmation of JNK inhibition leading to increased autophagy, this implicates that JNK acts as a 
“brake” in autophagy regulation in MCF7 cells, and that NFκB regulates autophagy via 
phosphorylation of JNK [Massen et al, manuscript in preparation] 
 
 
Figure D-3 - Expansion of a literature-derived autophagy regulation scheme, with our experimental findings. In contrast 
to previous studies, TNFR activation did not lead to induced autophagy, presumably because of the simultaneous activation of 
activating and inhibiting pathways. Bcl-2 seemed to play a minor activating role in the regulation of MCF7 starvation induced 
autophagy. In contrary, we have identified the pro-apoptotic JNK as a major critical brake in the regulation of autophagy. NFκB 
showed to be necessary for autophagy induction, presumably through inhibition of JNK activation. 
 
The dynamic balance between death and survival signals showed to be even more complex, 
calling into question how well we understand the balance between pro-survival and pro-death 
signaling events. Overall, our results indicate that pro-survival NFκB pathways can also positively 
regulate autophagy, a potent cytoprotective mechanism [138], and pro-death JNK pathways are 
inhibiting autophagy. However, JNK-associated promotion of autophagic cell death (PCD II) [139], 
likely involves the participation of additional pathways, including DAPK [140], which is presumably 
absent in our MCF7 model [141].  
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This work clearly illustrates the need for a methodical re-evaluation of early versus late signaling 
events pertaining to autophagy. Future work, integrating new perturbation strategies based on the 
topology established here with time-resolved measurements, will require the assistance of 
mathematical tools to integrate and predict solutions to non-intuitive results [142, 143]. 
Furthermore, such an approach outlined here indicates the possibility of standardizing autophagy 
measurements across model systems which would allow for a more direct comparison across 
laboratories. 
 
D.4.3 Sorafenib inhibits autophagy induction and induces 
apoptosis in A-375 cells 
With the establishment of a solid method for the quantification of autophagy, the intention was to 
clarifiy the impact of MAPK inhibition on the induction of autophagy. Upon treatment for 24 hours 
with the MAPK inhibitors U0126, AZD6244 and Sorafenib, the autophagic response in MCF7-
GFP LC3 cells was evaluated in a first step (Figure R-26). In full medium, I could not detect an 
impact of the MEK inhibitors U0126 and AZD6244, but Sorafenib, in contrast, mediated strong 
inhibiton of autophagy: Under cumulative conditions, i.e. in presence of BafA1, in Sorafenib-
treated cells, we did not observe a subpopulation shift towards medium and high spot counts as 
usually seen - instead, cumulative levels almost perfectly matched steady-state conditions. This 
becomes clearly visible by calculating the % change for Sorafenib-treated cells, and identifies 
Sorafenib as a strong inhibitor of autophagy induction in MCF7 GFP-LC3 cells. The analysis of 
the corresponding phosphorylation states regarding ERK1/2, MEK1 and Akt revealed most 
importantly, that Sorafenib treatment did not result in inhibition of p-ERK1/2 in contrast to both 
MEK inhibitors (Appendix Figure 1). This observation suggests that the phosphorylation status of 
ERK1/2 may be relevant for autophagy induction in MCF7 cells. This striking difference to the 
inhibition of p-ERK1/2 in melanoma lines prompted us to analyze the situation in melanoma. 
We have made use of stably transfected A-375 GFP-LC3 cells to evaluate the effects on 
autophagy and apoptosis in a MAPK-driven melanoma cell system. Our findings of phosphoplex 
analysis concerning the modulation of p53, JNK and Akt, already suggest a possible shift in the 
“balance” between autophagy and apoptosis. Along these lines we sought to combine an 
ImageStream based approach for the quantification of apoptosis with our approach of autophagy 
quantification. Detection of apoptotic cells with the ImageStream is based on occurring nuclear 
fragmentation that can be visualized by Hoechst DNA staining [84]. The simultaneous inspection 
of GFP-LC3 and Hoechst staining made it possible to evaluate both, apoptosis and autophagy on 
single cell levels simultaneously in A-375 GFP-LC3 cells. After 3 hours of starvation, with respect 
to autophagy, we have observed inhibiting effects of Sorafenib treatment in this model system too 
(Figure R-27). Careful evaluation of steady-state and cumulative levels, shows a modulated 
response in steady-state conditions. The “low” spot count population of cells decreased, 
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corresponding to an increase in the “medium” population of cells. Although an increase in the 
“low” cell population was also seen under cumulative conditions, the inhibiting effect of Sorafenib 
appeared to be most prominent under steady-state conditions. The increase in medium 
autophagic activity under steady-state conditions, leads to the assumption that Sorafenib may be 
able to block the degradation of newly formed autophagosomes, possibly interfering with the 
transport of cytoplasmic organelles or the fusion of autophagosomes to lysosomes. The inhibiting 
effect could only be observed in starvation medium, and was not visible in full medium conditions 
within 3 hours. This implicates, that it is probably due to the higher rate of autophagy in starvation 
medium.  
The simultaneous quantification of apoptotic cells shows a corresponding picture (Figure R-28): 
In starvation conditions the same amount of apoptotic cells in DMSO treated samples in steady-
state and cumulative conditions was observed, indicating that starvation for 3 hours alone does 
not induce apoptosis. In starvation medium under steady-state conditions, 8% apoptotic cells 
were detectable in DMSO samples, and 14% apoptotic cells in Sorafenib-treated cells. Sorafenib 
showed the highest levels of apoptosis-induction compared to the two MEK inhibitors. In 
starvation medium and under cumulative conditions, meaning disturbed autophagy, DMSO 
samples still show only 10% apoptotic cells. But of note, this was substantially increased to 35% 
in Sorafenib treated cells. This 3.5 fold increase of apoptotic cells compared to the corresponding 
DMSO control samples exceeds the effects of U0126 and AZD6244 substantially. Thus, 
Sorafenib treatment simultaneously reduced autophagy and increased apoptosis, i.e. shifts the 
balance towards apoptosis, but U0126 and AZD6244 did not. Even though this does not prove a 
direct connection between apoptosis and autophagy, it strongly implicates a cytoprotective role of 
autophagy under starvation conditions, and dysregulation of autophagy seems to promote 
apoptosis. 
Several scenarios could provide an explanation for this increase in apoptotic cells. Possibly, 
starvation results in apoptosis, if autophagy is inhibited through Sorafenib, while in DMSO control 
cells, fully functional autophagy is able to counteract the induction of apoptosis. Another option 
would be the induction of apoptosis through Sorafenib, independently from inhibiting effects of 
Sorafenib on autophagy. This would imply a coincidental correlation of inhibited autophagy and 
increased amounts of apoptotic cells. Claerhout et al have shown for metastatic skin cancer, that 
chemoresistance to cisplatin depends on induction of autophagy, since inhibition of autophagy 
with 3-MA in addition to cisplatin significantly enhanced cytotoxicity of cisplatin treatment [144]. 
This, among other studies shows that it is more likely that inhibition of autophagy with Sorafenib 
induces higher levels of apoptosis in starvation medium. 
We wanted to further characterize this Sorafenib specific behavior in longer treatment periods. 24 
hours of starvation would be rather toxic, that is why we had to focus on full medium conditions. 
Similar to the effect previously shown for MCF7 GFP-LC3 cells, almost complete inhibition of 
autophagy in A-375 GFP-LC3 cells was observed (Figure R-29). The evaluation of apoptotic cells 
reveals enhanced levels of apoptotic cells in Sorafenib-treated A375 GFP-LC3 cells compared to 
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DMSO, even though cells were cultured in full medium. Of note, we could not detect any changes 
in induced apoptosis in full medium within 3 hours (Figure R-28). Even though the amount of 9% 
apoptotic cells might seem rather low, we suggest that this number is probably underestimating 
the amount of apoptotic cells, because cells that get detached within these 24 hours of treatment 
are not included in the measurement due to washing steps prior to DNA staining with Hoechst, 
which resembles a selection for attached, i.e. living cells. The high amount of apoptotic cells after 
3 hours of starvation and Sorafenib treatment (Figure R-28), is probably unaffected by this 
“selection”, because these early-apoptotic cells, have probably not yet detached from the plate. 
We possibly observe a multiplicative effect of Sorafenib treatment. On the one hand, it induces 
apoptosis within 24 hours of treatment, and on the other hand it inhibits the cytoprotective 
function of autophagy, to further enhance the effect of induced apoptosis. The amount of 
apoptotic cells after 24 hours of treatment corresponds well to the levels we have observed in full 
medium conditions after 3 hours.  
Although this balance between autophagy and apoptosis is clearly modulated by Sorafenib in a 
similar fashion in different tumor cells (MCF7 and A-375) harbouring different constitutive 
signaling pathways, it is still puzzling to observe almost 100% non-autophagic cells but <50% 
apoptotic cells. This discrepancy suggests that non-autophagic cells do not automatically undergo 
apoptosis but rather additional events may drive them to the “point of no return” on their way to 
apoptosis. Before this point of no return, the direction seems to be “reversible”. Taken together, 
the simultaneous quantification of autophagy and apoptosis at the single cell level allows a 
detailed view on the delicate balance between these two cellular reactions. Since several 
pathways are involved in the adjustment of this balance according to the nutrient conditions, it is 
not surprising that perturbation of these pathways can either inhibit or promote autophagy. 
However, the reaction of tumor cells to these perturbations may be determined by the individual 
oncogenic signaling that is driven in part by mutations in signaling nodes like BRaf, NRas and 
PI3K components. In consequence, this would argue for a detailed analysis of autophagy and 
apoptosis in the context of the “driver” mutations in order to understand how the oncogenic 
signaling pathways impact tumor cell survival and resistance to apoptosis. This novel conncetion 
between oncogenic signaling, depending on the mutational status of the tumor cell, 
microenvironment, immune recognition and balance between autophagy and apoptosis will be 
further investigated in the context of malignant melanoma. In a larger perspective, our data may 
be relevant, especially when deep-sequencing of tumors will generate comprehensive mutation 
patterns – because our studies provide a link to the functional consequences for tumor biology. 
Whithout this information, it will be fairly impossible to use the sequence information for the 
prediction of responder versus non-responder subgroups of patients. 
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Abbreviations 
ADCC antibody-dependent cellular cytotoxicity 
AR activating receptor 
ATP adenosine-triphosphate 
Baf Bafilomycin 
BF bright-field 
CD107a, LAMP-1 lysosomal-associated protein 1 
CI cell index (xCELLigence) 
CP cytoplasmic part 
DNAM-1 DNAX accessory molecule-1 
EBSS Earle’s balanced salt solution (starvation medium) 
EGFR epidermal growth factor receptor 
ER endoplasmatic reticulum 
ERK extracellular signal-regulated kinase 
FACS fluorescenceactivated cell sorting 
FLT-3 fms-related tyrosine kinase-3 
GDP guanindiphosphate 
GFP green-fluorescent protein 
GRB2 growth-factor-receptor bound-2 
GTP guanintriphosphate 
HLA human leukocyte antigen 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin 
IR inhibitory receptor 
ITIM immunoreceptor tyrosine-based inhibitory motif 
LC3 rat microtubule-associated protein 1 light chain 
MAPK mitogen-activated protein kinase 
MEK MAPK ERK kinase 
MFI mean/median fluorescence intensity 
MHC major histocompatibility complex 
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mTOR mammalian target of rapamycin 
NEAA non-essential amino acids 
NK cell natural killer cell 
PAS pre-autophagosomal structure 
PBL peripheral blood leukocytes 
PBMC peripheral blood mononuclear cells 
PCD programmed cell death 
PDGFR platelet-derived growth factor receptor 
PFA paraformaldehyde 
PI3K phophatidylinositol-3-kinase 
PIP2(3) Phosphatidylinositol-bi(tri)phosphate 
p-protein phosphorylated protein 
RT room temperature 
RTCA real-time cell analyzer 
RTK receptor tyrosine kinase 
SAPE Streptavidine-PE 
SHP-2 SH2-containing tyrosine phosphatase-2 
SOS son-of-sevenless 
SrcK Src kinase family members 
SSC side scatter 
TM “tumor medium” 
TNF tumor necrosis factor 
t-protein total protein 
V-EGFR vascular endothelial growth factor receptor 
WB western blot 
WM Wortmannin 
β2m β2-microglobuline 
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Appendix Figure 1 MCF7 GFP-LC3 cells are BRaf wild-type, but have a constitutively active PI3K pathway. Cells have 
been treated with U0126 (10µM), AZD6244 (3µM) and Sorafenib (5µM) for 48 hours. AZD6244 displays, as in melanoma cells, 
increasing phosphorylation of MEK1 upon treatment. Both, MEK1 and ERK1/2 phosphorylation is rather low, underlining the 
wild-type BRaf signaling. Phosphorylation of ERK1/2 is effectively inhibited with both MEK inhibitors, but Sorafenib, of note, 
leads to increased phosphorylation of ERK1/2 until 24 hours of treatment. The analysis of Akt phosphorylation displays the 
constitutively active PI3K signaling, not altered upon inhibition of the MAPK pathway.  
 
